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Abstract 
 
 
Toll-like receptors (TLR)-7/-8 are innate immune receptors present in the endosomal compartment that 
are activated by single-stranded RNA (ssRNA) molecules of viral as well as nonviral origin, inducing the 
production of inflammatory cytokines necessary for the development of adaptive immunity, and are thus 
useful as vaccine adjuvants. A general introduction to TLRs, with an emphasis on the role of TLR7 
activation in mobilizing innate and adaptive immune responses is presented in Chapter 1.  
Synthetic small molecule agonists of TLR7 include the imidazoquinoline class of compounds such as 
Gardiquimod [1-(4-amino-2-((ethylamino)methyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol]. En 
route to the synthesis of gardiquimod, its des-amino 3H regioisomer was found to be antagonistic at TLR7 
(Chapter 2).  
Using the 3H imidazoquinoline as a lead, the syntheses, characterization, and biological evaluation of a 
pilot library of 3H imidazoquinolines was undertaken, which led to the identification of a dual TLR7/TLR8 
antagonist (Chapter 3).  
With the goal of developing more potent TLR7 agonists as adjuvants, derivatives of gardiquimod were 
synthesized and a detailed SAR study on the imidazoquinoline chemotype was performed, which led to 
the discovery of a highly potent, lipophilic, human TLR7 agonist (Chapter 4). 
Further exploration on the imidazoquinoline chemotype led us to a highly active TLR7/8 dual agonistic 
molecule bearing a free primary amine on the N1 substituent. This molecule was utilized to synthesize 
fluorescent imidazoquinoline analogues that retained TLR7/8-agonistic activity, and were used to study 
the distribution of TLR7 and also to examine its differential uptake in lymphocytic subsets (Chapter 5). 
Homodimers of imidazoquinolines were synthesized in order to test whether such constructs would 
behave as modulators of TLR3 (Chapter 6).  
The TLR7/8 dual agonistic molecule was also used as a convenient precursor for the synthesis of 
isothiocyanate and maleimide derivatives, enabling its direct conjugation to protein and polysaccharide 
antigens to make self adjuvanting vaccine constructs. The isothiocyanate derivative was covalently 
coupled to a model antigen, -lactalbumin, and this self-adjuvanting -lactalbumin construct induced 
robust, high-affinity immunoglobulin titers in murine models of vaccination (Chapter 7). 
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Abbreviations 
AIDS  acquired immune deficiency syndrome 
AP-1  activator protein-1 
APC  allophycocyanin 
APCs  antigen presenting cells 
CCR  chemokine receptor 
CD  cluster of differentiation 
CTL  cytotoxic T lymphocytes 
DBU  1,8-diazabicyclo[5.4.0]undec-7-ene 
DCs  dendritic cells 
DMAP  4-dimethylaminopyridine 
DMF  N,N-dimethylformamide 
DPLA  diphosphoryl lipid A 
dsDNA  double-stranded DNA 
dsRNA  double-stranded RNA 
EC50  half-maximal effective concentration 
EDCI.HCl 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
ELISA  enzyme linked immunosorbent assay 
ESI-TOF electrospray ionization-time of flight 
FDA  Food and Drug Administration  
FITC  fluorescein isothiocyanate 
FSC  forward scatter 
GCOS  genechip operating software 
GI  gastrointestinal 
GM-CSF granulocyte macrophage-colony stimulating factor 
HATU  2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate 
HBTU  2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate 
HEK-293 human embryonic kidney 293 
HCV  hepatitis C virus 
HIV  human immunodeficiency virus 
HSA  human serum albumin 
IC50  half-maximal inhibitory concentration 
IFN  interferon 
Ig  immunoglobulin 
IL  interleukin 
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IRAK4  IL-1-receptor-associated kinase 4 
JNK  Jun N-terminal kinase 
LPS  lipopolysaccharide 
MAPK  mitogen-activated protein kinases 
m-CPBA meta-chloroperoxy benzoic acid 
MHC  major histocompatibility complex 
MIP-1 macrophage inflammatory proteins-1alpha 
MPLA  monophosphoryl lipid A 
MyD88  myeloid differentiation primary response gene (88)  
Nalp3  NACHT, LRR and PYD domains-containing protein 3  
N-Boc  N-tert-butyl carbamate 
NF-B  nuclear factor-kappa B 
NK cells natural killer cells 
NOD  nucleotide-binding oligomerization domain 
NOE  nuclear overhauser effect 
PAMP  pathogen associated molecular pattern 
PBMCs peripheral blood mononuclear cells 
PE  phycoerythrin 
RIG  retinoic acid inducible gene 
RNA  ribonucleic acid 
sAP  secreted alkaline phosphatase 
SAR  structure activity relationship 
SNAr  aromatic nucleophilic substitution 
SSC  side scatter 
ssRNA  single stranded RNA 
TGF-  transforming growth factor beta 
Th1  helper T–type 1 
THF  tetrahydrofuran 
TIR  toll-interleukin 1 receptor domain 
TLRs  toll like receptors 
TNF-  tumor necrosis factor – alpha 
Tregs  human T-regulatory cells 
TRIF  toll-interleukin 1 receptor domain-containing adapter-inducing  
interferon-β 
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       Chapter 1.  Introduction 
 
Introduction 
Target: TLR7
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1.1. Introduction − Adjuvants, Toll-like Receptors (TLRs), and Other Microbial Sensors. 
 
 
 
As interesting as this method is from a practical point of view, it 
may be just as interesting from a theoretical point of view, because 
of the research it could stimulate to understand the intimate 
mechanism of either the increase in antitoxin induced in this case, 
or the generation of antitoxins within the animal” 
Gaston Ramon, 1926 
 
 
 
Just as the prescient comment by Gaston Ramon was relegated to the last footnote of his 1925 
paper,1 so has research on the mechanisms of action of adjuvants, until recently, languished as 
parenthetical annotations and addenda in the archives of immunology and vaccine development.  
Ramon defined immunological adjuvants as “substances used in combination with a specific antigen 
that produced a more robust immune response than the antigen alone.” Interestingly enough, he was 
referring to his empirical findings that the addition of bread crumbs, tapioca, saponin, and ‘starch oil’ 
to antigenic preparations greatly enhanced antibody responses to diphtheria or tetanus.2 A year later, 
the adjuvanticity of aluminum salts (primarily phosphate and hydroxide) was discovered by Glenny 
and coworkers.3 In the eighty-one years that have elapsed, the repertoire of investigational adjuvants 
has grown to encompass a very wide range of materials,4 but aluminum salt-based mineral salts 
(generically, and incorrectly, termed “alum”) have remained the only adjuvants currently approved by 
the FDA. Aluminum salts have enjoyed a good safety record, but they are weak adjuvants for 
antibody induction and induce a Th2-skewed, rather than a Th1 response.5;6 Furthermore, not only 
are aluminum salts ineffective at inducing cytotoxic T lymphocyte (CTL) or mucosal IgA antibody 
responses, but also have a propensity to induce IgE responses, which have been associated with 
allergic reactions in some subjects.5;6 Very recent reports implicate the Nalp3 inflammasome, a 
component of the innate immune response, as the effector limb of alum-associated adjuvanticity.7-9 
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In 1962, Dresser observed that injection of purified soluble proteins not only failed to stimulate an 
immune response, but tolerized animals unless a bacterial extract was admixed with the protein 
immunogen.10-12 This led him to redefine adjuvanticity “as a property of a substance which can act as 
a physiological switch, directing at least some immunologically competent cells to respond by making 
antibody rather than by becoming immunologically paralyzed by the antigen”,13 confirming Johnson’s 
earlier observations that lipopolysaccharide from Gram-negative bacteria exerted potent adjuvant 
properties,14 and perhaps paved the way for the subsequent discovery of the wide range of 
microorganism-derived adjuvants shown in Table 1.15 
 
While it is indisputable that progress in developing adjuvants had been stymied due to the lack of a 
detailed understanding of the mechanistic bases underlying their immunopotentiatory properties as 
well as the pronounced systemic toxicity of bacterial products, it is astonishing that purely empirical 
observations (which predate by many decades the discovery of what is taken for granted today, such 
as the professional antigen presenting cell, or the immunological synapse) had fueled incremental 
advances, driving the field slowly to a point where it is now poised to reach ‘critical mass’ due to the 
convergence of the decade-old science of innate immunity,16-20 and the nascent field of toll-like 
Table 1. Adjuvants and their usage of innate immune receptors. 
Reproduced from Ref. 15. 
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receptors (TLRs),15;21-25 and other Pathogen-Associated Molecular Pattern (PAMP)-recognizing 
elements such as the nucleotide-binding oligomerization domain (NOD)-like26-31 and retinoic acid 
inducible gene (RIG)-like receptors.32-36 Safety and the lack of toxicity, alongside efficacy are, 
obviously, the central issues in the choice of a vaccine adjuvant. In the 1950s, Salk vaccinated 
humans with influenza virus emulsified in Freund’s incomplete adjuvant (water-in-oil emulsion of 
mineral oil and the surfactant mannide monooleate). Based on the reported safety of the adjuvant in 
influenza vaccine trials,37 other investigators explored Freund’s incomplete adjuvant (Montanide ISA 
720 and ISA 5138) for use in single dose vaccines. A high incidence of severe local reactions, 
however, led to an abrupt termination of the trials.39;40 Clinical trials on Isatoribine41-43 (ANA975), a 
TLR7 agonist, have recently been terminated because of toxicity in animal models.44 The search for 
immunopotentiators with a wide margin of safety continues, but the pace of discovery, until very 
recently, had been hampered by the lack of understanding of the structure-function correlates 
underlying immunostimulatory versus inflammatory activities. 
 
Toll-like receptors (TLRs) are pattern recognition receptors present on diverse cell types. TLRs 
recognize specific molecular patterns present in molecules that are broadly shared by pathogens but 
are sufficiently different so as to be distinguishable from host molecules, and are collectively referred 
to as pathogen-associated molecular patterns (PAMPs).24;45 There are 10 TLRs in the human 
genome; these are trans-membrane proteins with an extracellular domain having leucine-rich repeats 
(LRR) and a cytosolic domain called the Toll/IL-1 receptor (TIR) domain.45 The ligands for these 
receptors are highly conserved microbial molecules such as lipopolysaccharides (LPS) (recognized 
by TLR4), lipopeptides (TLR2 in combination with TLR1 or TLR6), flagellin (TLR5), single stranded 
RNA (TLR7 and TLR8), double stranded RNA (TLR3), CpG motif-containing DNA (recognized by 
TLR9), and profilin present on uropathogenic bacteria (TLR11).46;47 TLR1, -2, -4, -5, and -6 respond 
to extracellular stimuli, while TLR3, -7, -8 and -9 respond to intracytoplasmic PAMPs, being 
associated with the endolysosomal compartment.45 The activation of TLRs by their cognate ligands 
leads to production of inflammatory cytokines, and up-regulation of MHC molecules and co-
stimulatory signals in antigen-presenting cells as well as activating natural killer (NK) cells (innate 
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immune response), in addition to priming and amplifying T-, and B-cell effector functions (adaptive 
immune responses).22;23;48;49 Thus, TLR stimuli serve to link innate and adaptive immunity48 and can 
therefore be exploited as powerful adjuvants in eliciting both primary and anamnestic immune 
responses.  
 
A detailed understanding of the structural and mechanistic bases of adjuvanticity and toxicity is 
pivotal in rationally developing novel adjuvants. The progression from early experiments 
demonstrating the adjuvanticity of highly toxic LPS14 to Ribi’s ‘detoxified’ monophosphoryl lipid A 
(MPLA) in the 1980s,50-54 culminating in commercialization as MPL™ in such vaccines as Fendrix® 
and Cervarix® is instructive, and the lessons learned can be successfully applied toward the rapid 
development of other TLR agonistic adjuvants. Kusumoto’s landmark total synthesis of lipid A, the 
toxic moiety of endotoxic LPS,55 allowed the formal verification that synthetic, 1-dephospho-lipid A, 
as well as 3-deacyl monophosphoryl lipid A isolated by mild acid hydrolysis of Gram-negative 
bacteria-derived lipid A, were nontoxic, and yet immunostimulatory and adjuvantic.50;56;57 The 
mechanism of immunopotentiation of LPS and lipid A, however, remained obscure until the discovery 
of TLR4-agonistic effects of LPS and lipid A derivatives in the late 1990s,23;58-63 and it was not until 
2007 that the basis of the dissociation between toxicity of diphosphoryl lipid A (DPLA) on the one 
hand, and the potent adjuvanticity (and nontoxicity) of monophosphoryl lipid A, on the other, became 
apparent.  Whereas DPLA, upon binding to TLR4, signals via both myeloid differentiation factor 88 
(MyD88) as well as Toll-interleukin 1 receptor domain-containing adapter inducing interferon- 
(TRIF)-dependent pathways,24;64-67 MPLA appears to predominantly trigger the TRIF-dependent 
pathway.68 Activation of MyD88-dependent signaling is thought to be associated with 
proinflammatory outcomes, while activation of TRIF-dependent pathways are correlated with 
immunostimulation.68  
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In an effort to explore and develop strategies for the rapid and simultaneous evaluation of both 
adjuvantic potency and proinflammatory activities of relatively large focused libraries of compounds 
being generated by our synthetic programs, we have examined representative members of virtually 
the entire compendium of known TLR agonists in a series of hierarchical assays including primary 
TLR-reporter assays, secondary indices of immune activation such as cytokine induction and 
activation of lymphocytic subsets in whole human blood, and tertiary screens characterizing 
transcriptomal activation patterns with a view to identifying optimal immunostimulatory chemotypes. 
Of all the innate immune stimuli examined, we found that TLR2 (thioacylglycerol lipopeptide 
chemotype), TLR4 (LPS and monophosphoryl lipid A), TLR5 (flagellin), and TLR7 (imidazoquinoline 
chemotype) were immunostimulatory; the imidazoquinoline class of TLR7 agonists was found to be 
extraordinarily immunostimulatory, stimulating virtually all subsets of lymphocytes, and yet without 
inducing dominant proinflammatory cytokine responses (unlike TLR8 agonists, for instance, which, 
like LPS, were proinflammatory and therefore may exert systemic toxicity; Figs 1, 2).69 
 
Primary Gate: Lymphocytes Secondary Gate: CD3/CD56 
CD3-CD56+ 
NK cells 
CD3+CD56+ 
CIK cells 
CD69 Expression in Subsets  
Fig. 1. Schematic for flow cytometric analyses of CD69 expression in various lymphocytic subsets in whole human blood 
stimulated with 1 g/mL of various TLR agonists. Primary gating was performed on FSC/SSC-gated lymphocytes. Fully-
compensated CD3/CD56 subsets could be resolved with ease, and CD69 expression was measured in each of the subsets. 
Similar three-color experiments were also performed with CD3, CD4/CD8/CD19, and CD69 combinations. Data from Ref. 
69. 
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Fig. 2. CD69 expression in lymphocytic subsets in whole human blood stimulated with TLR agonists (box-and-whisker 
plots). Analysis of data obtained from five independent experiments using blood donated by six different donors. Data 
from Ref. 69. 
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1.2. Intracellular TLR7 Activation: Imidazoquinoline ligands:  
 
 
Single-stranded RNA (ssRNA) molecules of viral as well as nonviral origin (poly dT; thymidine 
homopolymer phosphorothioate) induce the production of inflammatory cytokines, mediated by the 
recognition in the endosomal compartment by TLR7.70-72 Small molecule, non-polymeric, synthetic 
agonists include the imidazoquinolines (Imiquimod, Resiquimod [R-848], and Gardiquimod),73-75 as 
well as guanosine analogues such as loxoribine76-78 (Fig. 3) 
 
Long before the fact that these synthetic analogues specifically engaged and activated TLR7 was 
known, it was recognized that these compounds were potently adjuvantic76-82 in addition to displaying 
anti-viral effects via the induction of IFN-.70;75;83;84  It became apparent as early as 1991 that 
loxoribine (7-allyl 8-oxoguanosine) potentiated anti-tetanus-specific IgG antibody anamnestic 
responses in a dose-dependent manner in human peripheral blood mononuclear cells,78 as well as 
strongly activating NK cells in an IL-12-dependent manner.76;79;80  In human blood stimulated ex vivo 
with TLR7 agonists, upregulation of the surface expression of costimulatory molecules such as 
CD40, CD80, and CD86 occurred in both CD11c- plasmacytoid DCs and CD11c+ myeloid DCs; 
furthermore,  the Th1 stimulatory ability of both DC subsets was enhanced in response to TLR7 
ligands.85 Because TLR7 agonists transmit a T-helper-like signal to antibody-producing B cells, it is a 
highly effective adjuvant even for synthetic peptides that lack T-cell epitopes, possibly even replacing 
the function of T-helper cells, and providing a potential T-cell-independent vaccination strategy.81  
Loxoribine Imiquimod Gardiquimod 
Fig. 3. Representative synthetic, non-polymeric TLR7 agonists. 
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One potential drawback is that small molecules such as the imidazoquinolines quickly diffuse out of 
the vaccination site, thereby limiting their utility as an adjuvant. This has been addressed by 
conjugating the TLR7 ligand to the immunogen(s) of interest. For instance, non-human primates 
immunized with HIV Gag protein-TLR7 agonist conjugate showed dramatic enhancement of the 
magnitude and the quality of Th1 responses, as well as eliciting Gag-specific CD8+ CTL responses 
compared with animals immunized with HIV Gag protein and the TLR7 agonist as a noncovalent 
mixture.86 A number of preclinical studies with TLR7 agonists as adjuvants are currently in 
progress.87-92  
 
1.3. Intracellular TLR8 Activation: Imidazoquinoline and Thiazoloquinolone ligands:  
TLR7 and TLR8 are phylogenetically and structurally related and, like TLR7, single-stranded RNA 
(ssRNA) molecules are recognized in the endosomal compartment also by TLR8, but significant 
species specificities exist: murine TLR7 and human TLR8 mediate the recognition of GU-rich 
ssRNA.93  In human cells, TLR8 agonists activate myeloid dendritic cells, monocytes, and monocyte-
derived dendritic cells, with the production of GM-CSF/IL-4/TGF-beta. TLR7-selective agonists were 
found to be more effective than TLR8-selective agonists at inducing IFN- and IFN--regulated 
chemokines, whereas TLR8 agonists induce a dominant proinflammatory cytokine profile including 
TNF-, IL-12, and MIP-1.94  Not surprisingly, several imidazoquinolines have mixed TLR7/8 
agonistic activity, but a thiazoloquinolone compound (3M-002) is characterized as a pure TLR8 
agonist (Fig. 4).95 The prominent NF-B- and JNK-mediated stimulatory effects of TLR8-agonists on 
antigen-presenting cells95;96 as well as the activation of NK cells,97 leads to robust IL-12-driven Th1-
type responses.98  
 
Studies of human neonatal APCs cultured in vitro have demonstrated that TLR7/8 agonists possess 
unique efficacy to induce the Th1-polarizing cytokine TNF- at both the transcriptional and 
translational levels.98 TLR8 agonists, including the imidazoquinoline congeners R848 (TLR7/8) and 
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3M-003 (TLR7/8), the amidinothiazoline 3M-002 (TLR8), as well as ssRNAs (TLR8) induce a marked 
production of the Th1-polarizing cytokines TNF- and IL-12 from neonatal APCs that substantially 
exceeds responses induced by TLR2, -4, or -7 agonists.98 TLR7/8 agonists are thus uniquely 
efficacious in activating co-stimulatory responses in neonatal APCs, suggesting that these agents 
are promising candidate adjuvants for enhancing immune responses in newborns. 
 
 
 
 
 
 
 
Reversal of Treg suppressive effects by TLR8 agonists:  
Human T-regulatory cells (Tregs), classified immunophenotypically as naturally occurring 
(CD4+CD25+Foxp3+) or induced (CD4+CD25high), down-regulate and suppress a broad array of 
immune responses, including the non-specific suppression of both CD4+ and CD8+ T-cells via cell-
cell contact and via production of immunosuppressive cytokines such as IL-10 and TGF-.99-105 Tregs 
express abundant TLR8 mRNA, and TLR8 agonists have been shown to reverse Treg function via a 
TLR8-MyD88 (myeloid differentiation factor 88)-IRAK4 (IL-1-receptor-associated kinase 4) signaling 
pathway.106 Engagement and activation of TLR8, therefore, strongly induces innate immunity and 
enhances adaptive immunity (Fig. 5). In addition to the direct effects on Tregs described above, the 
production of IL-6 in the milieu renders CD4+ cells refractory to Treg suppression.107  
Fig. 4. Representative structures of synthetic, non-polymeric, mixed TLR7/8 imidazoquinoline agonists and a 
pure thiazoloquinolone TLR8 agonist. 
N
NH2
N
N O
OH
R848 (TLR7/8 Agonist)
N
NH2
N
H
N O
CL075 (TLR8 Agonist)
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N
CL097 (TLR7/8 Agonist)
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Potential problems with pure, high-potency TLR8 agonists, and a case for a mixed 
TLR7/TLR8 activator: 
Pure TLR8 agonists are perhaps unique in their ability to very strongly induce the production of 
proinflammatory cytokines such as TNF-. This property is thought to be related to the ability of the 
TLR8 pathway to strongly induce TLR-mediated intracellular signaling via the p38 MAPK and NF-B 
pathways.98 We have confirmed that 3M-002 (CL-075) induced a very potent and sustained 
proinflammatory response in human whole blood (TNF-, IL-6, and IL-8), which is not paralleled by a 
commensurate activation of NK cells or the production of type I or type II interferon, while the 
converse is true with a pure TLR7 agonist.  Local and/or systemic toxicity is to be anticipated and is 
Fig. 5. TLR8 agonists strongly activate human APCs to induce protective Th1-type immune responses, including 
production of IL-12 and upregulation of the co-stimulatory molecule CD40. TLR8 agonists also reverse suppression 
mediated by human Treg cells, via both direct action on Treg as well as by induction of IL-6, which renders responder 
T cells refractory to Treg-mediated inhibition. Reproduced with modifications from Ref. 106. 
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therefore a potential concern with potent TNF--inducing molecules; indeed such an effect appears 
to have been contributory to the GI toxicity that has been observed with clinical trials on Isatoribine 
given orally. 41;42;108  
Based on our preliminary results,69 we propose that a mixed TLR7/TLR8 agonist, with balanced 
Th1/IFN/NK cell activating profiles, but with attenuated proinflammatory cytokine induction potency 
may be beneficial. An extensive synthetic program that adequately explores chemical space around 
the TLR7/8 chemotype which is coupled optimally to a panel of bioassays should guide not only a 
careful evaluation of structure-activity correlates in such molecules, but will also likely yield useful 
molecules with potent adjuvanticity, and with a very wide margin of safety. 
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     Chapter 2.   Regioisomerism-
dependent TLR7 Agonism and Antagonism in an 
Imidazoquinoline 
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2.1. Introduction. 
 
 
Chronic immune activation is a hallmark of progressive HIV infection which is strongly associated 
with dysregulated cellular and humoral immune responses;109;110 furthermore, the resulting 
accelerated turnover of CD4+ lymphocytes provides a milieu for HIV replication.111 The majority of the 
lymphocytic pool resides in the gastrointestinal tract and it has recently been demonstrated that 
during acute HIV infection, a tremendous depletion submucosal CD4+ lymphocytes occurs as a result 
of massive viral replication.112-114  The loss of mucosal integrity due to the resultant enteropathy has 
been shown to contribute to sustained systemic immune activation as a consequence of 
translocation of bacterial products such as lipopolysaccharide,115 an agonist of toll-like receptor 4 
(TLR4).116 The engagement of TLR7 and -9 by single-stranded viral RNA has recently been reported 
to play a central role in immune activation-driven HIV replication. For instance, progressive CD4+ T 
lymphocyte depletion in non-human primates is highly correlated with TLR7-mediated interferon- 
(IFN-) by plasmacytoid dendritic cells, and antagonists of TLR7 inhibit immune activation.117  
 
The only known class of TLR7 antagonists is single-stranded phosphorothioate oligonucleotides,118 
and the availability of a selective and potent small-molecule TLR7 antagonist should allow the formal 
testing of potential benefits of suppression of TLR7-mediated immune activation in HIV/AIDS. 
Gardiquimod is a commercially-available N1-substituted 1H-imidazoquinoline TLR7 agonist,119 the 
synthesis of which had not been published. We undertook the syntheses of gardiquimod and en 
route, its 3H regioisomer as well (Scheme 1); the 3H regioisomer was found to be completely 
inactive as a TLR7 agonist and was, in fact, weakly antagonistic. A des-amino precursor of the 3H 
regioisomer was more potent as a TLR7 antagonist, with an IC50 value of 7.5 M. This class of 
compound may serve as a useful lead and a starting point for the development of small-molecule 
inhibitors of TLR7. Gardiquimod was also synthesized, and its activity was found to be identical to 
that of the commercially available compound. 
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Scheme 1: Synthesis of Gardiquimod, the 3H regioisomer, and its des-amino analogue
4-Desamino-3H-Regioisomer
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2.2. Results and Discussion. 
 
 
Following literature precedents,120 anthranilic acid  1 was condensed with 2-nitroacetaldehyde oxime 
which was prepared in situ from nitromethane and sodium hydroxide to give 2-(2-nitro 
ethylideneamino)benzoic acid, 2; this was then cyclized to form the quinoline ring using acetic 
anhydride and potassium acetate to give 3-nitro-4-hydroxyquinoline, 3. Treatment with phosphorous 
oxychloride afforded 3-nitro-4-chloroquinoline, 4, which served as the common precursor for the 
synthesis of gardiquimod, as well as its regioisomer. 1-amino-2-methylpropan-2-ol, 18 was obtained 
by reacting NH4OH with 2,2-dimethyloxirane at 0 
oC; isolation and purification were facilitated by 
temporary N-Boc protection, which was eventually deprotected with CF3CO2H. The N-Boc-protected 
N-ethylglycine derivative 22, was synthesized from the methyl ester of glycine 19 via reductive 
amination using acetaldehyde and sodium cyanoborohydride, followed by N-Boc protection using 
(Boc)2O and subsequent ester hydrolysis by LiOH. 
 
Synthesis of gardiquimod: An SNAr reaction on 4 with 1-amino-2-methylpropan-2-ol, 18 afforded 
the 3-nitro-4-aminoquinoline derivative 5, which was converted to the imidazoquinoline 7 via 
sequential Pd-catalyzed reduction of the nitro group 6, amidation with the N-Boc-protected amino 
acid 22, followed by cyclization with NaOH to afford the intermediate 7.121 N-oxidation of the 
quinoline nitrogen of 7 with m-CPBA yielded 8, which was reacted with benzoyl isocyanate in 
dichloromethane to provide a 4-N-benzoyl derivative. This amide was cleaved using NaOMe in 
MeOH as has been reported122 to yield the N-Boc-protected precursor of gardiquimod. Final 
deprotection was performed with CF3CO2H to give the target molecule, 9, as the TFA salt, which was 
as active as the commercially-available reference compound (Fig. 1, overleaf). 
 
Synthesis of the 3H regioisomer of gardiquimod: An SNAr displacement of 4 to the corresponding 
azido derivative 10 with NaN3, followed by reduction of both the 3-nitro- and the 4-azido groups with 
Pd/C under hydrogenation conditions gave the 3, 4-diaminoquinoline 11. Amidation of 11 with 22, 
followed by cyclization using NaOH afforded the C-2-substituted imidazoquinoline scaffold 12. 
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Reaction of 12 with excess of the 2,2-dimethyloxirane in the presence of DBU afforded the N-3 
substituted imidazoquinoline 13. Subsequent steps, similar to the ones described above afforded the 
3H regioisomer 15. 
  
TLR7 agonism and antagonism: A reporter gene assay using TLR7-dependent NF-B induction 
was used. The induction of NF-B was quantified using HEK-Blue-cells as previously described by 
us.123 HEK293 cells were stably transfected with plasmids encoding TLR7 as well as an NF-B 
reporter gene coupled to secreted alkaline phosphatase (sAP) (InvivoGen, San Diego, CA), and 
were maintained in HEK-Blue™ Selection medium containing zeocin and normocin. Stable 
expression of secreted alkaline phosphatase (sAP) under control of NF-B/AP-1 promoters is 
inducible by the TLR7 agonists, and extracellular sAP in the supernatant is proportional to NF-B 
induction. HEK-Blue-7 cells were incubated at a density of ~105 cells/mL in a volume of 80 µl/well, in 
384-well, flat-bottomed, cell culture-treated microtiter plates until confluency was achieved, and 
subsequently graded concentrations of stimuli.  sAP was assayed spectrophotometrically using an 
alkaline phosphatase-specific chromogen (present in HEK-detection medium as supplied by the 
vendor) at 620 nm. The TLR7 agonistic potency of 9 was indistinguishable from that of the 
Fig. 1. NF-B induction activities of 9 and reference 
gardiquimod in a TLR7-specific reporter gene assay. 
IC50 values of both compounds is 0.65 g/mL. 15 was 
inactive at the highest concentration test (25 g/mL) 
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commercially available gardiquimod (Fig. 1), while 15 was devoid of agonistic activity (Fig. 1). None 
of the perecursors of 9 displayed any significant agonistic activities (data not shown).  
 
Antagonistic activities were examined by incubating HEK-Blue-7 cells with graded concentrations of 
test compounds in the presence of 250 ng/mL of gardiquimod. 15 displayed weak TLR7 antagonism 
(25 M, Fig. 2), which prompted us to carefully examine all its precursors. The des-amino compound 
16 obtained after deprotecting 13 was found to be maximally antagonistic with an IC50 of 7.5 M. 
Compound 16, fortuitously, also crystallized with ease in MeOH, the structure of which is shown in 
Fig. 2. 
 
2.3. Conclusions. 
 
Compound 16, was the first small molecule with TLR7-antagonistic activity, and a focused library has 
been generated for this 3H-imidazoquinoline chemotype toward the generation of more potent small-
molecule TLR7 receptor antagonists (Chapter 3). Compound 9 i.e. gardiquimod was further 
derivatized and SAR has been studied in Chapter 4. 
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Fig. 2. Left: TLR7-antagonistic activities of the 3H regioisomer 15, and of its des-amino precursor 16. Right: 
Crystal structure of 16 as the di-TFA salt. The locations of all the hydrogens were determined from a difference 
Fourier and refined as individual isotropic atoms. 
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2.4. Experimental. 
 
Unless otherwise mentioned, the compounds synthesized were obtained as solids. 
Synthesis of Compound 18: 1-amino-2-methylpropan-2-ol. 
 
The literature compound 18 was synthesized as reported previously (Close, W.J. J. Am. Chem. Soc. 
1951, 73, 95-98). 2,2-Dimethyloxirane 17 (1 g, 13.88 mmol) was added dropwise to 36 mL ice cooled 
solution of ammonium hydroxide. The reaction mixture was stirred for 12 hours. The solvent was 
removed under vacuum and the residue was dissolved in methanol. Di-tert-butyl dicarbonate (7.5 g, 
34.7 mmol) was added to the reaction mixture and stirred for 4 hours .The mixture was purified using 
column chromatography (24% EtOAc/hexane) to obtain tert-butyl 2-hydroxy-2-
methylpropylcarbamate (2.1 g). The pure tert-butyl 2-hydroxy-2-methylpropylcarbamate was 
dissolved in 8 mL of trifluoroacetic acid and stirred for 35 minutes. The solvent was removed under 
reduced pressure to afford 1-amino-2-methylpropan-2-ol as colorless oil (2.13 g, 80%).  
 
Synthesis of Compound 20: methyl 2-(ethylamino)acetate. 
 
To a solution of methyl 2-aminoacetate 19 (2 g, 22.5 mmol) in anhydrous methanol was added 
acetaldehyde (346 mg, 7.8 mmol), sodium cyanoborohydride (496 mg, 7.8 mmol) and 5-6 drops of 
acetic acid. The reaction mixture was stirred for 12 hours. Concentrated HCl was added to the 
reaction mixture till the pH became acidic (1-2). The solvent was removed under reduced pressure 
and the residue was purified using column chromatography (5% methanol/dichloromethane) to afford 
methyl 2-(ethylamino)acetate 20 as colorless oil (373 mg, 57%). 1H NMR (500 MHz, MeOD) δ 3.90 
(s, 2H), 3.75 (s, 3H), 3.03 (q, J = 7.3 Hz, 2H), 1.23 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 
168.28, 53.53, 47.75, 43.97, 11.35. MS (ESI) calculated for C5H11NO2, m/z 117.08, found 118.09 (M 
+ H)+. 
H2N
OH 18
MeO2C
H
N 20
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Synthesis of Compound 22: 2-(tert-butoxycarbonyl(ethyl)amino)acetic acid. 
 
Methyl 2-(ethylamino)acetate 20 (200 mg, 1.71 mmol) was dissolved in 10 mL of methanol. Di-tert-
butyl dicarbonate (746 mg, 3.42 mmol) and triethylamine (207 mg, 2.05 mmol) was added to the 
reaction mixture. The reaction was monitored by thin layer chromatography, and after 2 hours the 
solvent was evaporated under vacuum. The residue was dissolved in 10 mL of THF/methanol (3:1). 
A solution of lithium hydroxide (164 mg, 6.84 mmol) in 2 mL of water was added to the reaction 
mixture. Reaction mixture was stirred for 12 hours and then solvent was removed under reduced 
pressure. Water was added to the residue, followed by acidification of the residue using 10% HCl 
until the pH dropped to ~2. The residue was then dissolved in ethylacetate, washed with water and 
dried over sodium sulfate to afford 2-(tert-butoxycarbonyl(ethyl)amino)acetic acid 22 as colorless oil 
(274 mg, 79%). 1H NMR (500 MHz, CDCl3) δ 4.00 (s, 1H), 3.91 (s, 1H), 3.34 (dq, J = 28.4, 6.9 Hz, 
2H), 1.51 – 1.37 (m, 9H), 1.12 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.05, 173.22, 
154.14, 152.91, 78.61, 78.42, 46.46, 46.40, 41.50, 40.80, 26.32, 26.21, 11.50, 11.19. Doubling of 
resonances due to tautomerization was observed. MS (ESI) calculated for C9H17NO4, m/z 203.12, 
found 202.11 (M - H)-. 
 
Synthesis of Compound 2: 2-(2-nitroethylideneamino)benzoic acid. 
 
Nitromethane (4.32 mL, 80 mmol) was added dropwise to a solution of NaOH (9.6 g, 250 mmol) in 
10 mL of water, kept in an ice-bath. The mixture was then warmed to 40 oC and nitromethane (4.32 
mL, 80 mmol) was again added slowly at 40-45 oC. The temperature was maintained until a clear 
solution was obtained. The reaction mixture was then heated to 50-55 oC for 2-5 minutes, cooled to 
HO2C N
Boc
22
N
COOH
NO2
2
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30 oC, poured onto ice and acidified with 22 mL conc. HCl. The resultant solution of methazonic acid 
was added immediately to a filtered solution of anthranilic acid 1 (10 g, 73 mmol) and 6.6 mL of conc. 
HCl in 75 mL of water. The reaction mixture was allowed to stand at room temperature for 12 hours. 
After filtration, the residue obtained was washed with water, and dried at 110 0C to yield a yellow 
solid powder of 2-(2-nitroethylideneamino)benzoic acid 2 (12.94 g, 85%). 1H NMR (400 MHz, MeOD) 
δ 8.14 (d, J = 7.7 Hz, 1H), 7.83 (d, J = 6.1 Hz, 1H), 7.68 – 7.59 (m, 2H), 7.22 (t, J = 7.4 Hz, 1H), 6.73 
(d, J = 6.3 Hz, 1H). 13C NMR (101 MHz, MeOD) δ 168.57, 141.25, 136.64, 134.31, 131.98, 123.21, 
116.75, 114.55, 99.99. MS (ESI) calculated for C9H8N2O4, m/z 208.05, found 207.04 (M - H)-. 
 
Synthesis of Compound 3: 3-nitroquinolin-4-ol. 
 
A solution of 2-(2-nitroethylideneamino)benzoic acid 2 (12.94 g, 62.2 mmol) in 50 mL of acetic 
anhydride was placed in a 2-neck flask fitted with a reflux condenser. It was stirred and heated to 
100-105 oC until a clear solution was obtained. Heating was then discontinued and potassium 
acetate (6.22 g, 63.5 mmol) was added. The mixture was then again refluxed for 15 minutes with 
vigorous stirring, until a solid started to precipitate. The reaction mixture was then slowly cooled to 
room temperature. The residue was filtered, washed with glacial acetic acid until the washings were 
colorless, then suspended in water, filtered, washed with water and dried at 110 oC to get 3-
nitroquinolin-4-ol 3 (4.68 g, 40%). 1H NMR (500 MHz, DMSO) δ 13.04 (s, 1H), 9.21 (s, 1H), 8.25 (dd, 
J = 8.1, 1.1 Hz, 1H), 7.83 – 7.77 (m, 1H), 7.74 – 7.70 (m, 1H), 7.52 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H). 
13C NMR (126 MHz, DMSO) δ 167.64, 142.46, 138.25, 133.22, 130.89, 128.04, 125.95, 125.83, 
119.49. MS (ESI) calculated for C9H6N2O3, m/z 190.04, found 213.03 (M + Na
+). 
 
 
 
 
N
OH
NO2
3
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Synthesis of Compound 4: 4-chloro-3-nitroquinoline.  
 
3-Nitroquinolin-4-ol 3 (4.5 g, 23.7 mmol) was added to 30 mL of phosphorous oxychloride with 
stirring. The reaction mixture was refluxed for 30 minutes. The solvent was then evaporated under 
vacuum and the residue was poured over crushed ice while stirring. After an hour the solid that 
formed was filtered, washed with cold water and dissolved in dichloromethane and some methanol. 
The solution was then extracted with ice cold NaOH (1 N) and dried over sodium sulfate, with the 
addition of activated charcoal. The solution was filtered over celite, and the solvent was evaporated. 
The residue was triturated with diethyl ether and dried under vacuum to obtain 4-chloro-3-
nitroquinoline 4 (3.69 g, 75%). 1H NMR (400 MHz, CDCl3) δ 9.28 (s, 1H), 8.50 – 8.44 (m, 1H), 8.24 
(d, J = 8.5 Hz, 1H), 8.01 – 7.94 (m, 1H), 7.84 (t, J = 7.7 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
149.23, 144.44, 141.23, 136.53, 133.10, 130.27, 129.66, 125.95, 125.51. MS (ESI) calculated for 
C9H4ClN2O2, m/z 208.00, found 209.01 (M + H)
+. 
 
Synthesis of Compound 11: quinoline-3,4-diamine.  
 
To a solution of 4-chloro-3-nitroquinoline 4 (1 g, 4.87 mmol) in 15 mL of DMF, sodium azide (625 mg, 
9.62 mmol) was added. The reaction was stirred for an hour and solvent was evaporated under 
vacuum. The residue was dissolved in dichloromethane, washed with water, followed by drying over 
sodium sulfate. The filtrate was concentrated under reduced pressure to get crude 4-azido-3-
nitroquinoline 10 (1 g, 97% crude). The crude 10 was then dissolved in methanol and subjected to 
catalytic hydrogenation over Pd/C at 60 psi hydrogen pressure for 4 hours. The solution was then 
filtered using celite and filtrate was evaporated under reduced pressure to afford the quinoline-3,4-
N
Cl
NO2
4
N
NH2
NH2
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diamine 11 (700 mg, 95%). 1H NMR (400 MHz, MeOD) δ 8.22 (s, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.72 
(d, J = 8.5 Hz, 1H), 7.43 (t, J = 7.5 Hz, 1H), 7.36 (t, J = 7.5 Hz, 1H). 13C NMR (101 MHz, MeOD) δ 
141.66, 139.29, 136.20, 125.60, 124.41, 122.57, 122.13, 118.92, 116.93. MS (ESI) calculated for 
C9H9N3, m/z 159.08, found 160.09 (M + H)
+. 
Synthesis of Compound 12: tert-butyl (1H-imidazo[4,5-c]quinolin-2-yl)methyl(ethyl) 
carbamate.  
 
Quinoline-3,4-diamine 11 (161 mg, 1 mmol), 2-(tert-butoxycarbonyl(ethyl)amino)acetic acid 22 (165 
mg, 0.8 mmol), O-(7-Azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyl uronium hexafluorophosphate 
(HATU) (426 mg, 1.1 mmol), triethylamine (113 mg, 1.1 mmol) and catalytic amount of DMAP were 
dissolved in 10 mL of  DMF. The reaction mixture was stirred for 10-12 hours. The solvent was 
evaporated under vacuum. The residue was dissolved in ethylacetate, washed with water and dried 
over sodium sulfate to obtain the crude residue. The crude residue was dissolved in 10 mL of ethanol 
and solution of NaOH (105 mg, 2.62 mmol) in 1 mL of water was added to it. The reaction mixture 
was refluxed for 5-6 hours, followed by evaporation under reduced pressure. The crude mixture was 
purified by column chromatography (3% methanol/dichloromethane) to obtain tert-butyl (1H-
imidazo[4,5-c]quinolin-2-yl)methyl(ethyl)carbamate 12 (158 mg, 60%). 1H NMR (500 MHz, MeOD) δ 
8.98 (s, 1H), 8.31 (d, J = 6.0 Hz, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.66 – 7.55 (m, 2H), 4.71 (s, 2H), 3.39 
(m, 2H), 1.42 (s, 5H), 1.20 (s, 4H), 1.08 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 175.53, 157.20, 
152.53, 144.10, 129.79, 127.40, 126.60, 121.11, 81.10, 45.32, 43.67, 29.70, 28.41, 13.64. MS (ESI) 
calculated for C18H22N4O2, m/z 326.17, found 327.18 (M + H)
+. 
 
Synthesis of Compound 13: tert-butyl ethyl((3-(2-hydroxy-2-methylpropyl)-3H-imidazo[4,5-
c]quinolin-2-yl)methyl)carbamate. 
N
N
H
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To a solution of  tert-butyl (1H-imidazo[4,5-c]quinolin-2-yl)methyl(ethyl)carbamate 12 (95 mg, 0.29 
mmol) in 5 mL of 2,2-dimethyloxirane 17, 1,8-Diazabicyclo[5.4.0]-undec-7-ene (DBU) (110 mg, 0.73 
mmol) was added. The reaction mixture was refluxed for 18 hours. The solvent was evaporated 
under vacuum and the residue was purified using column  chromatography (2% 
methanol/dichloromethane) to obtain  tert-butyl ethyl((3-(2-hydroxy-2-methylpropyl)-3H-imidazo[4,5-
c]quinolin-2-yl)methyl)carbamate 13 (80 mg, 70%). 1H NMR (400 MHz, MeOD) δ 9.26 (s, 1H), 8.64 – 
8.52 (m, 1H), 8.14 (dd, J = 6.6, 2.9 Hz, 1H), 7.77 – 7.67 (m, 2H), 4.95 (s, 2H), 4.52 (s, 2H), 3.48 (s, 
2H), 1.51 (s, 6H), 1.32 (s, 9H), 1.22 – 1.13 (m, 3H). 13C NMR (126 MHz, MeOD) δ 154.82, 153.28, 
142.27, 141.88, 136.95, 128.72, 126.91, 126.29, 125.72, 120.63, 120.26, 79.27, 69.60, 53.15, 41.76, 
40.86, 26.16, 25.12, 10.88. MS (ESI) calculated for C22H30N4O3, m/z 398.23, found 421.22 (M + Na+). 
 
Synthesis of Compound 14: 2-((tert-butoxycarbonyl(ethyl)amino)methyl)-3-(2-hydroxy-2-
methylpropyl)-3H-imidazo[4,5-c]quinoline 5-oxide. 
 
tert-Butyl ethyl((3-(2-hydroxy-2-methylpropyl)-3H-imidazo[4,5-c]quinolin-2-yl)methyl)carbamate 13 
(64 mg, 0.81 mmol) was dissolved in 10 mL of dichloromethane/chloroform (1:1) and 0.5 mL of 
methanol. 3-Chloro-peroxybenzoic acid (69 mg, 0.4 mmol) was added and the reaction mixture was 
refluxed for 30 minutes. The reaction mixture was concentrated under reduced pressure and the 
residue was purified using column chromatography (5% methanol/dichloromethane) to obtain 2-
((tert-butoxycarbonyl(ethyl)amino)methyl)-3-(2-hydroxy-2-methylpropyl)-3H-imidazo[4,5-c]quinoline 
N
N
N
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N
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5-oxide 14 (228 mg, 72%). 1H NMR (400 MHz, CDCl3) δ 9.46 (s, 1H), 8.70 (s, 1H), 8.49 (s, 1H), 7.83 
– 7.65 (m, 2H), 4.94 (s, 2H), 4.33 (s, 2H), 3.35 (s, 2H), 1.53 (s, 9H), 1.39 (s, 6H), 1.08 (t, J = 6.9 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 154.02, 151.88, 135.69, 135.52, 127.48, 126.90, 126.43, 120.53, 
120.39, 118.18, 114.15, 78.87, 69.22, 53.46, 41.31, 39.47, 26.51, 25.16, 11.03. MS (ESI) calculated 
for C22H30N4O4, m/z 414.23, found 415.23 (M + H)
+. 
 
Synthesis of Compound 15: 1-(4-amino-2-((ethylamino)methyl)-3H-imidazo[4,5-c]quinolin-3-
yl)-2-methylpropan-2-ol.  
 
2-((tert-Butoxycarbonyl(ethyl)amino)methyl)-3-(2-hydroxy-2-methylpropyl)-3H-imidazo[4,5-c]quinoline 
5-oxide 14 (40 mg, 0.1 mmol) was dissolved in 4 mL of anhydrous dichloromethane. 
Benzoylisocyanate (29 mg, 0.19 mmol) was added to the reaction mixture and refluxed for 30 
minutes. The solvent was then removed under vacuum and the residue was dissolved in 5 mL of 
anhydrous methanol. Excess of sodium methoxide was added and the reaction mixture was refluxed 
for 2-3 hours. After evaporating solvent under reduced pressure, the crude residue was purified 
using column chromatography (3% methanol/dichloromethane) to afford  tert-butyl (4-amino-3-(2-
hydroxy-2-methylpropyl)-3H-imidazo[4,5-c]quinolin-2-yl)methyl(ethyl)carbamate (30 mg, 75%). The  
tert-butyl (4-amino-3- (2-hydroxy-2-methylpropyl) -3H-imidazo[4,5-c]quinolin-2-yl)methyl(ethyl) 
carbamate (27 mg, 0.07 mmol) was dissolved in 5 mL trifluoroacetic acid and stirred for 35 minutes. 
The solvent was removed under reduced pressure to afford quantitatively 35 mg of 1-(4-amino-2-
((ethylamino)methyl)-3H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol as trifluoroacetate salt 15. 
The compound was eluted using column chromatography to obtain the free base form of 15 (10% 
methanol/dichloromethane). 1H NMR (400 MHz, MeOD) δ 8.35 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 8.3 
Hz, 1H), 7.58 – 7.52 (m, 1H), 7.40 (t, J = 7.5 Hz, 1H), 4.55 (s, 2H), 4.37 (s, 2H), 3.07 – 2.96 (m, 2H), 
N
N
N
OHNH2
HN
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1.35 (s, 6H), 1.30 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, MeOD) δ 152.66, 148.34, 144.65, 141.87, 
127.69, 123.62, 122.99, 121.05, 120.44, 118.80, 70.07, 54.56, 44.34, 43.23, 26.12, 12.17. MS (ESI) 
calculated for C17H23N5O, m/z 313.19, found 314.20 (M + H)
+. 
 
Synthesis of Compound 5: 2-methyl-1-(3-nitroquinolin-4-ylamino)propan-2-ol.  
 
The trifluoroacetate salt of 1-amino-2-methylpropan-2-ol 18 (974 mg, 4.8 mmol) was added to the 
solution of 4-chloro-3-nitroquinoline 4 (500 mg, 2.4 mmol) and N,N-diethylpropan-2-amine (1.07 mL, 
6 mmol) in 4:1 mixture of toluene and 2-propanol. The mixture was heated to 70 oC for half an hour 
until a solid started precipitating. The reaction mixture was then cooled, filtered, washed with 
toluene/2-propanol (7:3), ether and cold water. The residue was dried at 80 oC to obtain 2-methyl-1-
(3-nitroquinolin-4-ylamino)propan-2-ol 5 (450 mg, 72%). 1H NMR (400 MHz, DMSO) δ 9.91 (s, 1H), 
9.18 (s, 1H), 8.47 (d, J = 8.4 Hz, 1H), 7.91 (d, J = 8.1 Hz, 1H), 7.85 (t, J = 7.5 Hz, 1H), 7.59 (t, J = 7.5 
Hz, 1H), 5.15 (s, 1H), 3.86 (d, J = 4.5 Hz, 2H), 1.18 (s, 6H). 13C NMR (101 MHz, DMSO) δ 151.14, 
150.15, 147.31, 133.28, 129.92, 128.15, 126.08, 125.60, 119.55, 69.25, 59.48, 27.55. MS (ESI) 
calculated for C13H15N3O3, m/z 261.11, found 262.12 (M + H)
+. 
 
Synthesis of Compound 6: 1-(3-aminoquinolin-4-ylamino)-2-methylpropan-2-ol.  
 
2-Methyl-1-(3-nitroquinolin-4-ylamino)propan-2-ol 5 (450 mg, 1.72 mmol) was dissolved in methanol 
and hydrogenated over Pd/C as catalyst at 60 psi hydrogen pressure for 4 hours. The solution was 
then filtered using celite, followed by evaporation of solvent under reduced pressure to afford 1-(3-
N
NH
NO2
OH
5
N
NH
NH2
OH
6
 34  
aminoquinolin-4-ylamino)-2-ethylpropan-2-ol 6 (380 mg, 96%). 1H NMR (400 MHz, MeOD) δ 8.37 (s, 
1H), 8.11 – 8.04 (m, 1H), 7.85 – 7.78 (m, 1H), 7.50 – 7.43 (m, 2H), 3.34 (s, 2H), 1.29 (s, 6H). 13C 
NMR (101 MHz, MeOD) δ 142.97, 142.19, 137.67, 130.54, 127.43, 125.63, 125.22, 122.82, 120.93, 
70.50, 56.39, 26.07. MS (ESI) calculated for C13H17N3O, m/z 231.14, found 232.14 (M + H)
+. 
 
Synthesis of Compound 7: tert-butyl ethyl((1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-
c]quinolin-2-yl)methyl) carbamate.  
 
1-(3-Aminoquinolin-4-ylamino)-2-methylpropan-2-ol 6 (108 mg, 0.24 mmol), 2-(tert-
butoxycarbonyl(ethyl)amino)acetic acid 22 (43 mg, 0.21 mmol), O-(7-Azabenzotriazol-1-yl)-
N,N,N’,N’-tetramethyl uronium hexafluorophosphate (HATU) (109 mg, 0.29 mmol), triethylamine (73 
mg, 0.72 mmol) and catalytic amount of DMAP were dissolved in 5 mL of  DMF. The reaction mixture 
was stirred for 10-12 hours. The solvent was evaporated under vacuum and the residue was 
dissolved in ethylacetate, washed with water, dried over sodium sulfate and concentrated under 
reduced pressure to obtain the crude residue. The crude residue was dissolved in 10 mL of ethanol 
and solution of sodium hydroxide (33 mg, 0.83 mmol) in 1 mL of water was added. The reaction 
mixture was refluxed for 5-6 hours and the crude mixture was purified using column chromatography 
(4% methanol/dichloromethane) to obtain tert-butyl (1H-imidazo[4,5-c]quinolin-2-
yl)methyl(ethyl)carbamate 7 (82 mg, 80%). 1H NMR (400 MHz, CDCl3) δ 9.26 (s, 1H), 8.34 (d, J = 8.2 
Hz, 1H), 8.24 (d, J = 8.3 Hz, 1H), 7.63 (dt, J = 15.3, 7.0 Hz, 2H), 4.72 (s, 4H), 3.69 (s, 1H), 3.32 (s, 
2H), 1.52 (s, 9H), 1.45 – 1.12 (m, 6H), 1.03 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 152.39, 
145.33, 145.15, 136.12, 135.19, 131.17, 126.92, 125.93, 120.37, 118.31, 80.82, 72.14, 55.43, 44.28, 
41.68, 28.40, 12.87. MS (ESI) calculated for C22H30N4O3, m/z 398.23, found 399.17 (M + H)
+. 
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Synthesis of Compound 8: 2-((tert-butoxycarbonyl(ethyl)amino)methyl)-1-(2-hydroxy-2-
methylpropyl)-1H-imidazo [4,5-c]quinoline 5-oxide.  
 
tert-Butyl ethyl((1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl)methyl)carbamate 7 
(270 mg, 0.68 mmol) was dissolved in 20 mL of dichloromethane/chloroform (1:1) and 2 mL of 
methanol. 3-Chloro-peroxybenzoic acid (326 mg, 1.7 mmol) was added and the reaction mixture was 
refluxed for 30 minutes. The reaction mixture was concentrated under reduced pressure and the 
residue was purified using column chromatography (7% methanol/dichloromethane) to afford 2-((tert-
butoxycarbonyl (ethyl)amino)methyl)-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinoline 5-
oxide 8 (228 mg, 82%). 1H NMR (500 MHz, CDCl3) δ 8.72 (d, J = 8.4 Hz, 1H), 8.36 (s, 1H), 8.23 (s, 
1H), 7.66 (t, J = 7.4 Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H), 5.48 (s, 2H), 4.69 (d, J = 28.5 Hz, 2H), 4.37 (s, 
1H), 3.27 (d, J = 68.9 Hz, 2H), 1.65 – 1.40 (m, 15H), 1.00 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 153.52, 151.85, 135.13, 132.33, 127.83, 127.54, 125.64, 125.57, 119.99, 118.15, 115.86, 
78.24, 69.22, 53.31, 40.95, 38.97, 25.94, 25.07, 10.47. MS (ESI) calculated for C22H30N4O4, m/z 
414.23, found 437.18 (M + Na+). 
 
Synthesis of Compound 9: 1-(4-amino-2-((ethylamino)methyl)-1H-imidazo[4,5-c]quinolin-1-yl)-
2-methyl propan-2-ol.  
 
2-((tert-Butoxycarbonyl (ethyl)amino)methyl)-1- (2-hydroxy-2- methylpropyl)-1H-imidazo[4,5-c] 
quinoline 5-oxide 8 (64 mg, 0.16 mmol) was dissolved in 5 mL of anhydrous dichloromethane. 
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Benzoylisocyanate (34 mg, 0.23 mmol) was added to the reaction mixture and refluxed for 30 
minutes. The solvent was then removed under vacuum and the residue was dissolved in 5 mL of 
anhydrous methanol. Excess of sodium methoxide was added and the reaction mixture was refluxed 
for 2-3 hours. After evaporating solvent under reduced pressure, the crude residue was purified 
using column chromatography (7% methanol/dichloromethane) to obtain tert-butyl (4-amino-1-(2-
hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl)methyl(ethyl)carbamate (46 mg, 72%). tert-
Butyl (4-amino-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl)methyl(ethyl)carbamate 
(13 mg, 0.03 mmol)  was dissolved in 3 mL of trifluoroacetic acid and stirred for 35 minutes. The 
solvent was removed under reduced pressure to afford quantitatively 16 mg of 1-(4-amino-2-
((ethylamino)methyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol as the trifluoroacetate salt 
9. The compound was eluted using column chromatography to obtain the free base form of 9 (13% 
methanol/dichloromethane). 1H NMR (400 MHz, MeOD) δ 8.28 (d, J = 7.7 Hz, 1H), 7.73 (dd, J = 8.4, 
1.0 Hz, 1H), 7.60 – 7.53 (m, 1H), 7.45 – 7.38 (m, 1H), 4.74 (s, 2H), 4.59 (s, 2H), 3.16 (q, J = 7.3 Hz, 
2H), 1.37 (t, J = 7.3 Hz, 3H), 1.30 (s, 6H). 13C NMR (101 MHz, MeOD) δ 151.14, 149.51, 142.03, 
135.36, 127.86, 125.74, 123.85, 122.53, 121.07, 114.71, 71.00, 55.27, 43.87, 42.97, 26.34, 11.26. 
MS (ESI) calculated for C17H23N5O, m/z 313.19, found 314.20 (M + H)
+. 
 
Synthesis of Compound 16: 1-(2-((ethylamino)methyl)-3H-imidazo[4,5-c]quinolin-3-yl)-2-
methylpropan-2-ol.  
 
tert-Butyl ethyl((3-(2-hydroxy-2-methylpropyl)-3H-imidazo[4,5-c]quinolin-2-yl)methyl)carbamate 13 
(15 mg, 0.04 mmol) was dissolved in 3 mL of trifluoroacetic acid and stirred for 35 minutes. The 
solvent was then removed under reduced pressure to obtain 1-(2-((ethylamino)methyl)-3H-
imidazo[4,5-c]quinolin-3-yl)-2-methylpropan-2-ol  as the trifluoroacetate salt 16 (19 mg, 95%). 1H 
N
N
N
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NMR (500 MHz, MeOD) δ 9.62 (d, J = 20.0 Hz, 1H), 8.67 (d, J = 8.1 Hz, 1H), 8.17 (d, J = 8.3 Hz, 
1H), 7.91 (dd, J = 11.3, 4.2 Hz, 1H), 7.87 (t, J = 7.5 Hz, 1H), 4.82 (s, 2H), 4.48 (s, 2H), 3.29 (q, J = 
7.2 Hz, 2H), 1.36 (t, J = 7.3 Hz, 3H), 1.23 (s, 6H). 13C NMR (126 MHz, MeOD) δ 156.46, 148.73, 
138.39, 135.72, 132.16, 131.12, 130.48, 123.81, 123.75, 122.85, 71.99, 56.31, 44.65, 44.63, 27.48, 
11.48. MS (ESI) calculated for C17H22N4O, m/z 298.18, found 299.19 (M + H)
+. 
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3.1. Introduction. 
 
Chronic immune activation is a hallmark of several infectious and autoimmune diseases. 
Dysregulated cellular and humoral immune responses in progressive HIV infection,109;110 for instance, 
leads to accelerated turnover of CD4+ lymphocytes, thereby providing a milieu for HIV replication.111 
The engagement of toll-like receptor-7 (TLR7) by single-stranded viral RNA (ssRNA) has recently 
been reported to play a central role in immune activation-driven HIV replication.117  Progressive CD4+ 
T lymphocyte depletion in non-human primate models is highly correlated with TLR7-mediated 
interferon- (IFN-) production by plasmacytoid dendritic cells, and antagonists of TLR7 have been 
shown to inhibit immune activation.117 In contrast to the predominantly CD4+ T lymphocyte-driven 
activation by TLR7- and 8- mediated recognition of HIV ssRNA, autoreactive B lymphocytes are 
thought to play an important role in the sustained generation of autoantibodies directed against both 
cytosolic and nuclear components contributing to the pathophysiology of disease states such as 
Systemic Lupus Erythematosis and Sjögren’s syndrome.124-129 TLR7 and TLR8 are thus logical 
targets for pharmacological intervention, and inhibitors for these endosomal receptors are being 
actively studied for potential use in the therapy of such autoimmune diseases.125;130;131 
  
Whereas small molecule agonists of TLR7 are well known,69;119;132 the only known class of TLR7 
antagonists, until recently, were single-stranded phosphorothioate oligonucleotides.133-136 En route to 
the synthesis of a TLR7-agonistic imidazoquinoline, gardiquimod, we synthesized its 3H regioisomer, 
which was found to be a weak TLR7 antagonist (Chapter 2).137 A des-amino precursor of the 3H 
regioisomer (4a, Scheme 1) was more potent as a TLR7 antagonist, with an IC50 value of 7.5 M;137 
negligible TLR8-antagonstic activity, however, was observed with this compound. Given the potential 
value of a detailed exploration of this chemotype toward obtaining leads for novel, and more potent 
TLR7/8 dual antagonists, we undertook the syntheses and evaluation of a preliminary library of 3H 
imidazoquinolines with the aim of identifying potential chemotypes capable of inhibiting both TLR7 
and TLR8.  
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3.2. Results and Discussion. 
 
Our point of departure was 4a (Scheme 1), a 4-desamino, 3H imidazoquinoline with a 2-methyl-
propan-2-ol substituent at N3, and a 2-(ethylamino)methylene substituent at C2.137 We first 
synthesized the N-oxide and C4-N-benzoyl derivatives (10, and 11, respectively; Scheme 1). Upon 
finding that neither compound showed any appreciable activity (Table 1), we elected to first examine 
a small subset of compounds with varying substituents at N3 (5a, 6a, 7a, 8a; Scheme 1). These 
compounds also were found to be either inactive (6a) or of low potency (5a, 7a, 8a; Table 1). 
 
Scheme 1. Syntheses of derivatives of 4a and N3-substituted 3H imidazoquinolines. 
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ii. DBU, 2,2-dimethyloxirane; iii. CF3COOH; iv. 3-Chloroperoxybenzoic acid, CH2Cl2, CHCl3, MeOH; v. (a) Benzoyl
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Structure Compound 
Number 
TLR7 
Antagonistic 
Activity (M) 
TLR8 
Antagonistic 
Activity (M) 
 
10 ND 46.5 
N
N
N
NH
NHCOPh
OH
 
11 ND 21.17 
 
4a 7.5 56.31 
N
N
N
O
NH
 
5a 28.02 59.64 
N
N
N
OH
NH
 
6a ND ND 
N
N
N
NH
 
7a 26.1 28.13 
 
8a 30.44 35.43 
Table 1. TLR7- and TLR8-antagonistic activities of the title compounds. ND denotes no significant activity 
detected at the highest concentration tested (250 M).  
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4b ND 38.42 
N
N
N
O
 
5b ND ND 
 
6b ND 37.24 
N
N
N
 
7b 14.85 13.71 
 
8b 21.63 25.81 
 
4c ND 38.73 
N
N
N
O
 
5c 19.9 40.01 
 
6c ND 20.32 
Table 1. contd.  N.D. denotes no significant activity detected at the highest concentration tested (250 M). 
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N
N
N
 
7c 21.87 21.12 
 
8c 22.04 24.3 
 
4d 14.4 52.94 
N
N
N
C9H19
O
 
5d 19.44 46.4 
N
N
N
C9H19
OH
 
6d ND 4.81 
N
N
N
C9H19
 
7d 8.58 10.07 
 
8d 10.14 68.8 
N
N
N
O
O
Cl- 12 2.79 4.55 
Table 1. contd.  N.D. denotes no significant activity detected at the highest concentration tested (250 M).  
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We next attempted generating a small subset (15 compounds) in which the substituents at N3 and C2 
were combinatorially varied. Since this was an exploratory library, we chose the C2 substituents from 
among planar, aromatic (phenyl), a cycloaliphatic (cyclohexyl), and a long-chain aliphatic (nonyl) 
groups (Scheme 2), while preserving the N3 substituents that we had used in Scheme 1. Alkylation of 
the 3 series of compounds afforded, as expected, three sets of regioisomers. In order to 
unambiguously characterize the position of the alkyl groups in these isomers, we correlated the 
crystal structure of 4b with its 2D-NOESY spectrum (Fig. 1, overleaf). The NOESY spectrum showed 
diagnostic NOEs between the methylene protons on N3 (atom 20) with the quinoline proton (atom 9), 
as well as the phenyl protons (atoms 15, 19). Also seen, as would be expected, are NOEs between 
the methylene protons on N3 (atom 20) with the terminal dimethyl protons on the N3 substituent (Fig. 
1). 
 
Scheme 2. Syntheses of N3 and C2 modified 3H imidazoquinoline compounds. 
N
NH2
NH2
N
N
H
N
R1
N
N
N
R1
N
N
N
R1
N
N
N
R1N
N
N
N
N
N
R1
OH O
OH
ii iii iv v vi
Reagents: i. Polyphosphoric acid, R1-COOH, 180
oC; ii. DBU, 2,2-dimethyloxirane;
iii. 1-(Chloromethyl)-4-methoxybenzene, DBU, THF, 80 oC; iv. 3-Bromo-1-propanol, DBU, DMF, 80 oC;
v. Propargyl bromide, DBU, THF, 90 oC; vi. Methyl iodide, DBU, THF.
C9H19R1 = , ,
b c d
1 3 b-d
4 b-d 5 b-d 6 b-d 7 b-d 8 b-d
i
R1
 45  
Most of these compounds displayed modest activity, with exceptions being the C2-nonyl-substituted 
7d and 8d compounds exhibiting low micromolar TLR7-inhibitory activity. 7d was also found to be 
TLR8-antagonistic (IC50: 10 M, Table 1).  
 
During the synthesis of 5b, one of the side-products, 12, corresponded in mass- and NMR-spectral 
characteristics to a bis-alkylated compound. This was isolated and was found to be the best-in-class 
in both TLR7- and TLR8-antagonism assays, with IC50 values of 2.79 and 4.55 M, respectively 
(Table 1). In order to determine whether 12 was a quinolinium or imidazolinium species, we 
synthesized the mono-alkylated quinolinium 13 and the 1H regioisomer 17 (Scheme 3, overleaf).  
The structure of compound 13 could be either the charged species or its uncharged tautomer as 
shown in Scheme 3. The dialkyl species 12 was obtained using an excess of 1-(chloromethyl)-4-
methoxybenzene, using DBU as base, and in THF at 150 oC, whereas 13 was obtained in the 
absence of DBU and in DMF at 1200C. The 1H regioisomer 17 was synthesized by pre-installing the 
p-methoxybenzyl substituent on N1 (Scheme 3). We characterized the monoalkylated regioisomers 
5b, 13, and 17 (Scheme 3) via 2D-NOESY experiments (Fig. 2, overleaf). 
 
Fig. 1. Crystal structure (Left) and 2D-NOESY (right) of Compound 4b. 
 
 46  
 
 
 
 
 
 
N
N
N
O
O
12
N
N
H
N
N
N
H
N
O
3b
13
N
N
N
16
N
Cl
NO2
O
N
NH
NO2
15
O
14
H2N
O
17
Reagents: i. 1-(Chloromethyl)-4-methoxybenzene, DBU, THF, 150 oC; ii. 1-(Chloromethyl)-4-methoxybenzene,
DMF, 120 oC; iii. N,N-diethylpropan-2-amine, toluene:2-propanol (4:1), 70 oC; iv. (a) H2, Pd/C, 60 psi, MeOH; (b)
Benzoic acid, HBTU, Et3N, DMAP, DMF.
i
ii
iii iv
Cl-
N
N
N
O
or
Scheme 3. Syntheses of analogues of 5b. 
Fig. 2. 2D-NOESY spectra of compounds 5b, 13, 17 and 12. 
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Compounds 5b, 13, and 17 are all monoalkylated species, with the p-methoxybezyl substituent at the 
N3 (imidazole), N5 (quinolinium), N1 (imidazole), respectively. Each of these compounds showed 
characteristic and diagnostic NOE crosspeaks. In 5b (as in 4b, discussed earlier), NOEs between 
the methylene protons on N3 (atom 20) with the quinoline proton (atom 9), as well as the phenyl 
protons (atoms 15, 19); compound 13 showed NOEs between the methylene protons on N5 (atom 
20) with the quinoline protons (atoms 9 and 6); compound 17 was distinguished by crosspeaks 
between phenyl protons (atoms 15, 19) and the quinoline proton (atom 3) (Fig. 2). The clear NOE 
patterns helped establish unequivocally that the additional p-methoxybenzyl substituent in compound 
12 was on the quinoline nitrogen (N5) because of NOEs similar to both 13 and 5b (Fig. 2). 
 
Compound 12, to our considerable surprise, showed the highest potency in simultaneously inhibiting 
both TLR7 and TLR8 (Table 1, Fig. 3). This was unexpected since the quinolinium compound with its 
fixed charge is generally thought to be relatively membrane-impermeant and, as discussed earlier, 
both TLR7 and TLR8 are compartmentalized in the endosome.  
 
 
Fig. 3. 2D-Scatter plot of TLR7 (abscissa) and TLR8 (ordinate) -antagonistic activities of the title compounds. 
Compounds that do not show significant inhibitory activity have been omitted. 
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3.3. Conclusions. 
 
A pilot library of 3H imidazoquinolines have been synthesized, characterized, and evaluated for 
biological activity. Although possessing modest activity, a dual TLR7/TLR8 antagonist (12) has been 
identified with micromolar potencies. These preliminary results have been instructive in that they 
already point to strategies for improvement in potency. For instance, the monoalkylated compounds 
7b and 7d, bearing propargyl groups on N3, ranked next in potency to 12, are attractive leads for 
additional alkylation with electron-rich substituents on the quinoline N5. As mentioned earlier, the 
quaternary amine on the quinolinium of 12 may deter optimal trans-membrane transport and 
concentration in the endosomal compartment, and carbocyclic analogues may be evaluated to 
carefully examine the effect of the fixed charge. 
 
The principal thrust in our laboratory, however, is on evaluating TLR agonists as potential vaccine 
adjuvants. Future chapters (Chapters 4-7), consequently, focuses on the syntheses and evaluation 
of TLR7 and TLR8 agonistic 1H imidazoquinolines. 
 49  
 
3.4. Experimental. 
 
All of the solvents and reagents used were obtained commercially and used as such unless noted 
otherwise. Moisture- or air-sensitive reactions were conducted under nitrogen atmosphere in oven-
dried (120 oC) glass apparatus. The solvents were removed under reduced pressure using standard 
rotary evaporators. Flash column chromatography was carried out using RediSep Rf ‘Gold’ high 
performance silica columns on CombiFlash Rf instrument unless otherwise mentioned, while thin-
layer chromatography was carried out on silica gel CCM pre-coated aluminum sheets. Purity for all 
final compounds was confirmed to be greater than 97% by LC-MS using a Zorbax Eclipse Plus 4.6 
mm x 150 mm, 5 m analytical reverse phase C18 column with H2O-isopropanol or H2O-CH3CN 
gradients and an Agilent ESI-TOF mass spectrometer (mass accuracy of 3 ppm) operating in the 
positive ion acquisition mode. All the compounds synthesized were obtained as solids. 
 
Synthesis of Compound 2: tert-butyl (1H-imidazo[4,5-c]quinolin-2-yl)methyl(ethyl) carbamate.  
 
To a solution of 2-(tert-butoxycarbonyl(ethyl)amino)acetic acid (575 mg, 2.83 mmol) in anhydrous 
DMF, were added HATU (1.31 g, 3.46 mmol), triethylamine (350 mg, 3.46 mmol), a catalytic amount 
of DMAP and 1 (500 mg, 3.14 mmol). The reaction mixture was stirred for 10-12 hours. The solvent 
was then removed under vacuum and the residue was dissolved in EtOAc, washed with water, dried 
over sodium sulfate and concentrated to obtain the residue, which was dissolved in 30 mL of ethanol 
and a solution of NaOH (300 mg, 7.46 mmol) in 2 mL of water was added to it. The reaction mixture 
was refluxed for 5-6 hours, followed by evaporation under reduced pressure to obtain the residue, 
which was then purified using column chromatography (3% MeOH/dichloromethane) to obtain the 
compound 2 (575 mg, 56%). 1H NMR (500 MHz, MeOD) δ 8.98 (s, 1H), 8.31 (d, J = 6.0 Hz, 1H), 8.03 
(d, J = 8.5 Hz, 1H), 7.66 – 7.55 (m, 2H), 4.71 (s, 2H), 3.39 (d, J = 39.4 Hz, 2H), 1.42 (s, 5H), 1.20 (s, 
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4H), 1.08 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 175.53, 157.20, 152.53, 144.10, 129.79, 127.40, 
126.60, 121.11, 81.10, 45.32, 43.67, 29.70, 28.41, 13.64. MS (ESI) calculated for C18H22N4O2, m/z 
326.1743, found 327.1209 (M + H)+. 
 
Synthesis of Compound 4a: 1-(2-((ethylamino)methyl)-3H-imidazo[4,5-c]quinolin-3-yl)-2-
methylpropan-2-ol.  
 
To a solution of 2 (95 mg, 0.29 mmol) in 5 mL of 2,2-dimethyloxirane, was added DBU (110 mg, 0.73 
mmol). The reaction mixture was refluxed for 18 hours. The solvent was then evaporated under 
vacuum and the residue was purified using column chromatography (2% MeOH/dichloromethane) to 
obtain the compound 3a. Compound 3a (15 mg, 0.04 mmol) was then dissolved in 3 mL of 
trifluoroacetic acid and stirred for 35 minutes. The solvent was then removed under reduced 
pressure to obtain the compound 4a (19 mg, 95%). 1H NMR (500 MHz, MeOD) δ 9.62 (d, J = 20.0 
Hz, 1H), 8.67 (d, J = 8.1 Hz, 1H), 8.17 (d, J = 8.3 Hz, 1H), 7.91 (dd, J = 11.3, 4.2 Hz, 1H), 7.87 (t, J = 
7.5 Hz, 1H), 4.82 (s, 2H), 4.48 (s, 2H), 3.29 (q, J = 7.2 Hz, 2H), 1.36 (t, J = 7.3 Hz, 3H), 1.23 (s, 6H). 
13C NMR (126 MHz, MeOD) δ 156.46, 148.73, 138.39, 135.72, 132.16, 131.12, 130.48, 123.81, 
123.75, 122.85, 71.99, 56.31, 44.65, 44.63, 27.48, 11.48. MS (ESI) calculated for C17H22N4O, m/z 
298.1794, found 299.1860 (M + H)+. 
 
Synthesis of Compound 10: 2-((ethylamino)methyl)-3-(2-hydroxy-2-methylpropyl)-3H-
imidazo[4,5-c]quinoline 5-oxide.  
N
N
N
OH
NH
4a
 51  
 
Compound 3a (145 mg, 0.36 mmol) was dissolved in 10 mL of anhydrous 
dichloromethane/chloroform (1:1) and 1 mL of anhydrous MeOH. 3-Chloro-peroxybenzoic acid (188 
mg, 1.09 mmol) was added and the reaction mixture was refluxed for 30 minutes. The solvent was 
then removed under vacuum and the residue was purified using column chromatography (4% 
MeOH/dichloromethane) to obtain the compound 9 (100 mg, 66%). Compound 9 (28 mg, 0.07 mmol) 
was then dissolved in 5 mL of trifluoroacetic acid and stirred for 30 minutes. The solvent was then 
removed and the residue was washed with diethyl ether to obtain the compound 10 (40 mg, 95%). 1H 
NMR (400 MHz, MeOD) δ 9.46 (s, 1H), 8.77 – 8.67 (m, 1H), 8.66 – 8.55 (m, 1H), 8.00 – 7.86 (m, 
2H), 4.81 (s, 2H), 4.41 (s, 2H), 3.39 (q, J = 7.3, 2H), 1.48 (t, J = 7.3, 3H), 1.31 (s, 6H). 13C NMR (101 
MHz, MeOD) δ 151.64, 139.07, 137.10, 129.59, 129.53, 128.75, 127.64, 122.22, 122.06, 119.15, 
70.58, 54.56, 43.12, 43.07, 26.06, 10.09. MS (ESI) calculated for C17H22N4O2, m/z 314.1743, found 
315.1764 (M + H)+. 
 
Synthesis of Compound 11: N-(2-((ethylamino)methyl)-3-(2-hydroxy-2-methylpropyl)-3H-
imidazo[4,5-c]quinolin-4-yl)benzamide. 
 
To a solution of 9 (68 mg, 0.16 mmol) in 5 mL of anhydrous dichloromethane, was added 
benzoylisocyanate (36 mg, 0.25 mmol) and the reaction mixture was refluxed for 30 minutes. The 
solvent was then removed under vacuum and the residue was purified using column chromatography 
to obtain tert-butyl (4-benzamido-3-(2-hydroxy-2-methylpropyl)-3H-imidazo[4,5-c]quinolin-2-
yl)methyl(ethyl)carbamate (30 mg, 35%), which was N-Boc deprotected by stirring in 5 mL of 
10
N
N
N
OH
NH
O
11
N
N
N
NH
NHCOPh
OH
 52  
trifluoroacetic acid for 30 minutes The solvent was then removed and the residue was washed with 
diethyl ether to obtain the compound 11 (35 mg, 95%). 1H NMR at 50oC (400 MHz, MeOD) δ 8.42 (d, 
J = 8.1 Hz, 1H), 8.25 (d, J = 7.3 Hz, 2H), 7.81 – 7.73 (m, 1H), 7.72 – 7.65 (m, 1H), 7.57 (t, J = 6.7 Hz, 
2H), 7.50 (t, J = 7.4 Hz, 2H), 5.19 (s, 2H), 4.80 (s, 2H), 3.35 (q, J = 7.3 Hz, 2H), 1.45 (t, J = 7.3 Hz, 
3H), 1.31 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 178.99, 155.88, 151.18, 145.60, 137.98, 133.28, 
131.79, 129.13, 128.93, 128.15, 125.10, 122.17, 118.43, 117.99, 70.60, 56.37, 45.68, 44.04, 27.42, 
14.81. MS (ESI) calculated for C24H27N5O2, m/z 417.2165, found 418.2137 (M + H)
+
. 
 
Synthesis of Compound 5a: N-((3-(4-methoxybenzyl)-3H-imidazo[4,5-c]quinolin-2-
yl)methyl)ethanamine. 
 
To a solution of 2 (50 mg, 0.15 mmol) in 1 mL of anhydrous THF, were added DBU (47 mg, 0.31 
mmol) and 1-(chloromethyl)-4-methoxybenzene (96 mg, 0.61 mmol). The solution was then heated in 
a sealed vessel at 80 oC for 1 hour. After cooling to room temperature, and removing solvent under 
vacuum, the residue was dissolved in EtOAc and washed with water, dried over sodium sulfate, 
concentrated and purified using column chromatography (1% MeOH/dichloromethane) to obtain the 
compound tert-butyl ethyl((3-(4- methoxybenzyl)-3H-imidazo [4,5-c]quinolin-2-yl)methyl)carbamate, 
which was dissolved in 5 mL of trifluoroacetic acid and stirred for 30 minutes. The solvent was then 
removed and the residue was washed with diethyl ether to obtain the compound 5a (18 mg, 21%). 1H 
NMR (400 MHz, MeOD) δ 9.46 (s, 1H), 8.85 – 8.71 (m, 1H), 8.28 (d, J = 8.0, 1H), 8.07 – 7.93 (m, 
2H), 7.31 (d, J = 8.8 Hz, 2H), 7.04 – 6.95 (m, 2H), 5.77 (s, 2H), 4.81 (s, 2H), 3.80 (s, 3H), 3.40 (q, J = 
7.3 Hz, 2H), 1.48 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, MeOD) δ 160.28, 153.97, 147.68, 133.33, 
130.79, 129.07, 128.77, 128.59, 125.90, 122.61, 122.29, 121.52, 114.47, 54.42, 47.95, 43.33, 42.91, 
10.00. MS (ESI) calculated for C21H22N4O, m/z 346.1794, found 347.1890 (M + H)
+
. 
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Synthesis of Compound 6a: 3-(2-((ethylamino)methyl)-3H-imidazo[4,5-c]quinolin-3-yl)propan-
1-ol. 
 
To a solution of 2 (50 mg, 0.15 mmol) in 1 mL of anhydrous THF, were added DBU (47 mg, 0.31 
mmol) and 3-bromopropan-1-ol (32 mg, 0.23 mmol). The solution was then heated in a sealed vessel 
at 80 oC for an hour. After cooling to room temperature, and removing solvent under vacuum, the 
residue was dissolved in EtOAc and washed with water, dried over sodium sulfate, concentrated and 
purified using column chromatography to obtain tert-butyl ethyl((3-(3-hydroxypropyl)-3H-imidazo[4,5-
c]quinolin-2-yl)methyl)carbamate (9 mg, 15%), which was dissolved in 8 mL of trifluoroacetic acid 
and stirred for 30 minutes. The solvent was then removed and the residue was washed with diethyl 
ether to obtain compound 6a (11 mg, 95%). 1H NMR (400 MHz, MeOD) δ 9.24 (s, 1H), 8.60 – 8.52 
(m, 1H), 8.21 – 8.09 (m, 1H), 7.81 – 7.67 (m, 2H), 4.68 (t, J = 6.8 Hz, 2H), 4.31 (s, 2H), 3.58 – 3.50 
(m, 2H), 2.88 (q, J = 7.2 Hz, 2H), 2.28 – 2.14 (m, 2H), 1.25 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, 
MeOD) δ 154.25, 143.61, 136.25, 128.49, 128.17, 127.45, 126.88, 121.74, 121.20, 57.03, 44.36, 
43.42, 40.91, 32.25, 13.04. MS (ESI) calculated for C16H20N4O, m/z 284.1637, found 285.1752 (M + 
H)+. 
 
Synthesis of Compound 7a: N-((3-(prop-2-ynyl)-3H-imidazo[4,5-c]quinolin-2-yl)methyl) 
ethanamine. 
To a solution 2 (65 mg, 0.2 mmol) in 1 mL of anhydrous THF, were added DBU (61 mg, 0.4 mmol) 
and 80% propargyl bromide in toluene (119 mg, 1.0 mmol). The solution was then heated in a sealed 
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vessel at 90 oC for 30 minutes. After cooling to room temperature, and removing the solvent under 
vacuum, the residue was dissolved in EtOAc and washed with water, dried over sodium sulfate, 
concentrated and purified using column chromatography to obtain tert-butyl ethyl((3-(prop-2-ynyl)-
3H-imidazo[4,5-c]quinolin-2-yl)methyl)carbamate, which was dissolved in 5 mL of trifluoroacetic acid 
and stirred for 30 minutes. The solvent was then removed and the residue was washed with diethyl 
ether to obtain the compound 7a (23 mg, 43%). 1H NMR (400 MHz, MeOD) δ 9.74 (s, 1H), 8.77 (dd, 
J = 8.1, 1.1 Hz, 1H), 8.30 (d, J = 8.1 Hz, 1H), 8.08 – 7.92 (m, 2H), 5.54 (d, J = 2.6 Hz, 2H), 4.95 (s, 
2H), 3.45 (q, J = 7.2 Hz, 2H), 3.27 (t, J = 2.5 Hz, 1H), 1.52 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, 
MeOD) δ 153.17, 147.34, 137.95, 133.55, 130.69, 129.01, 128.14, 123.11, 122.21, 121.49, 76.40, 
75.07, 43.38, 42.62, 34.26, 10.02. MS (ESI) calculated for C16H16N4, m/z 264.1375, found 265.1553 
(M + H)+. 
 
Synthesis of Compound 8a: N-((3-methyl-3H-imidazo[4,5-c]quinolin-2-yl)methyl)ethanamine. 
 
To a solution of 2 (50 mg, 0.15 mmol) in 1 mL of anhydrous THF, were added DBU (47 mg, 0.31 
mmol) and iodomethane (33 mg, 0.23 mmol). The solution was stirred for an hour and the solvent 
was then removed under vacuum. The residue was dissolved in EtOAc, washed with water, dried 
over sodium sulfate, concentrated and purified using column chromatography (30% 
EtOAc/dichloromethane) to obtain tert-butyl ethyl((3-methyl-3H- imidazo[4,5-c]quinolin-2-yl) 
methyl)carbamate (7 mg, 20%), which was dissolved in 5 mL of trifluoroacetic acid and stirred for 30 
minutes. The solvent was then removed and the residue was washed with diethyl ether to obtain the 
compound 8a (13 mg, 95%). 1H NMR (400 MHz, MeOD) δ 9.72 (s, 1H), 8.79 (d, J = 7.9 Hz, 1H), 8.30 
(d, J = 8.2 Hz, 1H), 8.14 – 7.91 (m, 2H), 4.91 (s, 2H), 4.18 (s, 3H), 3.45 (q, J = 7.3 Hz, 2H), 1.52 (t, J 
= 7.3 Hz, 3H). 13C NMR (101 MHz, MeOD) δ 154.89, 147.95, 136.50, 132.91, 130.97, 129.23, 
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129.14, 122.38, 121.87, 121.36, 43.38, 42.48, 30.57, 10.01. MS (ESI) calculated for C14H16N4, m/z 
240.1375, found 241.1476 (M + H)+. 
 
Synthesis of Compound 3b: 2-phenyl-3H-imidazo[4,5-c]quinoline. 
 
To a mixture of 1 (450 mg, 2.83 mmol) and benzoic acid (691 mg, 5.66 mmol), was added 
polyphosphoric acid (appx. 25 mL) and heated to 180 oC for an hour. The reaction mixture was then 
slowly cooled to room temperature and the polyphosphoric acid was slowly neutralized with 
ammonium hydroxide until the pH was around 8. The compound was then extracted using EtOAc 
and the EtOAc fraction was then washed with water, dried over sodium sulfate, concentrated and 
purified using column chromatography (4% MeOH/ dichloromethane) to afford the compound 3b 
(315 mg, 45%). 1H NMR (400 MHz, MeOD) δ 9.07 (s, 1H), 8.44 (d, J = 6.9 Hz, 1H), 8.18 – 8.16 (m, 
1H), 8.16 – 8.15 (m, 1H), 8.11 – 8.06 (m, 1H), 7.72 – 7.62 (m, 2H), 7.60 – 7.52 (m, 3H). 13C NMR 
(101 MHz, MeOD) δ 143.22, 130.45, 129.06, 128.84, 128.14, 127.48, 126.74, 126.63, 121.39. MS 
(ESI) calculated for C16H11N3, m/z 245.0953, found 246.1025 (M + H)
+
.  
 
Synthesis of Compound 4b: 2-methyl-1-(2-phenyl-3H-imidazo[4,5-c]quinolin-3-yl)propan-2-ol. 
 
To a solution of 3b (50 mg, 0.2 mmol) in 1 mL of 2,2-dimethyloxirane, was added DBU (62 mg, 0.41 
mmol) and the solution was heated under microwave conditions (600 W, 80 oC, 1h). After cooling to 
room temperature, and removing the solvent under vacuum, the residue was dissolved in EtOAc and 
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washed with water, dried over sodium sulfate, concentrated and purified using column 
chromatography (4% MeOH/dichloromethane) to obtain the compound 4b (24 mg, 38 %). 1H NMR 
(400 MHz, MeOD) δ 9.34 (s, 1H), 8.65 – 8.51 (m, 1H), 8.17 – 8.13 (m, 1H), 7.87 – 7.79 (m, 2H), 7.78 
– 7.69 (m, 2H), 7.67 – 7.63 (m, 3H), 4.59 (s, 2H), 1.00 (s, 6H). 13C NMR (101 MHz, MeOD) δ 155.90, 
143.40, 143.02, 139.02, 130.15, 129.95, 129.85, 129.76, 128.72, 128.04, 127.46, 126.80, 121.65, 
121.37, 70.71, 55.09, 26.19. MS (ESI) calculated for C20H19N3O, m/z 317.1528, found 318.1631 (M + 
H)+. 
 
Synthesis of Compound 5b: 3-(4-methoxybenzyl)-2-phenyl-3H-imidazo[4,5-c]quinoline. 
 
To a solution of 3b (50 mg, 0.2 mmol) in 1 mL of anhydrous THF, were added DBU (62 mg, 0.41 
mmol) and 1-(chloromethyl)-4-methoxybenzene (128 mg, 0.82 mmol). The solution was then heated 
in a sealed vessel at 80 oC for an hour. After cooling to room temperature, and removing the solvent 
under vacuum, the residue was dissolved in EtOAc and washed with water, dried over sodium 
sulfate, concentrated and purified using column chromatography (8% EtOAc/dichloromethane) to 
obtain the compound 5b (36 mg, 33%). 1H NMR (400 MHz, CDCl3) δ 8.92 (s, 1H), 8.73 – 8.69 (m, 
1H), 8.24 – 8.20 (m, 1H), 7.82 – 7.77 (m, 2H), 7.74 – 7.69 (m, 2H), 7.59 – 7.53 (m, 3H), 7.06 (d, J = 
8.8 Hz, 2H), 6.90 – 6.84 (m, 2H), 5.60 (s, 2H), 3.80 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 159.52, 
154.86, 144.69, 144.54, 136.63, 130.42, 129.67, 129.62, 129.55, 129.11, 129.01, 128.30, 127.66, 
127.53, 127.45, 126.86, 122.42, 121.87, 114.64, 55.33, 48.60. MS (ESI) calculated for C24H19N3O, 
m/z 365.1528, found 366.1491 (M + H)+. 
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Synthesis of Compound 6b: 3-(2-phenyl-3H-imidazo[4,5-c]quinolin-3-yl)propan-1-ol. 
 
To a solution of 3b (60 mg, 0.25 mmol) in 2 mL of anhydrous DMF, were added DBU (62 mg, 0.41 
mmol) and 3-bromopropan-1-ol (139 mg, 1.0 mmol). The solution was then heated in a sealed vessel 
at 80 oC for 2 hours. After cooling to room temperature, and removing the solvent under vacuum, the 
residue was dissolved in EtOAc and washed with water, dried over sodium sulfate, concentrated and 
purified using column chromatography (20% acetone/dichloromethane) to obtain the compound 6b 
(13 mg, 18%). 1H NMR (400 MHz, MeOD) δ 9.30 (s, 1H), 8.60 (dt, J = 5.0, 2.2 Hz, 1H), 8.21 – 8.17 
(m, 1H), 7.89 – 7.85 (m, 2H), 7.79 – 7.71 (m, 2H), 7.67 (dd, J = 4.2, 2.4 Hz, 3H), 4.74 – 4.60 (m, 2H), 
3.55 (t, J = 4.6 Hz, 2H), 2.12 – 2.03 (m, 2H). 13C NMR (101 MHz, MeOD) δ 155.37, 143.79, 143.53, 
136.59, 130.46, 129.65, 129.38, 129.15, 128.78, 128.22, 127.59, 126.93, 121.70, 121.40, 58.02, 
42.26, 32.70. MS (ESI) calculated for C19H17N3O, m/z 303.1372, found 304.1440 (M + H)
+
. 
 
Synthesis of Compound 7b: 2-phenyl-3-(prop-2-ynyl)-3H-imidazo[4,5-c]quinoline. 
To a solution of 3b (50 mg, 0.21 mmol) in 1 mL of anhydrous THF, were added DBU (62 mg, 0.41 
mmol) and 80% propargyl bromide in toluene (98 mg, 0.82 mmol). The solution was then heated in a 
sealed vessel at 90 oC for an hour. After cooling to room temperature, and removing the solvent 
under vacuum, the residue was dissolved in EtOAc and washed with water, dried over sodium 
sulfate, concentrated and purified using column chromatography (35% EtOAc/dichloromethane) to 
obtain the compound 7b (6 mg, 10%). 1H NMR (400 MHz, CDCl3) δ 9.31 (s, 1H), 8.72 – 8.67 (m, 1H), 
8.30 – 8.25 (m, 1H), 7.97 – 7.90 (m, 2H), 7.69 – 7.77 (m, 2H), 7.67 – 7.60 (m, 3H), 5.15 (d, J = 2.5, 
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2H), 2.59 (t, J = 2.5 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 144.90, 136.03, 130.66, 129.72, 129.69, 
129.17, 128.63, 127.60, 126.95, 121.90, 75.11, 35.35. MS (ESI) calculated for C19H13N3, m/z 
283.1109, found 284.1046 (M + H)+. 
 
Synthesis of Compound 8b: 3-methyl-2-phenyl-3H-imidazo[4,5-c]quinoline. 
 
To a solution of 3b (40 mg, 0.16 mmol) in 1 mL of anhydrous THF, were added DBU (73 mg, 0.48 
mmol) and iodomethane (114 mg, 0.8 mmol). The solution was stirred for 30 minutes and the solvent 
was then removed under vacuum to obtain the residue, which was dissolved in EtOAc, washed with 
water, dried over sodium sulfate, concentrated and purified using column chromatography (20% 
EtOAc/dichloromethane) to obtain the compound 8b (15 mg, 36%). 1H NMR (400 MHz, CDCl3) δ 
8.92 – 8.85 (m, 1H), 8.75 (s, 1H), 8.53 (dd, J = 8.3, 1.4 Hz, 2H), 7.83 – 7.67 (m, 3H), 7.55 – 7.44 (m, 
3H), 4.29 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.40, 154.97, 139.30, 135.84, 134.27, 134.02, 
129.75, 129.35, 128.61, 128.17, 126.36, 124.91, 121.36, 116.61, 43.88. MS (ESI) calculated for 
C17H13N3, m/z 259.1109, found 260.1188 (M + H)
+
. 
 
Synthesis of Compound 3c: 2-cyclohexyl-3H-imidazo[4,5-c]quinoline. 
 
To a mixture of 1 (450 mg, 2.83 mmol) and cyclohexanecarboxylic acid (725 mg, 5.66 mmol), was 
added polyphosphoric acid (appx. 25 mL) and heated to 180 oC for an hour. The reaction mixture 
was then slowly cooled to room temperature and the polyphosphoric acid was slowly neutralized with 
ammonium hydroxide until the pH was around 8. The compound was then extracted using EtOAc 
and the EtOAc fraction was then washed with water, dried over sodium sulfate, concentrated and 
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purified using column chromatography (3% MeOH/ dichloromethane) to afford the compound 3c (409 
mg, 58%). 1H NMR (500 MHz, MeOD) δ 8.93 (s, 1H), 8.25 (s, 1H), 7.98 (t, J = 8.2 Hz, 1H), 7.63 – 
7.52 (m, 2H), 3.02 – 2.87 (m, 1H), 2.09 – 2.01 (m, 2H), 1.83 (dd, J = 10.4, 7.3 Hz, 2H), 1.69 (dd, J = 
14.8, 8.0 Hz, 1H), 1.67 – 1.59 (m, 2H), 1.46 – 1.35 (m, 2H), 1.34 – 1.22 (m, 1H). 13C NMR (126 MHz, 
MeOD) δ 144.54, 129.56, 128.68, 127.95, 122.57, 40.03, 32.89, 27.16, 26.91. MS (ESI) calculated 
for C16H17N3, m/z 251.1422, found 252.1565 (M + H)
+
. 
 
Synthesis of Compound 4c: 2-methyl-1-(2-cyclohexyl-3H-imidazo[4,5-c]quinolin-3-yl)propan-2-
ol. 
To a solution of 3c (50 mg, 0.2 mmol) in 1 mL of 2,2-dimethyloxirane, was added DBU (61 mg, 0.4 
mmol) and the solution was heated under microwave conditions (600 W, 80 oC, 1h). After cooling to 
room temperature, and removing the solvent under vacuum, the residue was dissolved in EtOAc and 
washed with water, dried over sodium sulfate, concentrated and purified using column 
chromatography (5% MeOH/dichloromethane) to obtain the compound 4c (42 mg, 65 %). 1H NMR 
(400 MHz, MeOD) δ 9.19 (s, 1H), 8.70 – 8.56 (m, 1H), 8.14 – 8.05 (m, 1H), 7.74 – 7.61 (m, 2H), 4.43 
(s, 2H), 3.33 (dt, J = 3.3, 1.6 Hz, 1H), 2.07 – 1.80 (m, 7H), 1.62 – 1.42 (m, 3H), 1.32 (s, 6H). 13C 
NMR (101 MHz, MeOD) δ 162.55, 143.37, 143.26, 137.65, 128.97, 127.93, 127.12, 126.50, 121.56, 
121.47, 70.32, 53.88, 36.16, 31.55, 26.26, 25.84, 25.53. MS (ESI) calculated for C20H25N3O, m/z 
323.1998, found 324.2084 (M + H)+. 
 
Synthesis of Compound 5c: 2-cyclohexyl-3-(4-methoxybenzyl)-3H-imidazo[4,5-c]quinoline. 
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To a solution of 3c (50 mg, 0.2 mmol) in 1 mL of anhydrous THF, were added DBU (62 mg, 0.4 
mmol) and 1-(chloromethyl)-4-methoxybenzene (125 mg, 0.8 mmol). The solution was then heated in 
a sealed vessel at 80 oC for 1 hour. After cooling to room temperature, and removing the solvent 
under vacuum, the residue was dissolved in EtOAc and washed with water, dried over sodium 
sulfate, concentrated and purified using column chromatography (15% EtOAc/dichloromethane) to 
obtain the compound 5c (9 mg, 12%). 1H NMR (400 MHz, CDCl3) δ 8.88 (s, 1H), 8.70 – 8.60 (m, 1H), 
8.18 (dd, J = 6.6, 2.9 Hz, 1H), 7.72 – 7.60 (m, 2H), 7.04 (d, J = 8.8 Hz, 2H), 6.92 – 6.80 (m, 2H), 5.50 
(s, 2H), 3.79 (s, 3H), 2.96 (s, 1H), 2.00 – 1.67 (m, 7H), 1.41 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
159.52, 135.86, 129.47, 127.60, 127.07, 126.42, 122.31, 121.95, 114.57, 55.33, 47.06, 36.74, 31.84, 
26.25, 25.61. MS (ESI) calculated for C24H25N3O, m/z 371.1998, found 372.1990 (M + H)
+
. 
 
 
Synthesis of Compound 6c: 3-(2-cyclohexyl-3H-imidazo[4,5-c]quinolin-3-yl)propan-1-ol. 
 
To a solution of 3c (60 mg, 0.24 mmol) in 1 mL of anhydrous DMF, were added DBU (62 mg, 0.41 
mmol) and 3-bromopropan-1-ol (167 mg, 1.2 mmol). The solution was then heated in a sealed vessel 
at 80 oC for an hour. After cooling to room temperature, and removing the solvent under vacuum, the 
residue was dissolved in EtOAc and washed with water, dried over sodium sulfate, concentrated and 
purified using column chromatography (22% acetone/dichloromethane) to obtain the compound 6c 
(12 mg, 16%). 1H NMR (400 MHz, MeOD) δ 9.18 (s, 1H), 8.66 – 8.59 (m, 1H), 8.12 (dt, J = 4.8, 2.8 
Hz, 1H), 7.72 – 7.67 (m, 2H), 4.61 (t, J = 7.2 Hz, 2H), 3.64 (dd, J = 12.7, 7.0 Hz, 2H), 3.27 – 3.16 (m, 
1H), 2.15 – 2.09 (m, 2H), 2.05 – 1.85 (m, 8H), 1.66 – 1.39 (m, 2H). 13C NMR (101 MHz, MeOD) δ 
N
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161.46, 143.61, 135.86, 128.04, 127.90, 127.22, 126.61, 121.63, 121.44, 57.72, 40.52, 35.95, 32.95, 
31.62, 25.82, 25.49. MS (ESI) calculated for C19H23N3O, m/z 309.1841, found 310.1927 (M + H)
+
. 
 
Synthesis of Compound 7c: 2-cyclohexyl-3-(prop-2-ynyl)-3H-imidazo[4,5-c]quinoline. 
 
To a solution of 3c (60 mg, 0.24 mmol) in 1 mL of anhydrous THF, were added DBU (73 mg, 0.48 
mmol) and 80% propargyl bromide in toluene (143 mg, 1.2 mmol). The solution was then heated in a 
sealed vessel at 90 oC for 30 minutes. After cooling to room temperature, and removing the solvent 
under vacuum, the residue was dissolved in EtOAc and washed with water, dried over sodium 
sulfate, concentrated and purified using column chromatography (35% EtOAc/dichloromethane) to 
obtain the compound 7c (8 mg, 12%). 1H NMR (400 MHz, CDCl3) δ 9.16 (s, 1H), 8.65 – 8.56 (m, 1H), 
8.28 – 8.11 (m, 1H), 7.75 – 7.60 (m, 2H), 5.09 (d, J = 2.5 Hz, 2H), 3.00 (m, 1H), 2.48 (t, J = 2.5 Hz, 
1H), 2.11 (m, 2H), 2.04 – 1.89 (m, 6H), 1.47 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 159.48, 144.62, 
135.35, 129.54, 127.76, 127.20, 126.51, 121.95, 76.47, 74.50, 36.58, 33.42, 31.62, 26.20, 25.65. MS 
(ESI) calculated for C19H19N3, m/z 289.1579, found 290.1740 (M + H)
+
. 
 
Synthesis of Compound 8c: 2-cyclohexyl-3-methyl-3H-imidazo[4,5-c]quinoline. 
 
To the solution of 3c (65 mg, 0.26 mmol) in 1 mL of anhydrous THF, were added DBU (79 mg, 0.52 
mmol) and iodomethane (111 mg, 0.78 mmol) and the solution was stirred for 2 hours. The solvent 
was then removed under vacuum and the residue was dissolved in EtOAc, washed with water, dried 
over sodium sulfate, concentrated and purified using column chromatography (20% 
N
N
N
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EtOAc/dichloromethane) to obtain the compound 8c (8 mg, 12%). 1H NMR (400 MHz, CDCl3) δ 9.03 
(s, 1H), 8.70 – 8.57 (m, 1H), 8.25 – 8.13 (m, 1H), 7.74 – 7.57 (m, 2H), 3.97 (s, 3H), 3.00 – 2.94 (m, 
1H), 2.17 – 1.87 (m, 7H), 1.57 – 1.37 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 160.11, 144.46, 143.99, 
135.12, 129.50, 128.88, 126.96, 126.37, 122.25, 121.97, 36.55, 31.38, 30.24, 26.24, 25.68. MS (ESI) 
calculated for C17H19N3, m/z 265.1579, found 266.1666 (M + H)
+
. 
 
Synthesis of Compound 3d: 2-nonyl-3H-imidazo[4,5-c]quinoline. 
 
To the mixture of 1 (500 mg, 3.14 mmol) and decanoic acid (1.6 g, 9.43 mmol) was added 
polyphosphoric acid (appx. 5 mL) and heated under microwave conditions (1200 W, 180 oC, 30 
minutes). The reaction mixture was then slowly cooled to room temperature and the polyphosphoric 
acid was slowly neutralized with ammonium hydroxide till the pH is around 8. The compound was 
then extracted using EtOAc and the EtOAc fraction was then washed with water, dried over sodium 
sulfate, concentrated and purified using column chromatography (3% MeOH/ dichloromethane) to 
afford the compound 3d (355 mg, 38%). 1H NMR (500 MHz, MeOD) δ 8.93 (s, 1H), 8.22 (s, 1H), 8.00 
(d, J = 8.5 Hz, 1H), 7.62 – 7.53 (m, 2H), 2.91 (t, J = 7.7 Hz, 2H), 1.83 – 1.75 (m, 2H), 1.36 – 1.22 (m, 
4H), 1.14-1.17 (m, 8H), 0.75 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 158.61, 144.52, 
129.56, 128.72, 128.00, 122.49, 33.02, 30.55, 30.41, 30.37, 30.32, 29.92, 29.41, 23.74, 14.45. MS 
(ESI) calculated for C19H25N3, m/z 295.2048, found 296.2178 (M + H)
+
. 
 
Synthesis of Compound 4d: 2-methyl-1-(2-nonyl-3H-imidazo[4,5-c]quinolin-3-yl)propan-2-ol. 
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To a solution of 3d (40 mg, 0.14 mmol) in 1 mL of 2,2-dimethyloxirane, was added DBU (62 mg, 0.41 
mmol) and the solution was heated under microwave conditions (600 W, 90 oC, 1 h). After cooling to 
room temperature, and removing the solvent under vacuum, the residue was dissolved in EtOAc and 
washed with water, dried over sodium sulfate, concentrated and purified using column 
chromatography (50% EtOAc/dichloromethane) to obtain the compound 4d (11 mg, 18%). 1H NMR 
(400 MHz, MeOD) δ 9.17 (s, 1H), 8.58 (d, J = 6.4 Hz, 1H), 8.14 – 8.09 (m, 1H), 7.69 (dd, J = 6.8, 3.2 
Hz, 2H), 4.40 (s, 2H), 3.13 (t, J = 6.4 Hz, 2H), 2.02 – 1.88 (m, 2H), 1.49 (d, J = 6.3 Hz, 2H), 1.39 (d, J 
= 15.1 Hz, 2H), 1.38 – 1.20 (m, 14H), 0.92 – 0.86 (m, 3H). 13C NMR (101 MHz, MeOD) δ 158.89, 
143.39, 143.19, 137.44, 129.30, 127.99, 127.27, 126.65, 121.52, 121.46, 70.72, 54.40, 31.66, 29.27, 
29.22, 29.15, 29.05, 27.97, 27.32, 26.51, 22.37, 13.24. MS (ESI) calculated for C23H33N3O, m/z 
367.2624, found 368.2733 (M + H)+. 
 
Synthesis of Compound 5d: 3-(4-methoxybenzyl)-2-nonyl-3H-imidazo[4,5-c]quinoline. 
To a solution of 3d (50 mg, 0.17 mmol) in 1 mL of anhydrous THF, were added DBU (52 mg, 0.34 
mmol) and 1-(chloromethyl)-4-methoxybenzene (106 mg, 0.68 mmol). The solution was then heated 
in a sealed vessel at 80 oC for an hour. After cooling to room temperature, and removing the solvent 
under vacuum, the residue was dissolved in EtOAc and washed with water, dried over sodium 
sulfate, concentrated and purified using column chromatography (20% EtOAc/dichloromethane) to 
obtain the compound 5d (21 mg, 30%). 1H NMR (400 MHz, CDCl3) δ 8.89 (s, 1H), 8.66 – 8.58 (m, 
1H), 8.22 – 8.15 (m, 1H), 7.73 – 7.62 (m, 2H), 7.05 (d, J = 8.7 Hz, 2H), 6.91 – 6.82 (m, 2H), 5.47 (s, 
2H), 3.79 (s, 3H), 3.05 – 2.95 (m, 2H), 1.87 (dt, J = 15.6, 7.7 Hz, 2H), 1.49 – 1.38 (m, 2H), 1.33 – 
1.26 (m, 10H), 0.89 (t, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 159.57, 156.76, 144.46, 
144.11, 135.74, 129.54, 128.59, 127.69, 127.33, 127.14, 126.59, 122.20, 121.75, 114.57, 55.32, 
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47.36, 31.85, 29.54, 29.42, 29.29, 29.25, 28.28, 27.86, 22.66, 14.11. MS (ESI) calculated for 
C27H33N3O, m/z 415.2624, found 416.2560 (M + H)
+
. 
 
Synthesis of Compound 6d: 3-(2-nonyl-3H-imidazo[4,5-c]quinolin-3-yl)propan-1-ol. 
 
To a solution of 3d (42 mg, 0.14 mmol) in 1 mL of anhydrous DMF, were added DBU (65 mg, 0.43 
mmol) and 3-bromopropan-1-ol (99 mg, 0.71 mmol). The solution was then heated in a sealed vessel 
at 80 oC for an hour. After cooling to room temperature and removing the solvent under vacuum, the 
residue was dissolved in EtOAc and washed with water, dried over sodium sulfate, concentrated and 
purified using column chromatography (25% acetone/dichloromethane) to obtain the compound 6d 
(11 mg, 22%). 1H NMR (400 MHz, CDCl3) δ 9.12 (s, 1H), 8.58 (dt, J = 17.0, 8.1 Hz, 1H), 8.17 (dt, J = 
18.1, 9.6 Hz, 1H), 7.78 – 7.55 (m, 2H), 4.53 (t, J = 6.8 Hz, 2H), 3.72 (t, J = 5.6 Hz, 2H), 3.11 – 2.96 
(m, 2H), 2.22 – 2.03 (m, 2H), 1.94 (dt, J = 15.6, 7.7 Hz, 2H), 1.54 – 1.43 (m, 2H), 1.35 – 1.28 (m, 
10H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 156.89, 144.17, 144.08, 135.51, 129.19, 
128.53, 127.16, 126.59, 122.15, 121.79, 58.16, 40.70, 32.85, 31.86, 29.62, 29.46, 29.36, 29.26, 
28.43, 27.50, 22.66, 14.10. MS (ESI) calculated for C22H31N3O, m/z 353.2467, found 354.2401 (M + 
H)+. 
 
Synthesis of Compound 7d: 2-nonyl-3-(prop-2-ynyl)-3H-imidazo[4,5-c]quinoline. 
To a solution of 3d (60 mg, 0.2 mmol) in 1 mL of anhydrous THF, were added DBU (61 mg, 0.4 
mmol) and 80% propargyl bromide in toluene (119 mg, 1.0 mmol). The solution was then heated in a 
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sealed vessel at 90 oC for 30 minutes. After cooling to room temperature, and removing the solvent 
under vacuum, the residue was dissolved in EtOAc and washed with water, dried over sodium 
sulfate, concentrated and purified using column chromatography (40% EtOAc/dichloromethane) to 
obtain the compound 7d (10 mg, 15%). 1H NMR (400 MHz, CDCl3) δ 9.16 (s, 1H), 8.65 – 8.53 (m, 
1H), 8.29 – 8.16 (m, 1H), 7.76 – 7.61 (m, 2H), 5.07 (d, J = 2.5 Hz, 2H), 3.13 – 2.97 (m, 2H), 2.48 (t, J 
= 2.5 Hz, 1H), 1.96 (dt, J = 15.5, 7.7 Hz, 3H), 1.57 – 1.46 (m, 2H), 1.46 – 1.38 (m, 2H), 1.30 (dd, J = 
5.8, 4.2 Hz, 7H), 0.90 (t, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 156.03, 144.63, 144.11, 
135.27, 129.59, 127.89, 127.30, 126.70, 122.10, 121.76, 76.17, 74.63, 33.73, 31.86, 29.51, 29.44, 
29.31, 29.25, 28.17, 27.67, 22.66, 14.11. MS (ESI) calculated for C22H27N3, m/z 333.2205, found 
334.2291 (M + H)+. 
 
Synthesis of Compound 8d: 3-methyl-2-nonyl-3H-imidazo[4,5-c]quinoline. 
 
To a solution of 3d (50 mg, 0.17 mmol) in 1 mL of anhydrous THF, were added DBU (52 mg, 0.34 
mmol) and iodomethane (36 mg, 0.25 mmol) and the solution was stirred for 2 hours. The solvent 
was then removed under vacuum and the residue was dissolved in EtOAc, washed with water, dried 
over sodium sulfate, concentrated and purified using column chromatography (35% 
EtOAc/dichloromethane) to obtain the compound 8d (21 mg, 40%). 1H NMR (500 MHz, CDCl3) δ 
9.03 (s, 1H), 8.60 – 8.56 (m, 1H), 8.19 (dt, J = 8.0, 4.3, 1H), 7.73 – 7.61 (m, 2H), 3.96 (s, 3H), 3.08 – 
2.93 (m, 2H), 1.90 (dt, J = 15.6, 7.8, 2H), 1.48 (dt, J = 15.0, 7.0, 2H), 1.44 – 1.35 (m, 2H), 1.35 – 1.20 
(m, 8H), 0.88 (t, J = 7.0, 3H). 13C NMR (126 MHz, CDCl3) δ 156.38, 143.89, 143.52, 134.55, 128.98, 
128.49, 126.67, 126.14, 121.63, 121.31, 31.39, 30.06, 29.08, 28.99, 28.87, 28.80, 27.74, 27.22, 
22.20, 13.65. MS (ESI) calculated for C20H27N3, m/z 309.2205, found 310.2306 (M + H)
+
. 
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Synthesis of Compound 12: 3,5-bis(4-methoxybenzyl)-2-phenyl-3H-imidazo[4,5-c]quinolin-5-
ium chloride. 
 
To a solution of 3b (50 mg, 0.2 mmol) in 1 mL of anhydrous THF, were added DBU (91 mg, 0.61 
mmol) and 1-(chloromethyl)-4-methoxybenzene (159 mg, 1.02 mmol), and the solution was heated 
under microwave conditions (600 W, 150 oC, 0.5 h). After cooling to room temperature, and removing 
the solvent under vacuum, the residue was purified using column chromatography (10% 
MeOH/dichloromethane) to obtain the compound 5b (21 mg, 22%). 1H NMR (400 MHz, MeOD) δ 
9.63 (s, 1H), 8.96 (d, J = 7.8 Hz, 1H), 8.55 (d, J = 9.1 Hz, 1H), 8.13 – 8.08 (m, 1H), 8.07 – 8.02 (m, 
1H), 8.02 – 7.99 (m, 2H), 7.77 – 7.68 (m, 3H), 7.24 (d, J = 8.8 Hz, 2H), 7.10 (d, J = 8.7 Hz, 2H), 6.94 
(d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 6.20 (s, 2H), 5.86 (s, 2H), 3.82 (s, 3H), 3.79 (s, 3H). 13C 
NMR (101 MHz, MeOD) δ 163.08, 160.44, 159.97, 150.30, 135.98, 135.52, 132.27, 131.96, 129.73, 
129.40, 129.10, 129.03, 128.45, 127.98, 127.57, 126.49, 124.96, 123.80, 122.18, 119.33, 114.43, 
114.39, 59.82, 54.46, 54.43, 49.46. MS (ESI) calculated for C32H28N3O2
+, m/z 486.2176, found 
486.2140 (M + H)+. 
 
Synthesis of Compound 13: 5-(4-methoxybenzyl)-2-phenyl-3H-imidazo[4,5-c]quinolin-5-ium 
chloride. 
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To a solution of 3b (20 mg, 0.08 mmol) in 1 mL of anhydrous THF, was added 1-(chloromethyl)-4-
methoxybenzene (19 mg, 0.12 mmol) and the solution was heated in a sealed vessel at 120 oC for 
an 12-14 hours. After cooling to room temperature and removing the solvent under vacuum, the 
residue was subjected to column chromatography (8% MeOH/dichloromethane) to obtain the 
compound 13 (12 mg, 40%). 1H NMR (400 MHz, MeOD) δ 9.28 (s, 1H), 8.92 – 8.84 (m, 1H), 8.41 (d, 
J = 7.0 Hz, 2H), 8.24 – 8.14 (m, 1H), 7.84 – 7.74 (m, 2H), 7.54 (dq, J = 14.2, 7.0 Hz, 3H), 7.23 (d, J = 
8.6 Hz, 2H), 6.93 (d, J = 8.7 Hz, 2H), 6.05 (s, 2H), 3.76 (s, 3H). 13C NMR (101 MHz, MeOD) δ 
159.99, 138.62, 137.14, 134.14, 133.69, 129.64, 129.32, 128.37, 128.00, 127.75, 126.66, 123.91, 
121.38, 118.59, 114.25, 58.48, 54.35. MS (ESI) calculated for C24H20N3O
+, m/z 366.1601, found 
366.1760 (M + H)+. 
 
Synthesis of Compound 16: N-(4-methoxybenzyl)-3-nitroquinolin-4-amine. 
 
To a solution of 14 (147 mg, 0.71 mmol) in 4:1 mixture of toluene and 2-propanol were added N,N-
diethylpropan-2-amine (0.14 mL, 6 mmol) and 15 (121 mg, 0.88 mmol). The reaction mixture was 
heated to 70 oC for half an hour until a solid started to precipitate. The reaction mixture was then 
cooled, filtered and washed with toluene/2-propanol (7:3), ether and cold water. The residue was 
dried at 80 oC to obtain the compound 16 (200 mg, 91%). 1H NMR (400 MHz, CDCl3) δ 9.82 (s, 1H), 
9.41 (s, 1H), 8.34 (d, J = 8.4, 1H), 8.03 (d, J = 8.3, 1H), 7.79 (dd, J = 11.2, 4.1 Hz, 1H), 7.48 (dd, J = 
11.3 Hz, 4.2, 1H), 7.34 (d, J = 8.6 Hz, 2H), 6.97 (d, J = 8.6 Hz, 2H), 5.07 (d, J = 5.4 Hz, 2H), 3.85 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 159.76, 150.82, 150.64, 147.43, 132.72, 130.46, 128.83, 128.68, 
126.99, 126.20, 125.52, 119.22, 114.72, 55.37, 52.74. MS (ESI) calculated for C17H15N3O3, m/z 
309.1113, found 310.1268 (M + H)+. 
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Synthesis of Compound 17: 1-(4-methoxybenzyl)-2-phenyl-1H-imidazo[4,5-c]quinoline. 
 
Compound 16 (120 mg, 0.39 mmol) was dissolved in MeOH and hydrogenated over Pd/C as a 
catalyst at 60 psi hydrogen pressure for 4 hours. The solution was then filtered using celite, followed 
by evaporation of the solvent under reduced pressure to afford N4-(4-methoxybenzyl)quinoline-3,4-
diamine (85 mg, 94%). N4-(4-methoxybenzyl)quinoline-3,4-diamine (85 mg, 0.31 mmol), benzoic acid 
(41 mg, 0.34 mmol), HBTU (129 mg, 0.34 mmol), triethylamine (34 mg, 0.34 mmol) and a catalytic 
amount of DMAP were dissolved in 5 mL of DMF and stirred for 10-12 hours. The solvent was then 
removed under vacuum. The residue was dissolved in EtOAc and washed with water, dried over 
sodium sulfate and concentrated under reduced pressure to obtain the residue, which was dissolved 
in 10 mL of ethanol, and a solution of excess of sodium hydroxide in 1 mL of water was added. The 
reaction mixture was refluxed for 5-6 hours and then the solvent was removed to obtain the residue, 
which was purified using column chromatography (4% MeOH/dichloromethane) to obtain the 
compound 17 (82 mg, 80%). 1H NMR (400 MHz, CDCl3) δ 9.47 (s, 1H), 8.31 (d, J = 7.7 Hz, 1H), 7.94 
(d, J = 7.7 Hz, 1H), 7.71 (dd, J = 8.1 Hz, 1.4, 2H), 7.68 – 7.62 (m, 1H), 7.58 – 7.42 (m, 4H), 7.10 (d, J 
= 8.7 Hz, 2H), 6.95 – 6.91 (m, 2H), 5.81 (s, 2H), 3.82 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 159.35, 
154.84, 145.54, 137.06, 130.86, 130.33, 129.46, 128.91, 127.76, 127.07, 126.71, 126.52, 120.53, 
117.76, 114.91, 55.30, 50.12. MS (ESI) calculated for C24H19N3O, m/z 365.1528, found 366.1785 (M 
+ H)+. 
 
2D-NOESY experiments: The 2D-NOESY experiments were performed on the Bruker Avance 400 
or Avance AV-III 500 NMR instruments. Compounds were dissolved in appropriate deuterated 
N
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solvents and experiments were performed with mixing time (d8) of 0.5 sec (400 MHz) or 0.7 sec (500 
MHz). The data generated was processed using MestReNova 6.2.1 (Mestrelab Research S.L.). 
 
TLR-7/8 antagonism assay:  A reporter gene assay using TLR7132;137;138 (or TLR8)-dependent NF-
B induction was used. The inhibition of induction of NF-B, a key transcriptional activator of the 
innate immune system, was quantified using human embryonic kidney 293 cells stably transfected 
with plasmids encoding TLR7 as well as an NF-B reporter gene coupled to secreted alkaline 
phosphatase (sAP) (InvivoGen, San Diego, CA), and were maintained in HEK-Blue™ Selection 
medium containing zeocin and normocin. Stable expression of secreted alkaline phosphatase (sAP) 
under control of NF-B/AP-1 promoters is inducible by the gardiquimod (TLR7 agonist) or CL075 
(TLR8 agonist), and extracellular sAP in the supernatant is proportional to NF-B induction. HEK-
Blue-7 (or HEK-Blue-8) cells were incubated at a density of ~105 cells/mL in a volume of 80 µl/well, in 
384-well, flat-bottomed, cell culture-treated microtiter plates until confluency was achieved, and 
subsequently stimulated with 1g/mL of gardiquimod or CL075. Concurrent to stimulation, serially 
diluted concentrations of test compounds were added to the cell medium using a rapid-throughput, 
automated protocol employing a Bio-Tek P2000 liquid handler and left to incubate overnight. sAP 
was assayed spectrophotometrically using an alkaline phosphatase-specific chromogen (present in 
HEK-detection medium as supplied by the vendor) at 620 nm. 
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4.1. Introduction. 
 
 
As discussed in Chapter 1, we have recently examined representative members of 
virtually the entire compendium of known TLR agonists in a series of hierarchical assays including 
primary TLR-reporter assays, secondary indices of immune activation such as cytokine induction and 
activation of lymphocytic subsets in whole human blood, and tertiary screens characterizing 
transcriptomal activation patterns with a view to identifying optimal immunostimulatory chemotypes.69 
Of all the innate immune stimuli examined, we found that TLR7 agonists were extraordinarily 
immunostimulatory, stimulating virtually all subsets of lymphocytes, and yet without inducing 
dominant proinflammatory cytokine responses.69 We therefore became especially desirous of 
evaluating TLR7-active compounds as potential vaccine adjuvants.  
 
Long before endosomal TLR7 was discovered to serve as the primary sensor for short, 
single-stranded, GU-rich RNA sequences (ssRNA), mainly of viral origin,70-72 a number of small 
molecules were synthesized and evaluated in the 1970s and '80s for antiviral activities owing to their 
pronounced Type I interferon (IFN- and -) inducing properties.139-143 Although the mechanisms of 
innate immune stimulation of several of these compounds (such as tilorone141 and bromopirone143) 
remain yet to be formally elucidated, members of the 1H-imidazo[4,5-c]quinolines were found to be 
good Type I IFN inducers in human cell-derived assays,144 and FDA approval was obtained in 1997 
for Imiquimod (1, Fig. 1) for the treatment of basal cell carcinoma and actinic keratosis.145 It was not 
until 2002, however, that the mechanistic basis of IFN induction by the imidazoquinolines was found 
to be a consequence of TLR7 engagement and activation.119 Other than the original landmark 
studies performed by investigators at 3M Pharmaceuticals,144 structure-activity relationships of the 
imidazoquinoline chemotype remains poorly explored, perhaps attributable in part to recent interest 
in the 8-hydroxy-adenine compounds as alternate TLR7-agonists,146-149 which appear to lack emetic 
side-effects observed in ferrets upon oral administration.148  
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An aspect of our recent work in this area69;137;150 focuses on developing adjuvants for 
transcutaneous vaccines (needle-free vaccine patches).151-153 Given that imiquimod is already 
approved for topical use, it was of particular interest not only to explore chemical space around the 
imidazoquinolines, but also to carefully ‘immunophenotype’ such compounds in human TLR7-based 
assays to verify that they did not have any TLR8-driven proinflammatory properties. One of our goals 
was also to learn from such structure-activity studies optimal positions on the scaffold that would 
tolerate the introduction of electrophilic or photoactivable labels for purposes of developing self-
adjuvanting vaccine constructs154;155 by covalently modifying protein antigens. We report here the 
synthesis and evaluation of a focused library of variously substituted 1H-imidazo[4,5-c]quinolines, 
and the identification of a novel, pure TLR7 agonist whose potency is 250 times that of imiquimod.  
 
4.2. Results and Discussion. 
 
 
As alluded to earlier, long before the fact that imidazoquinolines specifically engaged and 
activated TLR7 was known, it was recognized that these compounds were potently adjuvantic77-79;81 
in addition to displaying anti-viral effects via the induction of IFN-.83;84 In human blood stimulated 
ex vivo with TLR7 agonists, upregulation of the surface expression of costimulatory molecules such 
as CD40, CD80, and CD86 occurred in both CD11c- plasmacytoid DCs and CD11c+ myeloid DCs; 
furthermore, the Th1 stimulatory ability of both DC subsets was enhanced in response to TLR7 
ligands.85 Because TLR7 agonists transmit a T-helper-like signal to antibody-producing B cells, it is a 
highly effective adjuvant even for synthetic peptides that lack T-cell epitopes, possibly even replacing 
the function of T-helper cells, and providing a potential T-cell-independent vaccination strategy.81  
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Our initial interest in exploring TLR7 agonists as vaccine adjuvants has been greatly 
reinforced by our recent observations that pure TLR7 agonists, unlike other TLR ligands, are potently 
immunostimulatory without activating inflammatory programs in human whole blood model 
systems.69 We elected to choose 1-(4-amino-2-((ethylamino)methyl)-1H-imidazo[4,5-c]quinolin-1-yl)-
2-methylpropan-2-ol [gardiquimod, 2 (Fig. 1)] as our point of departure in examining structure-activity 
relationships in the imidazoquinolines, rather than imiquimod because we had earlier established that 
this analogue was more active than the parent compound, and was also verified to be a pure TLR7 
agonist in human primary cells.69;137  
 
The synthesis of 2 has been described in Chapter 2.137 The only report on a detailed 
examination of SAR on the imidazoquinolines by the 3M group144 had used indirect bioassays 
(indirect assay for IFN- using inhibition of virus-induced cytopathic effect) which predated the 
discovery and development of TLR7-specific assays. In the studies reported below, all compounds 
have been evaluated in human TLR7 and TLR8 reporter gene assays; highly active compounds were 
further examined for IFN- induction in whole human blood using analyte-specific immunoassays. 
 
Recent studies show that the TLR7 agonistic imidazoquinolines are indeed potently 
adjuvantic in vaccine constructs;156;157 however, the route of administration appears to be crucial 
since intradermal, but not subcutaneous administration of the vaccine adjuvanted with 2 is 
immunogenic and protective.156 Epidermal Langerhans cells as well as dermal dendritic cells 
Fig. 1. Structures of Imiquimod (1) and Gardiquimod (2) 
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(myeloid and plasmacytoid subsets)158 function as specialized professional antigen presenting cells 
in the skin.159;160  The plasmacytoid dendritic cell subset appears to be the target cell-type for TLR7 
agonists.161 We hypothesized that the C2 ethylaminomethylene substituent of 2 renders the molecule 
sufficiently polar as to hinder transcutaneous penetration to effectively access and stimulate 
plasmacytoid dendritic cells. It was therefore desirable to evaluate more hydrophobic analogues of 2 
as potential candidate transcutaneous vaccine adjuvants.  
 
Unlike TLR2, TLR3, and TLR4 for which crystal structures are available as complexes 
with their cognate ligands,162 a detailed structural characterization of the mode of binding of the 
imidazoquinolines to TLR7 is not yet available. Therefore, our strategy in examining structure-activity 
relationships was focused rather on exploring chemical space systematically around the validated 
lead compound 2, toward realizing the two major objectives mentioned earlier. We began with 
derivatization of the secondary amine of the C2 ethylaminomethylene sidechain in an effort to 
examine whether this could be a potential site for introducing photoactivable or electrophilic 
functionalities. We found that modifications on this substituent are poorly tolerated, with only the N-
ethyl analogue 3 (Scheme 1) retaining partial activity, and acyl (4, 5) and guanidine163 (6) derivatives 
being bereft of activity (Table 1).  
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Scheme 1. Syntheses of 2-imidazolyl sidechain-modified analogues of 2. 
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The loss of activity appeared not to be a consequence of altered basicity of the amine; 
surmising that it may, in part, be due either to the hydrophobicity of the substituent, or the 
conformational constraint imposed by the amide or guanidine, we asked if a polar spacer group, such 
as triethyleneglycol (11) may mitigate loss of activity, but we were proven wrong because 11 was 
also found to be completely inactive. Concurrent with the syntheses of the above compounds, we 
also synthesized the N-propyleneisothiocyanate derivative (14) via the N-propyleneamino (13) and 
N-ethylenenitrile (12) precursors. Compound 14 was not tested in reporter gene assays because we 
anticipated spurious results on account of its reactivity; the reaction of 14 with the spermine 
derivative (used as a model amine) afforded the expected thiourea adduct (16) which, 
disappointingly, was also inactive. These results conclusively showed that the secondary amine on 
the C2 substituent was not amenable to modifications. Replacement of the terminal ethyl group on 
the C2 substituent with an n-undecanyl group in 22 resulted in complete loss of activity (Scheme 2, 
Table 1), signaling that the length of the C2 substituent was crucial; this was to become dramatically 
apparent when 32, with a pentyl substituent on C2 was evaluated later (see below).  
Desiring more lipophilic analogues which are expected to permeate the dermal barrier 
better, we sought to examine N1-benzyl analogues (Scheme 3) noting that similar substitutions have 
resulted in augmented activity in the 8-hydroxy-adenine series.146-149 Compound 32 was the first to 
be synthesized in this series which, to our pleasant surprise showed an activity twenty-fold greater 
than 2. Coupled with our observation that 22 was completely inactive, we sought to systematically 
explore SAR of the N1-benzyl C2 alkyl substituents. As depicted in Fig. 2, a very distinct relationship 
between alkyl length and TLR7-agonistic potency was observed, with the optimal compound being 
31 (C2-n-butyl), with an EC50 of 59 nM (Table 1). n-Butylene (38) and n-butylyne (43) analogues 
showed decrease in potency. It is noteworthy that a C2-n-butyl, N1-phenyl analogue synthesized by 
the 3M group144 was not the most active; our results indicate that an N1-benzyl substituent is 
preferred.  
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Scheme 2. Syntheses of 2-imidazolyl sidechain-modified analogues of 2. 
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Scheme 3. Syntheses of 1-benzyl-2-(alkyl)-1H-imidazo[4,5-c]quinolin-4-amines. 
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In recognition that bioactivity readouts using cell-culture systems may not always reflect with fidelity 
in vivo behavior owing to differential plasma protein binding (that we ourselves have observed and 
characterized),164 it was important to verify that the activity profiles observed in TLR7-specific 
reporter gene assays (Table 1) was  also seen in whole blood with its full complement of plasma 
proteins. It was gratifying that we observed the expected 31>>2~34 activity profile in whole blood 
IFN- induction experiments (Fig. 3). 
Fig. 2. Alkyl chain length dependence of TLR7-agonistic activity profiles of the N1-benzyl-C2-alkyl compounds (right 
panel). The activity of 2 (reference compound) is shown on the left. Error bars represent standard deviations obtained on 
quadruplicate samples. 
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Fig. 3. Dose-dependent induction of IFN- in whole human blood by 2, 31, and 34. Plasma IFN- was assayed in 
triplicate by ELISA. 
 
Bioisosteric replacements of the C4-NH2 group with -NMe, -OH and -SMe groups on the 
imiquimod scaffold have been explored earlier,144 and it was of interest to examine if the previously-
described SAR would hold true in our analogues, and also to test whether the introduction of phenyl, 
-NHNH2 and -NHOH groups would alter TLR7 activity (Scheme 4). The 4-Cl precursor (44) and the 
des-amino analogue 50, as well as the 4-OH (46) and 4-Ph (47) analogues were completely inactive, 
while the 4-NHOH (48) and 4-NHNH2 (49) compounds were substantially weaker (Table 1) than their 
4-NH2 counterparts (31, 32). These results indicate the importance of the preservation of the NH2 
group on C4 for maximal activity. 
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Up to this point in our SAR studies, the most active and chemically distinct species were 
compound 2, and the N1-benzyl-C2-n-butyl analogue 31.  We were curious to examine whether 
transposing the N1 and C2 substituents on these molecules would result in enhanced activity. 
Fortuitously, both the ‘hybrids’ (52, 54; Scheme 5) were very active. 54 was found to be 
extraordinarily potent with an EC50 of 8.6 nM (Fig. 4, Table 1).  
 
Scheme 4. Syntheses of 4-substituted-1-benzyl-2-(alkyl)-1H-imidazo[4,5-c]quinolines. 
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Scheme 5. Syntheses of C-2/N-1 substituent-swapped 31/2 hybrids. 
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Scheme 6. Syntheses of imidazole-modified analogues. 
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Fig. 4. TLR7-agonistic activities of active compounds in a human TLR7-specific reporter gene assay.  Error bars 
represent standard deviations obtained on quadruplicate samples.  
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Finally, we attempted to modify the imidazole ring of the scaffold. The triazole compounds 55 and 56, 
as well as the cyclic urea 57 were completely inactive, which emphasizes the role of the recognition 
of the imidazole ring system by TLR7. Mention must also be made that these studies have been 
useful in delineating possible sites for introducing labeling functionalities. Preliminary studies (data 
not shown) show that the N1-benzyl substituent may be appropriate for introducing arylazido 
functional groups, while the quinoline ring may be amenable to introducing electrophilic groups. 
These results will be communicated in a future publication. 
All of the C2-alkyl compounds reported herein were tested for TLR8 activity using the 
thiazoloquinoline CL075 (3M002) as a reference TLR8 agonist,165;166 and none had any appreciable 
activity in these assays. It should also be pointed out that while potencies of compounds are 
conventionally represented as EC50 (or IC50) values, that metric alone appears to be inadequate in 
rank-ordering the activities of the active compounds tested. An inspection of Fig. 4 indicates, for 
instance, that while the EC50 values of both imiquimod and 2 are comparable (~ 2 M), compound 2 
induces a more robust response than imiquimod. Similarly, the area-under-curve estimates of 54 
(analogous to combined ‘avidity’ and affinity measures of antigen-antibody interactions)167;168 indicate 
that consideration of the EC50 values alone may underestimate its potency.  
Given that TLR7 is sequestered in an acidic endolysosomal compartment, and these 
compounds are weak bases and are therefore expected to accumulate in that acidic organelle, we 
wondered if the observed SAR could simply be a consequence of differential hydrophobicity of the 
compounds, modulating uptake into the cell and entry into the endolysosomal compartment activity, 
rather than governing specific molecular interactions with TLR7. A comparison of observed retention 
times on C18-reverse-phase mass-chromatograms (a measure of hydrophobicity)
169;170 with the 
potencies of the active compounds indicate a distinct deviation from the trend of 54, suggesting 
specific and idiosyncratic effects, rather than bulk-effects (Fig. 5).  
 
 
 85  
Fig. 5. Correlation of TLR7-agonistic potency and hydrophobicity (measured as retention time on C18 reverse-phase 
chromatography).  
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Structure 
 
Compound Number 
 
TLR7-Agonistic 
Activity (M) 
N
N
N
NH2
 
1 2.12 
 
2 2.0 
 
3 7.71 
 
4 ND 
 
5 ND 
Table 1. EC50 values (M) of compounds in human TLR7-specific reporter gene assay. ND denotes no 
activity detected at 100 M. 
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N
N
N
NH2
OH
N
NH
N
N
 
6 ND 
 
11 ND 
 
12 8.39 
 
13 ND 
 
16 ND 
 
22 ND 
 
28 0.955 
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29 0.472 
 
30 0.647 
 
31 0.0591 
 
32 0.0915 
 
33 0.479 
 
34 0.822 
 
35 3.35 
 
36 ND 
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37 ND 
 
38 0.262 
N NH2
N
N
Bn
 
43 0.209 
 
44 ND 
 
46 ND 
 
47 ND 
N NHOH
N
N
Bn C4H9  
48 0.723 
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N NHNH2
N
N
Bn C4H9  
49 0.873 
 
50 ND 
N NH2
N
N
Bn NH  
52 0.385 
N NH2
N
N
HO  
54 0.00858 
N
N
N
Bn
Cl
N
 
55 ND 
N
N
N
Bn
NH2
N
 
56 ND 
 
57 ND 
 
4.3. Conclusions. 
 
A detailed structure-activity study on the imidazoquinoline chemotype has been 
undertaken, which have been instructive and rewarding in that they not only complement the seminal 
work at 3M, but also have led to the discovery of highly-potent, lipophilic, human TLR7 agonist, 54. 
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We note, not without irony, that this highly potent compound differs from its parent molecule by only 
a replacement of a secondary amine by a methylene unit. The oral bioavailability of 54 is predicted to 
be good, and it is possible that the systemic IFN- inducing effects of this imidazoquinoline may find 
additional uses in the treatment of conditions such as hepatitis,171 chronic myelogenous172 and hairy 
cell leukemias.173 However, for purposes of developing dermal vaccine adjuvants, 31 may be more 
efficacious for reasons discussed earlier.  
 
4.4. Experimental. 
 
 
All of the solvents and reagents used were obtained commercially and used as such unless noted 
otherwise. Moisture- or air-sensitive reactions were conducted under nitrogen atmosphere in oven-
dried (120 oC) glass apparatus. The solvents were removed under reduced pressure using standard 
rotary evaporators. Flash column chromatography was carried out using RediSep Rf ‘Gold’ high 
performance silica columns on CombiFlash Rf instrument unless otherwise mentioned, while thin-
layer chromatography was carried out on silica gel CCM pre-coated aluminum sheets. Purity for all 
final compounds was confirmed to be greater than 97% by LC-MS using a Zorbax Eclipse Plus 4.6 
mm x 150 mm, 5 m analytical reverse phase C18 column with H2O-isopropanol or H2O-CH3CN 
gradients and an Agilent ESI-TOF mass spectrometer (mass accuracy of 3 ppm) operating in the 
positive ion (or negative ion, as appropriate) acquisition mode. Unless otherwise mentioned, the 
compounds synthesized were obtained as solids. 
 
Synthesis of Compound 3: 1-(4-Amino-2-((diethylamino)methyl)-1H-imidazo[4,5-c]quinolin-1-
yl)-2-methylpropan-2-ol.  
N
N
N
NH2
OH
N
3
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To a solution of trifluoroacetate salt of 2 (75 mg, 0.14 mmol) in anhydrous MeOH, were added 
acetaldehyde (6.6 mg, 0.15 mmol), 12-14 drops of acetic acid and sodium cyanoborohydride (10 mg, 
0.15 mmol). After 4 hours the solvent was removed using vacuum and the residue was purified using 
column chromatography (7% MeOH/dichloromethane) to obtain the compound 3 (16 mg, 34%). 1H 
NMR (500 MHz, MeOD) δ 8.36 (d, J = 7.8 Hz, 1H), 7.73 (dd, J = 8.4, 1.0 Hz, 1H), 7.69 – 7.64 (m, 
1H), 7.52 (ddd, J = 8.4, 7.2, 1.2 Hz, 1H), 4.83 (s, 2H), 4.75 – 4.63 (m, 2H), 3.42 (dd, J = 14.2, 7.0 Hz, 
4H), 1.39 – 1.29 (m, 6H), 1.21 (dd, J = 13.5, 6.2 Hz, 6H). 13C NMR (126 MHz, MeOD) δ 150.85, 
150.16, 138.41, 136.09, 131.52, 126.42, 126.18, 123.69, 120.11, 114.65, 72.54, 56.68, 49.70, 49.56, 
27.65, 9.45. MS (ESI) calculated for C19H27N5O, m/z 341.22, found 342.24 (M + H)
+. 
 
Synthesis of Compound 4: N-((4-Amino-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-
c]quinolin-2-yl)methyl)-N-ethylacetamide. 
 
To a solution of trifluoroacetate salt of 2 (40 mg, 0.074 mmol) in anhydrous THF, were added 
triethylamine (23 mg, 0.22 mmol) and acetyl chloride (6 mg, 0.08 mmol). After 30 minutes, the 
solvent was removed under vacuum. The residue was dissolved in EtOAc, washed with water and 
dried over Na2SO4. The EtOAc fraction was then concentrated under vacuum and the residue was 
purified using column chromatography (6% MeOH/dichloromethane) to obtain the compound 4 as 
colorless oil (22 mg, 85%). 1H NMR (400 MHz, MeOD) δ 8.34 (d, J = 8.3 Hz, 1H), 7.71 (d, J = 8.3 Hz, 
1H), 7.53 (t, J = 7.7 Hz, 1H), 7.38 (t, J = 7.7 Hz, 1H), 5.23 (s, 2H), 4.81 (s, 2H), 3.63 (q, J = 7.1 Hz, 
2H), 2.23 (s, 3H), 1.34 – 1.13 (m, 9H). 13C NMR (101 MHz, MeOD) δ 172.18, 154.62, 136.88, 
134.07, 129.68, 129.48, 124.60, 122.64, 122.31, 118.21, 113.67, 70.85, 65.49, 55.12, 43.70, 41.79, 
19.68, 14.03, 12.30. MS (ESI) calculated for C19H25N5O2, m/z 355.20, found 356.21 (M + H)
+. 
N
N
N
NH2
OH
N
O
4
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Synthesis of Compound 5: N-((4-Amino-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-
c]quinolin-2-yl)methyl)-N-ethylpalmitamide.  
 
To a solution of trifluoroacetate salt of 2 (20 mg, 0.05 mmol) in anhydrous THF, were added 
triethylamine (15 mg, 0.15 mmol) and palmitoyl chloride (16 mg, 0.06 mmol). After 30 minutes the 
solvent was removed under vacuum, residue was dissolved in EtOAc and washed with water. The 
EtOAc fraction was then dried under vacuum and the residue was purified using column 
chromatography (5% MeOH/dichloromethane) to obtain the compound 5 as colorless oil (10 mg, 
30%). 1H NMR (400 MHz, CDCl3) δ 8.12 (d, J = 8.1 Hz, 1H), 7.88 (d, J = 8.3 Hz, 1H), 7.54 (t, J = 7.6 
Hz, 1H), 7.38 (t, J = 7.8 Hz, 1H), 4.75 (s, 2H), 3.56 (q, J = 6.8 Hz, 2H), 2.45 – 2.34 (m, 2H), 1.76 – 
1.57 (m, 2H), 1.58 – 1.11 (m, 35H), 0.90 (t, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 192.82, 
173.95, 152.03, 150.36, 135.45, 130.90, 128.29, 124.10, 123.24, 120.62, 114.81, 71.96, 55.58, 
42.81, 42.30, 33.06, 31.92, 29.68, 29.65, 29.52, 29.47, 29.42, 29.35, 25.37, 22.69, 14.12, 13.70, 
5.61. MS (ESI) calculated for C33H53N5O2, m/z 551.42, found 552.41 (M + H)
+. 
 
Synthesis of Compound 6: 1-((4-Amino-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-
c]quinolin-2-yl)methyl)-3-(3-(dimethylamino)propyl)-1,2-diethylguanidine.  
N
N
N
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N
C15H31
O
5
N
N
N
NH2
OH
N
NH
N
N
6
 94  
 
To a solution of trifluoroacetate salt of 2 (50mg, 0.092 mmol) in anhydrous DMF, were added 
triethylamine (51 mg, 0.51 mmol), EDCI.HCl (53 mg, 0.28 mmol) and a catalytic amount of DMAP. 
The reaction was stirred for 24-30 hours. The solvent was then removed under vacuum, and the 
residue was purified using C18 reverse-phase column chromatography to obtain the compound 6 (9 
mg, 24%). 1H NMR (400 MHz, MeOD) δ 8.48 (d, J = 8.4 Hz, 1H), 7.84 (d, J = 7.4 Hz, 1H), 7.76 (t, J = 
7.7 Hz, 1H), 7.63 (t, J = 7.2 Hz, 1H), 5.18 (s, 2H), 4.85 – 4.71 (m, 2H), 3.58 (q, J = 7.3 Hz, 2H), 3.54 
– 3.41 (m, 4H), 3.27 – 3.18 (m, 2H), 2.90 (d, J = 3.7 Hz, 6H), 2.27 – 2.00 (m, 2H), 1.30 (dt, J = 14.4, 
7.2 Hz, 12H). 13C NMR (101 MHz, MeOD) δ 160.10, 153.79, 137.08, 134.45, 129.86, 124.93, 122.19, 
118.63, 113.38, 71.07, 55.30, 54.69, 46.25, 45.16, 42.06, 41.41, 39.78, 24.50, 13.79, 11.77. MS 
(ESI) calculated for C25H40N8O, m/z 468.33, found 469.33 (M + H)
+ and 235.17 (M + 2H)2+. 
 
Synthesis of Compound 9: tert-Butyl 2-(2-(2-hydroxyethoxy)ethoxy)ethylcarbamate.  
 
To a solution of 7 (500 mg, 2.1 mmol) in anhydrous dichloromethane, cooled to 0 oC, were added 
triethylamine (420 mg, 4.2 mmol), tosyl chloride (609 mg, 3.54 mmol) and a catalytic amount of 
DMAP. The reaction was stirred for 16 hours and then the mixture was washed with water and dried 
over Na2SO4. The solvent was then removed under vacuum. This residue O-tosylated compound 
was dissolved in anhydrous DMF, to which sodium azide (273 mg, 4.2 mmol) was added and the 
reaction was heated at 70 oC for 1 hour. The solvent was then removed under vacuum and the 
residue was dissolved in EtOAc, washed with water and dried over Na2SO4. The EtOAc fraction was 
concentrated under vacuum to obtain the compound 8 (600mg). This 8 was then dissolved in MeOH 
and di-tert-butyl dicarbonate (687 mg, 3.5 mmol) was added to it. The solution was subjected to 
catalytic hydrogenolysis using Pd(OH)2/C at 60 psi hydrogen pressure for 4 hours. The solution was 
then filtered through celite and filtrate was evaporated under reduced pressure to afford the residue, 
which was purified using column chromatography (3% MeOH/dichloromethane) to obtain the 
O
O
NHBoc
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compound 9 as colorless oil (320 mg, 62%). 1H NMR (400 MHz, CDCl3) δ 5.13 (s, 1H), 3.77 (d, J = 
3.5 Hz, 2H), 3.70 – 3.61 (m, 6H), 3.58 (t, J = 5.2 Hz, 2H), 3.34 (d, J = 4.6 Hz, 2H), 2.50 (s, 1H), 1.46 
(s, 9H). 13C NMR (101 MHz, CDCl3) δ 159.62, 79.34, 72.55, 70.43, 70.29, 61.78, 40.34, 28.41. MS 
(ESI) calculated for C11H23NO5, m/z 249.16, found 272.15 (M + Na
+). 
 
Synthesis of Compound 11: 1-(4-Amino-2-(((2-(2-(2-aminoethoxy)ethoxy)ethyl) 
(ethyl)amino)methyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol.  
 
To a solution of 9 (200mg, 0.8 mmol) in 4 mL of 0.3M Dess Martin periodinane solution in 
dichloromethane, 10-12 drops of acetic acid were added and the reaction was stirred for 4-5 hours. 
The solvent was then removed under vacuum and the residue was purified using column 
chromatography (40-50% EtOAc/dichloromethane) to obtain the intermediate aldehyde derivative 10 
(71 mg). To a solution of trifluoroacetate salt of 2 (150 mg, 0.29 mmol) in anhydrous MeOH, were 
added 10 (71 mg, 0.29 mmol), 6-8 drops of acetic acid, and sodium cyanoborohydride (22 mg, 0.35 
mmol). The solution was stirred for 14-15 hours and the solvent was removed under vacuum to 
obtain the residue, which was purified using column chromatography (10% MeOH/dichloromethane) 
to obtain the intermediate N-Boc derivative. This was dissolved in 5 mL of trifluoroacetic acid and 
stirred for 30 minutes, followed by removal of the solvent by purging nitrogen and drying under 
vacuum to obtain the trifluoroacetate salt of the compound 11 as colorless oil (110 mg, 60%). 1H 
NMR (400 MHz, MeOD) δ 8.49 (d, J = 8.4 Hz, 1H), 7.84 (d, J = 7.4 Hz, 1H), 7.76 (t, J = 7.3 Hz, 1H), 
7.63 (t, J = 7.2 Hz, 1H), 4.82 (s, 4H), 3.88 (t, J = 5.1 Hz, 2H), 3.70 (d, J = 6.5 Hz, 6H), 3.50 (s, 2H), 
3.38 (s, 2H), 3.17 – 3.09 (m, 2H), 1.55 – 1.10 (m, 9H). 13C NMR (101 MHz, MeOD) δ 149.53, 148.21, 
136.86, 134.61, 130.12, 122.23, 118.64, 113.15, 71.15, 69.99, 69.93, 66.50, 64.83, 55.36, 52.60, 
11
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49.74, 48.69, 46.46, 39.10, 26.24, 7.96. MS (ESI) calculated for C23H36N6O3, m/z 444.29, found 
467.27 (M + Na+) and 223.15 (M + 2H)2+. 
Synthesis of Compound 12: 3-(((4-Amino-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-
c]quinolin-2-yl)methyl)(ethyl)amino)propanenitrile.  
 
To a solution of 2 (250 mg, 0.46 mmol) in anhydrous MeOH, were added triethylamine (117 mg, 1.16 
mmol) and acrylonitrile (61 mg, 1.16 mmol). The reaction was stirred for 30 hours, followed by 
removal of the solvent under vacuum. The residue was dissolved in EtOAc, washed with water and 
dried over Na2SO4. The EtOAc fraction was evaporated under vacuum and the residue was purified 
using column chromatography (11% MeOH/dichloromethane) to obtain the compound 12 (145 mg, 
86%). 1H NMR (400 MHz, CDCl3) δ 8.06 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 8.3 Hz, 1H), 7.55 (t, J = 7.6 
Hz, 1H), 7.36 (t, J = 7.7 Hz, 1H), 6.04 (s, 2H), 4.88 (s, 2H), 4.12 (s, 2H), 2.94 (t, J = 6.7 Hz, 2H), 2.75 
(q, J = 7.0 Hz, 2H), 2.54 (t, J = 6.7 Hz, 2H), 1.35 (s, 6H), 1.19 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 150.98, 150.41, 135.44, 127.81, 126.16, 122.48, 122.40, 122.18, 120.20, 118.64, 115.30, 
71.49, 56.48, 50.85, 47.92, 47.64, 27.99, 15.33, 11.12. MS (ESI) calculated for C20H26N6O, m/z 
366.22, found 367.22 (M + H)+ . 
 
Synthesis of Compound 13: 1-(4-Amino-2-(((3-aminopropyl)(ethyl)amino)methyl)-1H-
imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol.  
 
N
N
N
NH2
OH
N
CN
12
N
N
N
NH2
OH
N
NH2
13
 97  
To a solution of 12 (160 mg, 0.44 mmol) in glacial acetic acid, a catalytic amount of Pd(OH)2/C was 
added and the reaction mixture was subjected to hydrogenation at 55 psi hydrogen pressure for 4 
hours. The solution was then filtered. The filtrate was concentrated to obtain the acetate salt of the 
compound 13 (55 mg). This residue (20 mg, 0.05 mmol) was then dissolved in MeOH and di-tert-
butyl dicarbonate (18 mg, 0.08 mmol) was added. After 30 minutes, the solvent was removed under 
vacuum and the residue was purified using column chromatography (15% MeOH/dichloromethane) 
to obtain the intermediate N-Boc derivative. This was then dissolved in 2 mL of HCl solution in 
dioxane and stirred for 2 hours. The solvent was then removed under vacuum to obtain the 
hydrochloride salt of the compound 13 (15 mg, 74%). 1H NMR (400 MHz, MeOD) δ 8.51 (d, J = 8.2 
Hz, 1H), 7.85 (d, J = 8.3 Hz, 1H), 7.78 (t, J = 7.9 Hz, 1H), 7.65 (t, J = 7.7 Hz, 1H), 5.09 (s, 2H), 3.74 – 
3.50 (m, 6H), 3.12 (d, J = 7.0 Hz, 2H), 2.32 (s, 2H), 1.51 (t, J = 6.9 Hz, 3H), 1.35 (s, 6H). 13C NMR 
(126 MHz, MeOD) δ 156.18, 151.90, 140.30, 137.56, 129.79, 126.47, 124.63, 123.13, 123.00, 72.46, 
56.49, 53.02, 52.27, 48.77, 40.46, 27.84, 24.89, 11.74. MS (ESI) calculated for C20H30N6O, m/z 
370.25, found 371.26 (M + H)+. 
 
Synthesis of Compound 16: 1-(3-(((4-amino-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-
c]quinolin-2-yl)methyl)(ethyl)amino)propyl)-3-(3-(4-(3-aminopropylamino)butylamino)propyl) 
thiourea.  
 
To a solution of 13 (35 mg, 0.07 mmol) in anhydrous ethanol, were added triethylamine (22 mg, 0.21 
mmol) and CS2 (54 mg, 0.71 mmol). The reaction mixture was stirred for 30 minutes and then cooled 
to 0 oC. Di-tert-butyl dicarbonate (15 mg, 0.07 mmol) and a catalytic amount of DMAP dissolved in 
ethanol were added to the reaction mixture. After 30 minutes, the solvent was removed under 
vacuum and the residue was purified using column chromatography to obtain the compound 15. To a 
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solution of 15 (10mg, 0.02 mmol) in anhydrous dichloromethane, N1,N5,N10-tris Boc spermine (37 mg, 
0.073 mmol) was added. The reaction mixture was stirred for 3 hours. The solvent was then removed 
under vacuum and the residue was purified using column chromatography (6% 
MeOH/dichloromethane) to obtain the intermediate N-Boc derivative. This was dissolved in 5 mL of 
trifluoroacetic acid and stirred for 30 minutes, followed by removal of the solvent by purging nitrogen 
and drying under vacuum to obtain the trifluoroacetate salt of the compound 16 (5 mg, 20%). 1H 
NMR (500 MHz, MeOD) δ 8.45 (d, J = 8.5 Hz, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.76 (t, J = 7.8 Hz, 1H), 
7.67 – 7.56 (m, 1H), 4.96 (d, J = 6.9 Hz, 2H), 4.81 – 4.70 (m, 2H), 3.77 – 3.38 (m, 8H), 3.13 (dd, J = 
18.0, 10.2 Hz, 2H), 3.10 – 2.96 (m, 8H), 2.16 – 2.04 (m, 4H), 1.97 – 1.88 (m, 2H), 1.84 – 1.74 (m, 
4H), 1.44 (t, J = 7.2 Hz, 3H), 1.29 (s, 6H). 13C NMR (126 MHz, MeOD) δ 150.81, 138.54, 138.41, 
135.99, 131.60, 126.50, 123.71, 120.06, 114.65, 72.55, 56.76, 52.24, 50.71, 49.86, 49.68, 48.26, 
48.06, 46.25, 45.87, 37.80, 27.48, 25.39, 24.29, 9.47. MS (ESI) calculated for C31H54N10OS, m/z 
614.42, found 615.43 (M + H)+ and 308.22 (M + 2H)2+. 
 
Synthesis of Compound 19: 2-(tert-Butoxycarbonyl(undecyl)amino)acetic acid.137  
 
To a solution of 17 (200 mg, 1.6 mmol) in anhydrous MeOH, were added undecanal (218 mg, 1.28 
mmol), 5-6 drops of acetic acid and sodium cyanoborohydride (111 mg, 1.76 mmol). The reaction 
was stirred for 3 hours and then the solvent was removed under vacuum. The residue was dissolved 
in dichloromethane and washed with water, brine and dried over Na2SO4. The dichloromethane 
fraction was then concentrated to obtain the residue 18, which was dissolved in MeOH, followed by 
the addition of triethylamine (202 mg, 2 mmol) and di-tert-butyl dicarbonate (436 mg, 2 mmol). The 
reaction was stirred for 4 hours and the solvent was removed under vacuum. The residue was then 
dissolved in a solvent mixture of THF:MeOH (3:1) and lithium hydroxide that was dissolved in water 
was added until the pH went above 12. The reaction was stirred for 24 hours, followed by removal of 
the solvent under vacuum. The residue was dissolved in water and the solution was acidified using 
HO
O
N
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10% HCl until pH was less than 2. The water fraction was then extracted with EtOAc, followed by 
washing the EtOAc fraction with water and drying over Na2SO4. The EtOAc fraction was then 
concentrated under vacuum to obtain the compound 19 as colorless oil (320 mg, 61%). MS (ESI) 
calculated for C18H35NO4, m/z 329.26, found 328.25 (M - H)
-. 
 
Synthesis of Compound 22: 1-(4-Amino-2-((undecylamino)methyl)-1H-imidazo[4,5-c]quinolin-
1-yl)-2-methylpropan-2-ol.  
 
To a solution of 19 (171 mg, 0.52 mmol) in anhydrous DMF, were added HATU (217 mg, 0.57 
mmol), triethylamine (58 mg, 0.57 mmol), a catalytic amount of DMAP and 20 (120 mg, 0.52 mmol). 
The reaction mixture was stirred for 3-4 hours. The solvent was evaporated under vacuum. The 
residue was dissolved in EtOAc, washed with water and dried over Na2SO4 to obtain the residue. 
This was dissolved in 10 mL of ethanol and a solution of NaOH (105 mg, 2.62 mmol) dissolved in 1 
mL of water was added to it. The reaction mixture was refluxed for 5-6 hours, followed by 
evaporation under reduced pressure. The residue was purified by column chromatography (5% 
MeOH/dichloromethane) to obtain the compound 21 (165 mg). To a solution of 21 in a solvent 
mixture of MeOH:dichloromethane:chloroform (0.1:1:1), 3-chloroperoxybenzoic acid (135 mg, 0.79 
mmol) was added and the solution was refluxed at 45-50 oC for 40 minutes. The solvent was then 
removed and the residue was purified using column chromatography (7% MeOH/dichloromethane) to 
obtain the N-oxide derivative (75 mg). This was then dissolved in anhydrous dichloromethane, 
followed by the addition of benzoyl isocyanate (37 mg, 0.25 mmol) and heated at 45 oC for 15 
minutes. The solvent was then removed under vacuum and the residue was dissolved in anhydrous 
MeOH, followed by the addition of excess sodium methoxide and heating at 80 oC for 1 hour. The 
solvent was then removed under vacuum and the residue was purified using column chromatography 
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(8% MeOH/dichloromethane) to obtain the intermediate N-Boc derivative (27 mg). This was 
dissolved in 5 mL of trifluoroacetic acid and stirred for 30 minutes, followed by removal of the solvent 
by purging nitrogen and drying under vacuum to obtain the trifluoroacetate salt of the compound 22 
as colorless oil (33 mg, 12%). 1H NMR (400 MHz, CDCl3) δ 14.65 (s, 1H), 10.11 (s, 2H), 8.06 (s, 1H), 
7.99 (d, J = 8.3 Hz, 1H), 7.44 (t, J = 7.6 Hz, 1H), 7.37 (t, J = 7.8 Hz, 1H), 7.20 (d, J = 8.6 Hz, 1H), 
4.76 (s, 2H), 4.61 (s, 2H), 3.23 (s, 2H), 1.93 (s, 2H), 1.50 – 1.11 (m, 22H), 0.91 (t, J = 6.7 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 149.04, 148.91, 136.14, 134.18, 129.98, 124.99, 124.25, 120.76, 
119.24, 112.18, 72.07, 49.07, 44.01, 31.89, 29.55, 29.49, 29.34, 29.31, 28.98, 26.58, 25.46, 22.67, 
14.10, 5.61. MS (ESI) calculated for C26H41N5O, m/z 439.33, found 440.33 (M + H)
+ and 220.67 (M + 
2H)2+. 
  
Synthesis of Compound 24: 3-Nitroquinoline-2,4-diol.  
 
Compound 23 (5 g, 31 mmol) was dissolved in 30 mL of nitric acid and stirred at room temperature 
for 10 minutes, followed by heating the reaction mixture at 75 0C for another 15 minutes. The 
reaction mixture was then allowed to cool down to room temperature and was added to ice-water 
mixture to precipitate the product. The solid, yellow precipitate was filtered and dried to obtain the 
compound 24 (5.9 g, 92%). 1H NMR (400 MHz, DMSO) δ 12.00 (s, 1H), 8.04 (d, J = 7.9 Hz, 1H), 
7.66 (t, J = 7.5 Hz, 1H), 7.34 (d, J = 8.2 Hz, 1H), 7.28 (t, J = 7.7 Hz, 1H). 13C NMR (101 MHz, DMSO) 
δ 156.69, 156.23, 138.56, 133.61, 127.71, 124.92, 122.81, 116.32, 114.47. MS (ESI) calculated for 
C9H6N2O4, m/z 206.03, found 205.04 (M - H)
-. 
 
Synthesis of Compound 25: 2,4-Dichloro-3-nitroquinoline.  
N OH
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Compound 24 (2 g, 9.7 mmol) was dissolved in 20 mL of phenylphosphonyl dichloride and heated at 
135 0C for 3 hours. The reaction mixture was poured into ice-water and stirred vigorously to obtain 
the precipitate, which was filtered and dried to afford the compound 25 (2.24 g, 74%). 1H NMR (400 
MHz, CDCl3) δ 8.30 (ddd, J = 8.4, 1.4, 0.6 Hz, 1H), 8.14 (ddd, J = 8.5, 1.2, 0.6 Hz, 1H), 7.97 (ddd, J 
= 8.5, 7.0, 1.4 Hz, 1H), 7.84 (ddd, J = 8.3, 7.0, 1.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 146.64, 
139.73, 135.62, 133.44, 129.76, 129.37, 125.22, 124.46. 
 
Synthesis of Compound 26: N-Benzyl-2-chloro-3-nitroquinolin-4-amine.  
 
To a solution of 25 (2.24 g, 9.26 mmol) in 30 mL of anhydrous dichloromethane, were added 
triethylamine (1.4 g, 13.9 mmol) and benzylamine (1.19 g, 11.1 mmol). The reaction mixture was 
refluxed at 45 0C for 30 minutes. The solvent was then evaporated under vacuum and water was 
added to the residue to obtain the precipitate. This was filtered, washed several times with water and 
dried to obtain the compound 26 (2.1 g, 73%). 1H NMR (400 MHz, DMSO) δ 8.54 (dd, J = 12.9, 7.3 
Hz, 2H), 7.89 – 7.81 (m, 2H), 7.69 (td, J = 8.6, 5.0 Hz, 1H), 7.39 – 7.21 (m, 5H), 4.46 (d, J = 6.3 Hz, 
2H). 13C NMR (101 MHz, DMSO) δ 145.79, 144.82, 141.51, 138.27, 132.70, 129.08, 128.94, 127.89, 
127.40, 127.15, 126.96, 123.52, 120.12, 47.24. MS (ESI) calculated for C16H12ClN3O2, m/z 313.06, 
found 312.06 (M - H)-. 
 
Synthesis of Compound 27: N4-Benzyl-2-chloroquinoline-3,4-diamine.  
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To a solution of 26 (2.21g, 7.06 mmol) in 20 mL of EtOAc, were added a catalytic amount of Pt/C and 
Na2SO4. The reaction mixture was subjected to hydrogenation at 55 psi hydrogen pressure for 3 
hours. The reaction mixture was then filtered through celite and the filtrate was evaporated under 
vacuum to obtain the compound 27 (1.8 g, 90%). 1H NMR (400 MHz, MeOD) δ 7.90 (d, J = 8.2 Hz, 
1H), 7.70 (d, J = 8.4 Hz, 1H), 7.43 (t, J = 7.6 Hz, 1H), 7.38 – 7.31 (m, 3H), 7.25 (t, J = 7.5 Hz, 2H), 
7.20 (d, J = 7.0 Hz, 1H), 4.51 (s, 2H). 13C NMR (101 MHz, MeOD) δ 141.54, 141.28, 139.93, 137.86, 
128.45, 128.04, 127.44, 126.96, 126.80, 126.22, 125.31, 123.22, 121.40, 49.56. MS (ESI) calculated 
for C16H14ClN3, m/z 283.09, found 284.10 (M + H)
+. 
 
General Procedure for Synthesis of C-2 alkyl imidazoquinoline compounds (28-38).  
Synthesis of Compound 32: 1-Benzyl-2-pentyl-1H-imidazo[4,5-c]quinolin-4-amine.  
 
To a solution of 27 (50 mg, 0.18 mmol) in anhydrous THF, were added triethylamine (26 mg, 0.19 
mmol) and hexanoyl chloride. The reaction mixture was stirred at room temperature for 6 hours. The 
solvent was then removed under vacuum, and the residue was dissolved in ethyl acetate and 
washed with water. The ethyl acetate fraction was dried using Na2SO4 and evaporated under 
vacuum to obtain the intermediate amide compound. This was dissolved in 0.1 mL of 2M solution of 
ammonia in MeOH. The sealed reaction vessel was heated in microwave at 150 0C for 1 hour. The 
solvent was then removed under vacuum and the residue was purified using column chromatography 
(7% MeOH/dichloromethane) to obtain the compound 32 (8 mg; unoptimized yields). 1H NMR (500 
MHz, CDCl3) δ 7.81 (d, J = 8.3 Hz, 1H), 7.72 (dd, J = 8.3, 1.0 Hz, 1H), 7.44 (qd, J = 7.0, 3.5 Hz, 1H), 
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7.38 – 7.29 (m, 3H), 7.18 – 7.10 (m, 1H), 7.06 (d, J = 6.9 Hz, 2H), 5.74 (s, 2H), 5.60 (s, 2H), 2.95 – 
2.79 (m, 2H), 1.80 (dt, J = 15.6, 7.6 Hz, 2H), 1.42 – 1.27 (m, 4H), 0.87 (t, J = 7.2 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 153.50, 150.28, 134.61, 133.41, 128.61, 127.40, 126.51, 125.94, 125.85, 
124.85, 121.69, 119.07, 114.42, 48.20, 30.85, 26.97, 26.77, 21.65, 13.23. MS (ESI) calculated for 
C22H24N4, m/z 344.20, found 345.21 (M + H)
+. 2D 1H COSY and NOESY experiments (included in 
Supporting Information) provided unambiguous assignment of 1H resonances. 
 
28: 1-Benzyl-2-methyl-1H-imidazo[4,5-c]quinolin-4-amine.  
 
1H NMR (500 MHz, CDCl3) δ 7.81 (dd, J = 8.4, 0.8 Hz, 1H), 7.75 (dd, J = 8.3, 1.0 Hz, 1H), 7.45 (ddd, 
J = 8.4, 7.1, 1.4 Hz, 1H), 7.38 – 7.28 (m, 3H), 7.15 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H), 7.10 – 7.05 (m, 
2H), 5.73 (s, 2H), 5.64 (s, 2H), 2.63 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 149.17, 148.91, 142.26, 
133.27, 132.64, 127.74, 126.56, 125.74, 124.90, 124.82, 123.96, 120.90, 117.99, 113.37, 47.59, 
12.20. MS (ESI) calculated for C18H16N4, m/z 288.14, found 289.15 (M + H)
+
. 
 
29: 1-Benzyl-2-ethyl-1H-imidazo[4,5-c]quinolin-4-amine.  
 
1H NMR (500 MHz, CDCl3) δ 7.80 (dd, J = 8.4, 0.8 Hz, 1H), 7.73 (dd, J = 8.3, 1.0 Hz, 1H), 7.44 (qd, J 
= 7.2, 3.7 Hz, 1H), 7.37 – 7.28 (m, 3H), 7.13 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.09 – 7.01 (m, 2H), 5.73 
(s, 2H), 5.59 (s, 2H), 2.97 – 2.86 (m, 2H), 1.41 (t, J = 7.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
153.83, 149.91, 143.24, 134.14, 133.05, 128.19, 126.96, 126.04, 125.64, 125.52, 124.43, 121.20, 
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118.62, 114.05, 47.69, 19.72, 10.98. MS (ESI) calculated for C19H18N4, m/z 302.15, found 303.16 (M 
+ H)+. 
 
30: 1-Benzyl-2-propyl-1H-imidazo[4,5-c]quinolin-4-amine.  
 
1H NMR (500 MHz, CDCl3) δ 7.80 (dd, J = 8.4, 0.8 Hz, 1H), 7.71 (dd, J = 8.3, 1.0 Hz, 1H), 7.49 – 
7.42 (m, 1H), 7.40 – 7.30 (m, 3H), 7.18 – 7.10 (m, 1H), 7.10 – 7.05 (m, 2H), 5.74 (s, 2H), 5.66 (s, 
2H), 2.92 – 2.80 (m, 2H), 1.91 – 1.85 (m, 2H), 1.03 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
153.50, 150.46, 143.54, 134.77, 133.58, 128.82, 127.60, 126.73, 126.12, 126.05, 125.01, 121.90, 
119.30, 114.59, 48.36, 28.88, 20.92, 13.52. MS (ESI) calculated for C20H20N4, m/z 316.17, found 
317.17 (M + H)+. 
 
31: 1-Benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine.  
 
1H NMR (500 MHz, CDCl3) δ 7.80 (dd, J = 8.4, 0.8 Hz, 1H), 7.72 (dd, J = 8.3, 1.0 Hz, 1H), 7.43 (ddd, 
J = 8.4, 7.0, 1.4 Hz, 1H), 7.36 – 7.28 (m, 3H), 7.12 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H), 7.08 – 7.04 (m, 
2H), 5.73 (s, 2H), 5.56 (s, 2H), 2.91 – 2.83 (m, 2H), 1.84 – 1.74 (m, 2H), 1.43 (dq, J = 14.8, 7.4 Hz, 
2H), 0.92 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 152.56, 149.54, 142.97, 133.87, 132.54, 
127.81, 126.58, 125.61, 125.34, 125.21, 124.06, 120.78, 118.25, 113.71, 47.38, 28.54, 25.71, 21.04, 
12.28. MS (ESI) calculated for C21H22N4, m/z 330.18, found 331.19 (M + H)
+
. 
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33: 1-Benzyl-2-hexyl-1H-imidazo[4,5-c]quinolin-4-amine.  
 
1H NMR (400 MHz, CDCl3) δ 7.82 (d, J = 8.4 Hz, 1H), 7.72 (d, J = 8.2 Hz, 1H), 7.45 (t, J = 7.7 Hz, 
1H), 7.38 – 7.29 (m, 3H), 7.13 (t, J = 7.6 Hz, 1H), 7.07 (d, J = 7.4 Hz, 2H), 5.73 (s, 2H), 5.63 (s, 2H), 
2.93 – 2.83 (m, 2H), 1.87 – 1.73 (m, 2H), 1.40 (dd, J = 14.3, 6.7 Hz, 2H), 1.34 – 1.24 (m, 4H), 0.88 (t, 
J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 154.01, 151.10, 144.59, 135.38, 133.98, 129.25, 
128.02, 127.02, 126.87, 126.69, 125.54, 122.17, 119.70, 115.20, 48.84, 31.44, 29.05, 27.90, 27.46, 
22.46, 14.01. MS (ESI) calculated for C23H26N4, m/z 358.22, found 359.22 (M + H)
+
. 
 
34: 1-Benzyl-2-heptyl-1H-imidazo[4,5-c]quinolin-4-amine.  
 
1H NMR (500 MHz, CDCl3) δ 7.81 (dd, J = 8.4, 0.8 Hz, 1H), 7.71 (dd, J = 8.3, 1.0 Hz, 1H), 7.44 (ddd, 
J = 8.4, 7.1, 1.3 Hz, 1H), 7.35 – 7.29 (m, 3H), 7.12 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 7.05 (d, J = 6.9 Hz, 
2H), 5.72 (s, 4H), 2.86 (dd, J = 18.2, 10.2 Hz, 2H), 1.79 (dt, J = 15.5, 7.7 Hz, 2H), 1.39 (dt, J = 14.9, 
7.0 Hz, 2H), 1.34 – 1.18 (m, 6H), 0.86 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 152.52, 
149.22, 142.11, 133.55, 132.39, 127.57, 126.36, 125.49, 124.86, 124.69, 123.80, 120.69, 118.05, 
113.31, 47.15, 29.89, 27.60, 27.19, 26.21, 25.75, 20.85, 12.34. MS (ESI) calculated for C24H28N4, 
m/z 372.23, found 373.24 (M + H)+. 
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35: 1-Benzyl-2-nonyl-1H-imidazo[4,5-c]quinolin-4-amine.  
 
1H NMR (500 MHz, CDCl3) δ 7.85 – 7.79 (m, 1H), 7.71 (dd, J = 8.3, 0.9 Hz, 1H), 7.44 (qd, J = 6.9, 
3.4 Hz, 1H), 7.38 – 7.29 (m, 3H), 7.13 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 7.05 (d, J = 6.9 Hz, 2H), 5.85 
(s, 2H), 5.72 (s, 2H), 2.90 – 2.84 (m, 2H), 1.87 – 1.71 (m, 2H), 1.44 – 1.33 (m, 2H), 1.33 – 1.18 (m, 
10H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 152.31, 148.72, 141.13, 133.07, 132.10, 
127.20, 126.00, 125.25, 124.35, 123.92, 123.40, 120.47, 117.71, 112.77, 46.79, 29.72, 27.59, 27.26, 
27.24, 27.13, 27.12, 25.78, 25.35, 20.53, 12.00. MS (ESI) calculated for C26H32N4, m/z 400.26, found 
401.27 (M + H)+. 
 
36: 1-Benzyl-2-undecyl-1H-imidazo[4,5-c]quinolin-4-amine.  
 
1H NMR (500 MHz, CDCl3) δ 7.81 (d, J = 8.2 Hz, 1H), 7.71 (d, J = 7.7 Hz, 1H), 7.47 – 7.42 (m, 1H), 
7.36 – 7.28 (m, 3H), 7.15 – 7.11 (m, 1H), 7.06 (d, J = 7.0 Hz, 2H), 5.73 (s, 2H), 5.70 (s, 2H), 3.02 – 
2.71 (m, 2H), 1.79 (dt, J = 15.5, 7.8 Hz, 2H), 1.44 – 1.34 (m, 2H), 1.34 – 1.18 (m, 14H), 0.88 (t, J = 
7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 152.56, 149.23, 142.11, 133.58, 132.43, 127.60, 126.39, 
125.53, 124.89, 124.73, 123.83, 120.73, 118.08, 113.34, 47.19, 30.20, 27.88, 27.73, 27.67, 27.62, 
27.56, 26.24, 25.78, 20.98, 12.43. MS (ESI) calculated for C28H36N4, m/z 428.29, found 429.30 (M + 
H)+. 
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37: 1-Benzyl-2-pentadecyl-1H-imidazo[4,5-c]quinolin-4-amine.  
 
1H NMR (500 MHz, CDCl3) δ 7.81 (dd, J = 8.4, 0.8 Hz, 1H), 7.72 (dd, J = 8.3, 1.0 Hz, 1H), 7.44 (ddd, 
J = 8.4, 7.1, 1.3 Hz, 1H), 7.36 – 7.27 (m, 3H), 7.13 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H), 7.09 – 7.02 (m, 
2H), 5.73 (s, 2H), 5.69 (s, 2H), 2.91 – 2.83 (m, 2H), 1.79 (dt, J = 15.5, 7.7 Hz, 2H), 1.59 – 1.33 (m, 
2H), 1.33 – 1.16 (m, 22H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 151.99, 148.66, 
141.59, 133.01, 131.85, 127.03, 125.82, 124.96, 124.32, 124.17, 123.26, 120.16, 117.50, 112.78, 
46.62, 29.66, 27.43, 27.40, 27.39, 27.37, 27.32, 27.17, 27.11, 27.10, 26.99, 25.68, 25.21, 20.43, 
11.86. MS (ESI) calculated for C32H44N4, m/z 484.36, found 485.36 (M + H)
+
. 
 
38: 1-Benzyl-2-(but-3-enyl)-1H-imidazo[4,5-c]quinolin-4-amine.  
 
1H NMR (500 MHz, CDCl3) δ 7.80 (dd, J = 8.4, 0.8 Hz, 1H), 7.73 (dd, J = 8.3, 1.0 Hz, 1H), 7.46 – 
7.42 (m, 1H), 7.36 – 7.29 (m, 3H), 7.13 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 7.08 – 7.05 (m, 2H), 5.96 – 
5.84 (m, 1H), 5.74 (s, 2H), 5.58 (s, 2H), 5.11 – 4.97 (m, 2H), 3.03 – 2.93 (m, 2H), 2.64 – 2.54 (m, 
2H). 13C NMR (126 MHz, CDCl3) δ 150.99, 148.87, 134.50, 133.06, 131.93, 127.16, 125.97, 125.02, 
124.64, 124.58, 123.43, 120.17, 117.57, 113.92, 46.72, 29.59, 24.77. MS (ESI) calculated for 
C21H20N4, m/z 328.17, found 329.18 (M + H)
+
. 
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Synthesis of Compound 40: N-Benzyl-3-nitroquinolin-4-amine.  
 
To a solution of 39 (2.03 mg, 9.76 mmol) in 20 mL of anhydrous dichloromethane, were added 
triethylamine (1.48 g, 14.64 mmol) and benzylamine (1.36 g, 12.69 mmol). The reaction mixture was 
refluxed at 45 0C for 30 minutes. The solvent was then evaporated under vacuum and water was 
added to the residue to obtain the precipitate This was filtered, washed several times with water and 
dried to obtain the compound 40 (2.6 g, 95%). 1H NMR (400 MHz, CDCl3) δ 9.89 (s, 1H), 9.42 (s, 
1H), 8.31 (d, J = 8.6 Hz, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.79 (t, J = 7.6 Hz, 1H), 7.56 – 7.35 (m, 6H), 
5.13 (d, J = 5.7 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 151.01, 150.64, 147.37, 136.84, 132.73, 
130.51, 129.36, 128.54, 127.16, 126.84, 126.33, 125.58, 119.14, 53.06. MS (ESI) calculated for 
C16H13N3O2, m/z 279.10, found 280.11 (M + H)
+. 
 
Synthesis of Compound 41: N4-Benzylquinoline-3,4-diamine.  
 
To a solution of 40 (2.6 g, 7.06 mmol) in 10 mL of EtOAc, were added a catalytic amount of Pt/C and 
Na2SO4. The reaction mixture was subjected to hydrogenation at 55 psi hydrogen pressure for 4 
hours. The reaction mixture was then filtered through celite and the filtrate was evaporated under 
vacuum to obtain the compound 41 (2.3 g, 96%). 1H NMR (400 MHz, CDCl3) δ 8.53 (s, 1H), 8.00 (d, 
J = 8.3 Hz, 1H), 7.75 (d, J = 8.2 Hz, 1H), 7.56 – 7.29 (m, 7H), 4.43 (s, 2H), 4.05 (s, 1H), 3.78 (s, 2H). 
13C NMR (101 MHz, CDCl3) δ 143.59, 143.48, 141.10, 139.77, 129.89, 129.84, 128.81, 127.77, 
127.60, 126.05, 125.76, 120.06, 99.98, 50.98. MS (ESI) calculated for C16H15N3, m/z 249.13, found 
250.13 (M + H)+. 
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Synthesis of Compound 43: 1-Benzyl-2-(but-3-ynyl)-1H-imidazo[4,5-c]quinolin-4-amine.  
 
To a solution of pentynoic acid (37 mg, 0.38 mmol) in anhydrous DMF, were added HBTU (142 mg, 
0.38 mmol), triethylamine (52 mg, 0.51 mmol), a catalytic amount of DMAP and 41 (85 mg, 0.34 
mmol). The reaction mixture was then heated to 90 oC for 1 hour. The solvent was then removed 
under vacuum. The residue was dissolved in EtOAc, washed with water, dried over Na2SO4 and then 
concentrated to obtain the residue. This was purified using column chromatography (7% 
MeOH/dichloromethane) to obtain the compound 42 (60 mg). To a solution of 42 in a solvent mixture 
of MeOH:dichloromethane:chloroform (0.1:1:1), was added 3-chloroperoxybenzoic acid (83 mg, 0.48 
mmol), and the solution was refluxed at 45-50 oC for 40 minutes. The solvent was then removed 
under vacuum and the residue was purified using column chromatography (8% 
MeOH/dichloromethane) to obtain the N-oxide derivative (30 mg). This was then dissolved in 
anhydrous dichloromethane, followed by the addition of benzoyl isocyanate (20 mg, 0.14 mmol) and 
heated at 45 oC for 15 minutes. The solvent was then removed under vacuum and the residue was 
dissolved in anhydrous MeOH, followed by the addition of excess sodium methoxide. The reaction 
mixture was then heated at 80 oC for 1 hour. The solvent was removed under vacuum and the 
residue was purified using column chromatography (6% MeOH/dichloromethane) to obtain the 
compound 43 (15 mg, 12%). 1H NMR (500 MHz, CDCl3) δ 7.81 (dd, J = 8.4, 0.8 Hz, 1H), 7.74 (dd, J 
= 8.3, 1.0 Hz, 1H), 7.46 (ddd, J = 8.4, 5.7, 1.3 Hz, 1H), 7.37 – 7.30 (m, 3H), 7.15 (ddd, J = 8.3, 7.1, 
1.2 Hz, 1H), 7.09 – 7.05 (m, 2H), 5.79 (s, 2H), 5.68 (s, 2H), 3.11 (dd, J = 8.8, 6.4 Hz, 2H), 2.87 – 
2.71 (m, 2H), 1.99 (t, J = 2.6 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 150.49, 149.42, 133.45, 132.82, 
127.91, 126.75, 126.01, 125.19, 124.98, 124.08, 121.13, 118.33, 113.52, 81.16, 68.15, 47.46, 25.06, 
15.63. MS (ESI) calculated for C21H18N4, m/z 326.15, found 327.16 (M + H)
+. 
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Synthesis of Compound 44: 1-Benzyl-4-chloro-2-pentyl-1H-imidazo[4,5-c]quinoline.  
 
To a solution 27 (200 mg, 0.71 mmol) in anhydrous THF, were added triethylamine (179 mg, 1.77 
mmol) and hexanoyl chloride (143 mg, 1.06 mmol). The reaction mixture was then stirred for 6-8 
hours, followed by removal of the solvent under vacuum. The residue was dissolved in EtOAc, 
washed with water, brine and then dried over Na2SO4 to obtain the intermediate amide compound. 
This was dissolved in MeOH, followed by the addition of calcium oxide. The reaction mixture was 
then heated in microwave at 110 oC for 1 hour. The solvent was removed under vacuum and the 
residue was purified using column chromatography (3% MeOH/dichloromethane) to obtain the 
compound 44 (170 mg, 66%). 1H NMR (400 MHz, CDCl3) δ 8.16 (d, J = 8.4 Hz, 1H), 7.88 (d, J = 8.4 
Hz, 1H), 7.60 (t, J = 7.7 Hz, 1H), 7.42 (t, J = 7.7 Hz, 1H), 7.38 – 7.30 (m, 3H), 7.05 (d, J = 7.0 Hz, 
2H), 5.81 (s, 2H), 3.05 – 2.95 (m, 2H), 1.84 (dt, J = 15.6, 7.6 Hz, 2H), 1.48 – 1.24 (m, 4H), 0.88 (t, J 
= 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 156.40, 143.96, 143.60, 135.40, 134.74, 133.74, 
129.93, 129.42, 128.30, 127.56, 126.58, 125.40, 119.91, 117.29, 49.19, 31.63, 27.91, 27.70, 22.29, 
13.90. MS (ESI) calculated for C22H22ClN3, m/z 363.15, found 364.15 (M + H)
+. 
 
Synthesis of Compound 46: 1-Benzyl-2-pentyl-1H-imidazo[4,5-c]quinolin-4-ol.  
 
The compound 44 (50 mg, 0.14 mmol) was dissolved in 6M HCl and the solution was heated in 
microwave at 110 oC for 1 hour. The solvent was then removed under vacuum and the residue was 
purified using column chromatography (7% MeOH/dichloromethane) to obtain the compound 46 (38 
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mg, 80%). 1H NMR (400 MHz, DMSO) δ 11.59 (s, 1H), 7.74 (d, J = 8.2 Hz, 1H), 7.43 (d, J = 8.2 Hz, 
1H), 7.39 – 7.30 (m, J = 8.3 Hz, 3H), 7.30 – 7.23 (m, J = 7.2 Hz, 1H), 7.08 – 7.00 (m, J = 7.5 Hz, 3H), 
5.83 (s, 2H), 2.83 (t, J = 7.5 Hz, 2H), 1.79 – 1.65 (m, 2H), 1.40 – 1.16 (m, 4H), 0.82 (t, J = 7.0 Hz, 
3H). 13C NMR (101 MHz, DMSO) δ 157.78, 154.36, 137.04, 136.73, 134.44, 131.09, 129.43, 128.08, 
127.95, 125.94, 121.98, 121.27, 116.69, 112.04, 48.44, 31.22, 27.11, 26.69, 22.30, 14.26. MS (ESI) 
calculated for C22H23N3, m/z 345.18, found 346.19 (M + H)
+. 
Synthesis of Compound 47: 1-Benzyl-2-pentyl-4-phenyl-1H-imidazo[4,5-c]quinoline.  
 
Suzuki coupling of the compound 44 with phenyl boronic acid was performed. To a solution of 44 (70 
mg, 0.19 mmol) in THF, were added polystyrene-bound PPh3-Pd (9.5 mg, 0.00095 mmol), K2CO3 (40 
mg, 0.29 mmol) dissolved in water and phenyl boronic acid (28 mg, 0.23 mmol). The reaction was 
heated at 80 oC for 10-12 hours. The solution was filtered to remove the solid resin and the filtrate 
was evaporated under vacuum to obtain the residue. This was purified using column 
chromatography (30% EtOAc/hexane) to obtain the compound 47 (25 mg, 33%). 1H NMR (400 MHz, 
CDCl3) δ 8.81 – 8.77 (m, 1H), 8.33 (dd, J = 8.5, 0.8 Hz, 1H), 7.93 (dd, J = 8.4, 0.8 Hz, 1H), 7.64 – 
7.58 (m, 3H), 7.55 – 7.49 (m, 1H), 7.36 (dddd, J = 9.8, 6.9, 6.1, 2.2 Hz, 4H), 7.12 – 7.07 (m, 2H), 
5.84 (s, 2H), 3.03 – 2.85 (m, 2H), 1.91 (dt, J = 15.5, 7.6 Hz, 2H), 1.42 (ddt, J = 36.4, 21.9, 7.4 Hz, 
4H), 0.92 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 155.17, 151.02, 144.50, 138.18, 135.43, 
135.10, 135.01, 130.96, 130.01, 129.31, 129.27, 128.37, 128.05, 126.74, 125.76, 125.52, 119.61, 
117.17, 48.92, 31.58, 27.56, 27.48, 22.37, 13.97. MS (ESI) calculated for C28H27N3, m/z 405.22, 
found 406.23 (M + H)+. 
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Synthesis of Compound 48: N-(1-Benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-
yl)hydroxylamine.  
 
To a solution of 27 (100 mg, 0.35 mmol) in anhydrous THF, were added triethylamine (72 mg, 0.71 
mmol) and valeryl chloride (51 mg, 0.42 mmol). The reaction mixture was then stirred for 6-8 hours, 
followed by removal of the solvent under vacuum. The residue was dissolved in EtOAc, washed with 
water, brine and then dried over Na2SO4 to obtain the residue. This was dissolved in MeOH, followed 
by the addition of calcium oxide. The reaction mixture was then heated in microwave at 110 oC for 1 
hour. The solvent was removed under vacuum and the residue was purified using column 
chromatography (3% MeOH/dichloromethane) to obtain 45 (75 mg, 62%). To a solution of 45 (25 mg, 
0.072 mmol) in anhydrous MeOH, were added triethylamine (72 mg, 0.72 mmol) and hydroxylamine 
hydrochloride (76 mg, 1.08 mmol). The reaction mixture was heated at 50 oC for 10-12 hours. The 
solvent was then removed under vacuum and the residue was dissolved in EtOAc, washed with 
water and dried over Na2SO4. The EtOAc fraction was then evaporated under vacuum and the 
residue was purified using basic-alumina (pH>7) column chromatography (30% 
MeOH/dichloromethane) to obtain the compound 48 (10 mg, 40%). 1H NMR (500 MHz, CDCl3) δ 
7.41 (d, J = 8.1 Hz, 1H), 7.32 (dq, J = 25.0, 7.2 Hz, 4H), 7.21 (s, 1H), 7.06 (d, J = 7.1 Hz, 2H), 6.88 
(dd, J = 10.6, 5.7 Hz, 1H), 5.61 (s, 2H), 2.84 – 2.77 (m, 2H), 1.78 (dt, J = 15.5, 7.7 Hz, 2H), 1.40 (dt, 
J = 15.0, 7.4 Hz, 2H), 0.90 – 0.86 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 151.78, 133.18, 127.13, 
125.87, 125.13, 123.30, 119.10, 117.94, 46.50, 27.68, 24.81, 20.34, 11.58. MS (ESI) calculated for 
C21H22N4O, m/z 346.18, found 347.19 (M + H)
+. 
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Synthesis of Compound 49: 1-Benzyl-2-butyl-4-hydrazinyl-1H-imidazo[4,5-c]quinoline.  
 
 
To a solution of 45 (60 mg, 0.17 mmol) in anhydrous MeOH, was added tert-butyl carbazate (57 mg, 
0.43 mmol). After 15 hours, the solvent was removed under vacuum and the residue was purified 
using column chromatography (4% MeOH/dichloromethane) to obtain the intermediate N-Boc 
derivative. This was then dissolved in 5 mL of trifluoroacetic acid and stirred for 30 minutes, followed 
by removal of the solvent by purging nitrogen and drying under vacuum to obtain the trifluoroacetate 
salt of the compound 49 (55 mg, 57%). 1H NMR (500 MHz, MeOD) δ 7.82 (d, J = 8.4 Hz, 1H), 7.79 
(d, J = 8.3 Hz, 1H), 7.45 – 7.40 (m, 1H), 7.28 (dt, J = 25.5, 7.2 Hz, 3H), 7.15 – 7.10 (m, 1H), 7.03 (d, 
J = 7.4 Hz, 2H), 5.82 (s, 2H), 2.94 – 2.90 (m, 2H), 1.79 – 1.69 (m, 2H), 1.40 (dq, J = 14.8, 7.4 Hz, 
2H), 0.90 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 154.65, 151.25, 143.19, 135.64, 133.54, 
128.81, 128.68, 127.41, 126.96, 125.31, 125.10, 124.68, 122.23, 120.02, 114.47, 48.23, 29.28, 
26.26, 21.84, 12.51. MS (ESI) calculated for C21H23N5, m/z 345.20, found 346.20 (M + H)
+. 
 
Synthesis of Compound 50: 1-Benzyl-2-butyl-1H-imidazo[4,5-c]quinoline.  
 
To a solution of 41 (300 mg, 1.221 mmol) in anhydrous THF, were added triethylamine (183 mg, 1.82 
mmol) and valeryl chloride (174 mg, 1.45 mmol). The reaction mixture was then stirred for 6-8 hours, 
followed by removal of the solvent under vacuum. The residue was dissolved in EtOAc, washed with 
water, brine and then dried over Na2SO4 to obtain the intermediate amide compound. This was 
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dissolved in MeOH, followed by the addition of calcium oxide. The reaction mixture was then heated 
in microwave at 110 oC for an hour. The solvent was removed under vacuum and the residue was 
purified using column chromatography (9% MeOH/dichloromethane) to obtain the compound 50 (360 
mg, 94%). 1H NMR (400 MHz, CDCl3) δ 9.38 (s, 1H), 8.25 (d, J = 8.1 Hz, 1H), 7.93 (d, J = 8.5 Hz, 
1H), 7.66 – 7.57 (m, 1H), 7.42 (dd, J = 11.2, 4.1 Hz, 1H), 7.40 – 7.31 (m, 3H), 7.06 (d, J = 6.6 Hz, 
2H), 5.80 (s, 2H), 3.02 – 2.85 (m, 2H), 1.90 (dt, J = 15.4, 7.7 Hz, 2H), 1.57 – 1.39 (m, 2H), 0.96 (t, J 
= 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 155.81, 144.98, 144.75, 136.53, 135.14, 134.10, 
130.83, 129.35, 128.15, 126.72, 126.29, 125.47, 119.88, 117.58, 48.94, 29.57, 27.18, 22.53, 13.77. 
MS (ESI) calculated for C21H21N3, m/z 315.17, found 316.18 (M + H)
+. 
 
Synthesis of Compound 52: 1-Benzyl-2-((ethylamino)methyl)-1H-imidazo[4,5-c]quinolin-4-
amine.  
 
To a solution of 2-(tert-butoxycarbonyl(ethyl)amino)acetic acid (90 mg, 0.44 mmol) in anhydrous 
DMF, were added HBTU (167 mg, 0.44 mmol), triethylamine (53 mg, 0.52 mmol), a catalytic amount 
of DMAP and 41 (100 mg, 0.4 mmol). The reaction mixture was then heated to 70 oC for 18 hours. 
The solvent was then removed under vacuum. The residue was dissolved in EtOAc, washed with 
water, dried using Na2SO4 and then concentrated to obtain the residue, which was purified using 
column chromatography (6% MeOH/dichloromethane) to obtain the compound 51 (133 mg). To a 
solution of 51 in a solvent mixture of MeOH:dichloromethane:chloroform (0.1:1:1), 3-
chloroperoxybenzoic acid (138 mg, 0.8 mmol) was added and the solution was refluxed at 45-50 oC 
for 40 minutes. The solvent was then removed under vacuum and the residue was purified using 
column chromatography (10% MeOH/dichloromethane) to obtain the N-oxide derivative (31 mg). 
This was then dissolved in anhydrous dichloromethane, followed by the addition of benzoyl 
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isocyanate (16 mg, 0.11 mmol) and heated at 45 oC for 15 minutes. The solvent was then removed 
under vacuum and the residue was dissolved in anhydrous MeOH, followed by the addition of excess 
sodium methoxide and heated at 80 oC for 1 hour. The solvent was then removed under vacuum and 
the residue was purified using column chromatography (8% MeOH/dichloromethane) to obtain the 
intermediate N-Boc derivative. This was dissolved in 5 mL of trifluoroacetic acid and stirred for 30 
minutes, followed by removal of the solvent by purging nitrogen and drying under vacuum to obtain 
the trifluoroacetate salt of the compound 52 (26 mg, 20%). 1H NMR (400 MHz, MeOD) δ 8.02 (d, J = 
8.4 Hz, 1H), 7.82 (d, J = 8.4 Hz, 1H), 7.69 (t, J = 7.8 Hz, 1H), 7.49 – 7.32 (m, 4H), 7.15 (d, J = 7.6 
Hz, 2H), 6.00 (s, 2H), 4.71 (s, 2H), 3.38 (q, J = 7.3 Hz, 2H), 1.45 (t, J = 7.3 Hz, 3H). 13C NMR (101 
MHz, MeOD) δ 149.52, 148.45, 136.86, 134.46, 134.03, 130.18, 129.15, 128.12, 125.29, 125.15, 
124.97, 121.76, 118.34, 112.47, 48.94, 43.17, 42.36, 10.06. MS (ESI) calculated for C20H21N5, m/z 
331.18, found 332.19 (M + H)+. 
 
Synthesis of Compound 54: 1-(4-Amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)-2-
methylpropan-2-ol.  
 
To a solution of 20 (100 mg, 0.43 mmol) in anhydrous THF, were added triethylamine (66 mg, 0.65 
mmol) and valeryl chloride (62 mg, 0.52 mmol). The reaction mixture was then stirred for 6-8 hours, 
followed by removal of the solvent under vacuum. The residue was dissolved in EtOAc, washed with 
water, brine and then dried over Na2SO4 to obtain the intermediate amide compound. This was 
dissolved in MeOH, followed by the addition of calcium oxide and was heated in microwave at 110 oC 
for 1 hour. The solvent was then removed and the residue was purified using column 
chromatography (9% MeOH/dichloromethane) to obtain the compound 53 (58 mg). To a solution of 
53 in a solvent mixture of MeOH:dichloromethane:chloroform (0.1:1:1), was added 3-
N NH2
N
N
HO
54
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chloroperoxybenzoic acid (84 mg, 0.49 mmol) and the solution was refluxed at 45-50 oC for 40 
minutes. The solvent was then removed and the residue was purified using column chromatography 
(20% MeOH/dichloromethane) to obtain the N-oxide derivative (55 mg). This was then dissolved in 
anhydrous dichloromethane, followed by the addition of benzoyl isocyanate (39 mg, 0.26 mmol) and 
heated at 45 oC for 15 minutes. The solvent was then removed under vacuum and the residue was 
dissolved in anhydrous MeOH, followed by the addition of excess sodium methoxide. The reaction 
mixture was then heated at 80 oC for an hour. The solvent was removed under vacuum and the 
residue was purified using column chromatography (11% MeOH/dichloromethane) to obtain the 
compound 54 (40 mg, 30%). 1H NMR (400 MHz, MeOD) δ 8.26 (d, J = 8.3 Hz, 1H), 7.69 (d, J = 8.4 
Hz, 1H), 7.47 (t, J = 7.7 Hz, 1H), 7.31 (t, J = 7.7 Hz, 1H), 4.63 (s, 2H), 3.20 – 3.02 (m, 2H), 1.98 – 
1.80 (m, 2H), 1.62 – 1.45 (m, 2H), 1.27 (s, 6H), 1.04 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, MeOD) 
δ 156.33, 151.22, 143.80, 134.53, 126.75, 125.41, 125.12, 121.49, 120.93, 115.31, 71.16, 54.80, 
29.72, 27.12, 26.52, 22.24, 12.86. MS (ESI) calculated for C18H24N4O, m/z 312.20, found 313.20 (M 
+ H)+. 
 
Synthesis of Compound 55: 1-Benzyl-4-chloro-1H-[1,2,3]triazolo[4,5-c]quinoline.  
 
To a solution of 27 (60 mg, 0.21 mmol) in 1.5 mL of 1:1 acetic acid/water at 0 oC, was added 0.5N 
aqueous solution of sodium nitrite (0.56 mL, 0.28 mmol) and the reaction was stirred for 2 hours. The 
solvent was then removed under vacuum. The residue was dissolved in EtOAc, washed with water 
and dried over Na2SO4. The EtOAc fraction was then concentrated under vacuum to obtain the 
compound 55 (58 mg, 94%). 1H NMR (500 MHz, CDCl3) δ 8.12 (dd, J = 8.4, 0.7 Hz, 1H), 7.96 (dd, J 
= 8.2, 0.9 Hz, 1H), 7.70 (ddd, J = 8.4, 7.2, 1.4 Hz, 1H), 7.52 (ddd, J = 8.3, 7.2, 1.2 Hz, 1H), 7.30 – 
7.21 (m, 3H), 7.12 – 7.09 (m, 2H), 6.19 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 142.94, 141.16, 
136.74, 132.71, 131.61, 128.30, 127.80, 127.24, 126.61, 125.80, 124.24, 124.20, 120.01, 112.71, 
N
N
N
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Cl
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52.00. MS (ESI) calculated for C16H11ClN4, m/z 294.07, found 317.06 (M + Na
+) and 612.11 (M + M + 
Na+). 
 
Synthesis of Compound 56: 1-Benzyl-1H-[1,2,3]triazolo[4,5-c]quinolin-4-amine.  
 
Compound 55 (46 mg, 0.16 mmol) was dissolved in 0.1 mL of 2M ammonia solution in MeOH and 
the reaction was heated in microwave at 150 oC for 1 hour. The solvent was then removed under 
vacuum and the residue was purified using column chromatography (65% EtOAc/hexane) to obtain 
the compound 56 (35 mg, 82%). 1H NMR (500 MHz, TFA) δ 8.25 – 8.13 (m, 1H), 7.87 (d, J = 7.2 Hz, 
1H), 7.79 (d, J = 8.0 Hz, 1H), 7.63 (t, J = 6.1 Hz, 1H), 7.39 (s, 3H), 7.24 (s, 2H), 6.38 (d, J = 23.6 Hz, 
2H). 13C NMR (126 MHz, TFA) δ 134.33, 133.27, 131.52, 129.18, 129.06, 127.08, 125.83, 123.58, 
118.48, 117.54, 115.29, 113.04, 110.78, 54.87. MS (ESI) calculated for C16H11N5, m/z 275.12, found 
276.12 (M + H)+. 
 
Synthesis of Compound 57: 1-Benzyl-2-oxo-N-propyl-1H-imidazo[4,5-c]quinoline-3(2H)-
carboxamide.  
 
To a solution of 41 (30 mg, 0.12 mmol) in anhydrous THF, were added triethylamine (15 mg, 0.14 
mmol) and n-propyl isocyanate (33 mg, 0.39 mmol); the n-propylamine released as a consequence 
of cyclization en route to the cyclic urea was found to consume n-propyl isocyanate, necessitating 
the use of additional equivalents of the reagent. The reaction was heated in microwave at 100 oC for 
1 hour. The solvent was then removed under vacuum and the residue was purified using column 
N
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N
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chromatography (6% MeOH/dichloromethane) to obtain the compound 57 (26 mg, 61%). 1H NMR 
(500 MHz, CDCl3) δ 9.90 (s, 1H), 8.79 (s, J = 5.4 Hz, 1H), 8.15 (d, J = 8.5, 0.6 Hz, 1H), 7.91 (d, J = 
8.6, 0.6 Hz, 1H), 7.60 (t, J = 8.4, 6.9, 1.3 Hz, 1H), 7.40 (t, J = 8.3, 6.9, 1.2 Hz, 1H), 7.37 – 7.32 (m, 
2H), 7.31 – 7.28 (m, 1H), 7.26 (d, J = 6.7, 5.4 Hz, 2H), 5.60 (s, 2H), 3.49 – 3.45 (m, J = 7.1, 5.8 Hz, 
2H), 1.78 – 1.68 (m, 2H), 1.04 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 151.08, 148.67, 
143.44, 136.25, 132.69, 128.54, 127.08, 127.02, 125.87, 125.74, 124.61, 123.68, 118.43, 117.87, 
112.78, 44.45, 39.68, 20.57, 9.22. MS (ESI) calculated for C21H20N4O2, m/z 360.16, found 361.17 (M 
+ H)+. 
 
TLR7/8 Reporter Gene assays (NF-B induction): The induction of NF-B was quantified using 
HEK-Blue-7 cells and HEK-Blue-8 cells as previously described by us.69;137 HEK293 cells were stably 
transfected with human TLR7 (or human TLR8), MD2, and secreted alkaline phosphatase (sAP), and 
were maintained in HEK-Blue™ Selection medium containing zeocin and normocin. Stable 
expression of secreted alkaline phosphatase (sAP) under control of NF-B/AP-1 promoters is 
inducible by the TLR7 (or TLR8) agonists, and extracellular sAP in the supernatant is proportional to 
NF-B induction. HEK-Blue cells were incubated at a density of ~105 cells/mL in a volume of 80 
L/well, in 384-well, flat-bottomed, cell culture-treated microtiter plates until confluency was 
achieved, and subsequently graded concentrations of stimuli.  sAP was assayed 
spectrophotometrically using an alkaline phosphatase-specific chromogen (present in HEK-detection 
medium as supplied by the vendor) at 620 nm.  
 
IFN- induction in whole human blood: Aliquots (3 mL) of heparin-anticoagulated blood obtained 
from healthy human donors after informed consent and stimulated for 12 h with graded  
concentrations of test compounds. The plasma was isolated by centrifugation, diluted 1:20, and IFN-
 was assayed in triplicate using a high-sensitivity human IFN--specific ELISA kit (PBL Interferon 
Source, Piscataway, NJ).  
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5.1. Introduction. 
 
Our point of departure in the systematic evaluation of TLR agonists as vaccine adjuvants69;137;150 
focuses, as described in the preceding chapters, on identifying chemotypes which are strongly 
immunostimulatory, and yet devoid of dominant proinflammatory cytokine-inducing activities;69 the 
TLR7-agonistic imidazoquinolines have thus far seemed ideal in meeting these requirements.69 
Continuing work on characterizing the immunostimulatory activities of TLR7 agonists show, as  
expected from its immunostimulatory profile (see Chapters 1-2, ref. 69), clear involvement of 
plasmacytoid dendritic cells;,174 however, we have also observed a set of accessory cell-independent 
direct responses in  CD4+ and CD8+ T and CD3-CD56+ natural killer (NK) lymphocytes (not 
discussed in this thesis). We were specifically desirous of examining the uptake, intracellular 
distribution, and trafficking of the imidazoquinoline in immunological synapses,175;176 and it became 
necessary to develop probes of TLR7 that are fluorescently labeled.  
 
Our earlier SAR study on the TLR7-agonistic activities (Chapter 4) had exhaustively explored C2 
and C4 substituents on the imidazoquinoline scaffold, but proved unsuccessful in identifying potential 
positions that would tolerate the introduction of bulky aryl groups without compromising activity. Our 
attention subsequently turned to exploring the effect of varying substituents at N1, while holding the 
C2-n-butyl and C4-NH2 groups constant since these have been shown to correspond to maximal 
activity.132  The synthesis of a TLR7-active N1-(4-aminomethyl)benzyl substituted imidazoquinoline 
served as a convenient precursor for the covalent attachment of fluorophores without significant loss 
of activity. Fluorescence microscopy experiments show that the fluorescent analogues are 
internalized and distributed in the endosomal compartment. Flow cytometry experiments using whole 
human blood show differential partitioning into B, T, and natural killer (NK) lymphocytic subsets, 
which correlate with the degree of activation in these subsets. These fluorescently-labeled 
imidazoquinolines will likely be useful in examining in detail the trafficking of TLR7 in immunological 
synapses.  
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5.2. Results and Discussion. 
 
 
The N1-naphthylenemethyl-substituted compound 4a was inactive, and the N1-biphenyl-4-methyl 
compound 4b was weakly active (EC50: 396 nM); the N
1-(4-aminomethyl)benzyl substituted analogue 
5d was considerably more active (EC50: 20 nM; Scheme 1) than its N
1-(3-aminomethyl)benzyl 
regioisomer 5c (EC50: 110 nM). The free primary amine on the N
1 substituent of 5d was covalently 
coupled directly to commercially-available fluorescein isothiocyanate and rhodamine B 
isothiocyanate (Scheme 2). Conversely, the amine on 5d was converted first to the isothiocyanate 6, 
allowing the subsequent coupling of amine-bearing fluorophores, such as the bora-diazaindacene 
dye, BODIPY-TR-cadaverine (Scheme 2, overleaf). 
 
 
 
N Cl
Cl
NO2
N Cl
NH
NO2
N Cl
NH
NH2
N NH2
N
N
R C4H9
i ii iii
1 2a-2d 3a-3d
R R
HN
4a-4d
R =
a b c d
R1
Reagents: i. RNH2, Et3N, CH2Cl2; ii. Pt/C, H2, Na2SO4, EtOAc; iii. (a) C4H9COCl, Et3N, THF;
(b) NH3/MeOH, 150
o C; iv. HCl/dioxane.
NH
R1
N NH2
N
N
R C4H9
iv
5c, 5d
R1 = Boc for 2,3, and 4
R1 = H for 5
Scheme 1. Syntheses of N1-substituted imidazoquinolines. 
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iii. Rhodamine B isothiocyanate, Et3N, CH2Cl2; iii. BODIPY
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Scheme 2. Syntheses of fluorescent analogues of 5d. 
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All three fluorescent conjugates retain TLR7-agonistic activity, although their potencies are slightly 
attenuated relative to the parent compound, 5d (Fig. 1). 
 
Incubation of murine macrophage J774.A1 cells with 8 and 9, followed by intravital epi- and 
confocal fluorescence microcopy showed prominent perinuclear localization, which is consistent with 
the expected endosomal distribution of TLR7.177 Shown in Fig. 2 is a representative epifluorescence 
micrograph of J774 cells treated with 9 at 100 nM concentration.  
Our earlier immunoprofiling of the TLR7-agonistic imidazoquinolines had shown a very prominent 
activation of B- and NK-cells, but minimal activation of T cells,69 and we asked if a possible reason 
could be differential uptake of the TLR7 agonist in lymphocytic subsets. Flow cytometric analysis of 
the FITC-labeled 7 in experiments employing whole human blood indeed show a prominent uptake of 
7 in CD3-CD56+ NK and CD3-CD56- B lymphocytes as compared to CD3+CD56- T lymphocytes (Fig. 
3). 
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Fig. 1. Activities of 5d, 7, 8, and 9 in reporter gene assays using human TLR7. 
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5.3. Conclusions. 
 
The syntheses of fluorescent imidazoquinoline analogues that retain TLR7-agonistic activity are 
expected to be useful probes in examining the anatomical basis of their potential immunostimulatory 
and adjuvantic properties. 5d has also served as a convenient precursor for the synthesis of 
isothiocyanate and maleimide derivatives, enabling its direct conjugation to protein and 
polysaccharide antigens (Chapter 7). 
 
Fig. 2. Murine J774 cells treated with 100 nM of 9. An overlay of phase-contrast and
epifluorescence images is depicted. An excitation filter at 562nm and a long-pass emission filter
(601-800) were used. 
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Fig. 3. Uptake of 7 in lymphocytic subsets as examined by flow cytometry. Whole human blood was
incubated with graded concentrations of 7 for 30 min, lymphocytes stained with cell surface markers
(anti-CD3-phycoerythrin [PE], and anti-CD56-PE-allophycocyanin). Erythrocytes were lysed, and 105
total events were acquired per sample.
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5.4. Experimental. 
 
 
All of the solvents and reagents used were obtained commercially and used as such unless noted 
otherwise. Moisture- or air-sensitive reactions were conducted under nitrogen atmosphere in oven-
dried (120 oC) glass apparatus. The solvents were removed under reduced pressure using standard 
rotary evaporators. Flash column chromatography was carried out using RediSep Rf ‘Gold’ high 
performance silica columns on CombiFlash Rf instruments unless otherwise mentioned, while thin-
layer chromatography was carried out on silica gel CCM pre-coated aluminum sheets. Purity for all 
final compounds was confirmed to be greater than 97% by LC-MS using a Zorbax Eclipse Plus 4.6 
mm x 150 mm, 5 m analytical reverse phase C18 column with H2O-isopropanol or H2O-CH3CN 
gradients and an Agilent ESI-TOF mass spectrometer (mass accuracy of 3 ppm) operating in the 
positive ion acquisition mode. All the compounds synthesized were obtained as solids. 
 
Synthesis of Compound 4a: 2-Butyl-1-(naphthalen-1-ylmethyl)-1H-imidazo[4,5-c]quinolin-4-
amine.  
 
To a solution of 1 (100 mg, 0.41 mmol) in 5 mL of anhydrous dichloromethane, were added 
triethylamine (54 mg, 0.53 mmol) and naphthalen-1-ylmethanamine (71 mg, 0.45 mmol). The 
reaction mixture was refluxed at 45 0C for 30 minutes. The solvent was then evaporated under 
vacuum and product was isolated using column chromatography to obtain the intermediate 
compound 2a. To a solution of 2a in 10 mL of EtOAc, were added a catalytic amount of Pt/C and 
Na2SO4. The reaction mixture was subjected to hydrogenation at 55 psi hydrogen pressure for 4 
hours. The reaction mixture was then filtered through celite and the filtrate was evaporated under 
N NH2
N
N
C4H9
4a
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vacuum to obtain the compound 3a (90 mg). To a solution of 3a (90 mg, 0.27 mmol) in anhydrous 
THF, were added triethylamine (41 mg, 0.41 mmol) and valeryl chloride (39 mg, 0.32 mmol). The 
reaction mixture was stirred at room temperature for 6 hours. The solvent was then removed under 
vacuum, and the residue was dissolved in ethyl acetate and washed with water. The ethyl acetate 
fraction was then dried using Na2SO4 and evaporated under vacuum to obtain the intermediate 
amide compound, which was then dissolved in 2 mL of 2M solution of ammonia in MeOH. The 
sealed reaction vessel was heated 150 0C for 24 hours. The solvent was then removed under 
vacuum and the residue was purified using column chromatography (7% MeOH/dichloromethane) to 
obtain the compound 4a (62 mg; 40%). 1H NMR (500 MHz, DMSO) δ 8.40 (d, J = 8.3 Hz, 1H), 8.05 
(d, J = 8.1 Hz, 1H), 7.86 (d, J = 8.2 Hz, 1H), 7.77 (t, J = 7.2 Hz, 1H), 7.69 (t, J = 7.5 Hz, 1H), 7.62 (d, 
J = 8.2 Hz, 1H), 7.47 (d, J = 8.2 Hz, 1H), 7.33 (t, J = 7.5 Hz, 1H), 7.27 (t, J = 7.7 Hz, 1H), 7.08 (s, 
2H), 6.90 (t, J = 7.5 Hz, 1H), 6.39 (d, J = 7.1 Hz, 1H), 6.35 (s, 2H), 2.92 (t, J = 7.6 Hz, 2H), 1.69 (dt, J 
= 15.2, 7.6 Hz, 2H), 1.32 (dt, J = 14.6, 7.4 Hz, 2H), 0.80 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, 
DMSO) δ 154.39, 151.16, 133.62, 133.25, 131.77, 129.64, 128.74, 127.88, 126.91, 126.80, 126.48, 
126.15, 125.58, 123.07, 121.57, 121.42, 119.87, 114.11, 46.60, 29.45, 26.08, 21.70, 13.61. MS (ESI) 
calculated for C25H24N4, m/z 380.20, found 381.21 (M + H)
+. 
 
Compound 4b was synthesized similarly as described for compound 4a. 
4b: 1-(Biphenyl-4-ylmethyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine. 1H NMR (500 MHz, 
CDCl3) δ 7.88 (d, J = 7.9 Hz, 1H), 7.78 – 7.73 (m, 1H), 7.60 – 7.56 (m, 2H), 7.55 – 7.52 (m, 2H), 7.51 
– 7.47 (m, 1H), 7.45 – 7.40 (m, 2H), 7.35 (ddt, J = 8.5, 6.5, 1.4 Hz, 1H), 7.30 – 7.25 (m, 1H), 7.10 (d, 
J = 8.3 Hz, 2H), 5.81 (s, 2H), 2.94 – 2.91 (m, 2H), 1.84 (dt, J = 15.4, 7.6 Hz, 2H), 1.51 – 1.41 (m, 
N NH2
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2H), 0.95 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 156.27, 149.52, 141.25, 139.59, 135.17, 
132.65, 129.02, 128.64, 127.93, 127.52, 126.72, 125.52, 124.77, 124.58, 120.31, 120.23, 112.54, 
48.72, 29.17, 26.80, 22.15, 13.47. MS (ESI) calculated for C27H26N4, m/z 406.22, found 407.22 (M + 
H)+. 
 
Synthesis of Compound 5c: 1-(3-(Aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-
amine.  
 
To a solution of 1 (200 mg, 0.83 mmol) in 5 mL of anhydrous dichloromethane, were added 
triethylamine (92 mg, 0.91 mmol) and tert-butyl 3-(aminomethyl)benzylcarbamate (215 mg, 1.06 
mmol) dissolved in 2 mL of anhydrous MeOH. The reaction mixture was refluxed at 45 0C for 30 
minutes. The solvent was then evaporated under vacuum and product was isolated using column 
chromatography to obtain the intermediate compound 2c. To a solution of 2c in 10 mL of EtOAc, 
were added a catalytic amount of Pt/C and Na2SO4. The reaction mixture was subjected to 
hydrogenation at 55 psi hydrogen pressure for 4 hours. The reaction mixture was then filtered 
through celite and the filtrate was evaporated under vacuum to obtain the compound 3c (202 mg). To 
a solution of 3c (202 mg, 0.49 mmol) in anhydrous THF, were added triethylamine (64 mg, 0.64 
mmol) and valeryl chloride (73 mg, 0.54 mmol). The reaction mixture was stirred at room 
temperature for 6 hours. The solvent was then removed under vacuum, and the residue was 
dissolved in ethyl acetate and washed with water. The ethyl acetate fraction was then dried using 
Na2SO4 and evaporated under vacuum to obtain the intermediate amide compound, which was then 
dissolved in 2 mL of 2M solution of ammonia in MeOH. The sealed reaction vessel was heated 150 
0C for 24 hours. The solvent was then removed under vacuum and the residue was purified using 
N NH2
N
N
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column chromatography (9% MeOH/dichloromethane) to obtain the compound 4c (44 mg; 12%). 
This was then dissolved in 10 mL of HCl/dioxane solution and stirred for 12 hours. The solvent was 
then removed to obtain the compound 5c (52 mg, 15%). 1H NMR (500 MHz, MeOD) δ 7.85 (s, 1H), 
7.67 (d, J = 7.0 Hz, 1H), 7.52 (s, 1H), 7.39 – 7.18 (m, 4H), 7.02 (s, 1H), 5.92 (s, 2H), 4.01 (s, 2H), 
2.94 (s, 2H), 1.80 (s, 2H), 1.41 (d, J = 4.4 Hz, 2H), 0.88 (t, J = 6.1 Hz, 3H). 13C NMR (126 MHz, 
MeOD) δ 159.02, 150.28, 137.51, 135.84, 135.26, 131.34, 131.06, 129.95, 127.66, 127.46, 126.67, 
125.73, 123.01, 119.66, 114.08, 50.24, 44.18, 30.32, 27.98, 23.45, 14.25. MS (ESI) calculated for 
C22H25N5, m/z 359.21, found 360.22 (M + H)
+. 
 
Compound 5d was synthesized similarly as described for compound 5c. 
 
5d: 1-(4-(Aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine. 1H NMR (500 MHz, 
MeOD) δ 7.85 (d, J = 8.2 Hz, 1H), 7.69 (d, J = 8.3 Hz, 1H), 7.54 (t, J = 7.7 Hz, 1H), 7.40 (d, J = 7.7 
Hz, 2H), 7.26 (t, J = 7.6 Hz, 1H), 7.10 (d, J = 7.8 Hz, 2H), 5.93 (s, 2H), 4.01 (s, 2H), 2.94 (t, J = 7.6 
Hz, 2H), 1.83 – 1.71 (m, 2H), 1.43 – 1.32 (m, 2H), 0.86 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, 
MeOD) δ 159.02, 150.27, 137.51, 137.47, 135.33, 134.59, 131.17, 131.11, 127.54, 126.51, 125.53, 
122.95, 119.66, 114.03, 49.93, 43.81, 30.31, 27.78, 23.35, 14.12. MS (ESI) calculated for C22H25N5, 
m/z 359.21, found 360.22 (M + H)+. 
 
N NH2
N
N
C4H9 5d
NH2
 129  
Synthesis of Compound 6: 2-Butyl-1-(4-(isothiocyanatomethyl)benzyl)-1H-imidazo[4,5-
c]quinolin-4-amine.  
 
To a solution of 5d (150 mg, 0.35 mmol) in anhydrous dichloromethane, were added carbon disulfide 
(266 mg, 3.5 mmol) and triethylamine (106 mg, 1.05 mmol). The reaction mixture was stirred for an 
hour and then was cooled to 0 oC. Di-tert-butyl dicarbonate (76 mg, 0.35 mmol) and a catalytic 
amount of DMAP were added to the reaction mixture. The reaction mixture was stirred for 18 hours 
and then the solvent was removed under vacuum. The residue was purified using column 
chromatography (7% MeOH/ dichloromethane) to obtain the compound 6 (105 mg, 75%). 1H NMR 
(400 MHz, CDCl3) δ 7.87 – 7.83 (m, 1H), 7.68 (dd, J = 8.3, 0.8 Hz, 1H), 7.51 – 7.45 (m, 1H), 7.32 (d, 
J = 8.2 Hz, 2H), 7.23 – 7.17 (m, 1H), 7.10 (d, J = 8.2 Hz, 2H), 6.52 (s, 2H), 5.78 (s, 2H), 4.71 (s, 2H), 
2.94 – 2.86 (m, 2H), 1.82 (dt, J = 15.5, 7.6 Hz, 2H), 1.52 – 1.41 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 155.19, 150.27, 135.10, 134.65, 134.57, 128.20, 127.95, 126.10, 125.92, 
124.08, 123.59, 119.94, 113.99, 48.74, 48.21, 29.71, 27.12, 22.47, 13.76. MS (ESI) calculated for 
C23H23N5S, m/z 401.17, found 402.18 (M + H)
+. 
 
Synthesis of Compound 7: 2-(3-(4-((4-Amino-2-butyl-1H-imidazo [4,5-c]quinolin-1-
yl)methyl)benzyl)thioureido)-6-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid.  
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To a solution of fluorescein isothiocyanate (17 mg, 0.043 mmol) in anhydrous MeOH, were added 
triethylamine (13 mg, 0.13 mmol) and 5d (20mg, 0.043 mmol). The reaction mixture was then heated 
at 45 oC for 18 hours and then the solvent was removed under vacuum. The residue was then 
purified using column chromatography (22% MeOH/dichloromethane) to obtain the compound 7 (3 
mg, 10%). 1H NMR (500 MHz, DMSO) δ 10.13 (s, 3H), 8.44 (s, 1H), 8.21 (s, 1H), 7.88 – 7.67 (m, 
3H), 7.62 – 7.53 (m, 1H), 7.33 (t, J = 8.1 Hz, 2H), 7.26 – 7.13 (m, 2H), 7.07 – 6.94 (m, 3H), 6.67 (d, J 
= 2.1 Hz, 2H), 6.57 (tt, J = 5.4, 4.0 Hz, 5H), 5.87 (s, 2H), 4.74 (s, 2H), 2.97 – 2.84 (m, 2H), 1.77 – 
1.67 (m, 2H), 1.45 – 1.33 (m, 2H), 0.91 – 0.85 (m, 3H). MS (ESI) calculated for C43H36N6O5S, m/z 
748.25, found 749.26 (M + H)+. 
 
Synthesis of Compound 8: N-(9-(4-(3-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-
yl)methyl)benzyl)thioureido)-2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene)-N-
ethylethanaminium.  
 
To a solution of rhodamine B isothiocynate (50 mg, 0.12 mmol) in anhydrous dichloromethane, were 
added triethylamine (47 mg, 0.47 mmol) and 5d (64 mg, 0.12 mmol). The reaction mixture was then 
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stirred for 14 hours and then the solvent was removed under vacuum. The residue was then purified 
using column chromatography (50% MeOH/dichloromethane) to obtain the compound 8 (16 mg, 
16%). 1H NMR (500 MHz, DMSO) δ 10.06 (s, 1H), 8.49 (s, 2H), 7.84 (d, J = 8.4 Hz, 1H), 7.81 – 7.73 
(m, 2H), 7.56 (dd, J = 8.4, 1.0 Hz, 2H), 7.33 – 7.29 (m, 1H), 7.24 (d, J = 8.1 Hz, 2H), 7.03 – 6.95 (m, 
3H), 6.51 (dd, J = 12.7, 8.4 Hz, 4H), 6.46 – 6.41 (m, 4H), 5.82 (s, 2H), 4.63 (s, 2H), 3.36 (dd, J = 
11.9, 4.8 Hz, 8H), 2.92 – 2.83 (m, 2H), 1.70 (dt, J = 15.3, 7.6 Hz, 2H), 1.36 (dq, J = 14.7, 7.4 Hz, 2H), 
1.10 (t, J = 7.0 Hz, 12H), 0.85 (t, J = 7.4 Hz, 3H). MS (ESI) calculated for C51H55N8O3S
+, m/z 859.41, 
found 859.41 (M)+. 
 
Synthesis of Compound 9: BODIPY®-TR cadaverine conjugated to Compound 6.  
 
To a solution of BODIPY® TR cadaverine [5-(((4-(4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-
indacene-3-yl)phenoxy)acetyl)amino)pentylamine] hydrochloride (Invitrogen, Inc., 10 mg, 0.02 mmol) 
in anhydrous pyridine, was added 6 (11 mg, 0.03 mmol). The reaction mixture was then heated at 45 
oC for 18 hours and the solvent was then removed under vacuum. The residue was purified using 
column chromatography (8% MeOH/dichloromethane) to obtain the compound 9 (2.34 mg, 15%). 1H 
NMR (400 MHz, MeOD) δ 7.99 – 7.93 (m, 3H), 7.82 (d, J = 8.3 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 
7.56 (t, J = 6.7 Hz, 2H), 7.42 (s, 1H), 7.26 (t, J = 7.3 Hz, 3H), 7.17 (dd, J = 8.5, 4.3 Hz, 2H), 7.06 (dd, 
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J = 8.9, 2.6 Hz, 3H), 6.95 (d, J = 8.0 Hz, 2H), 6.83 (d, J = 4.3 Hz, 1H), 6.74 (d, J = 4.1 Hz, 1H), 5.73 
(s, 2H), 4.57 (s, 2H), 3.22 (ddd, J = 25.7, 16.1, 9.0 Hz, 4H), 2.88 – 2.83 (m, 2H), 1.76 (dt, J = 15.3, 
7.6 Hz, 3H), 1.51 (dt, J = 18.8, 9.6 Hz, 4H), 1.39 (dd, J = 15.1, 7.5 Hz, 2H), 1.36 – 1.24 (m, 3H), 0.90 
(t, J = 7.4 Hz, 3H). MS (ESI) calculated for C49H50BF2N9O2S2, m/z 909.36, found 910.37 (M + H)
+. 
 
NF-B induction in human TLR7-expressing reporter gene assays: The induction of NF-B was 
quantified using HEK-Blue-7 cells as previously described by us.137;178 HEK293 cells were stably 
transfected with human TLR7, MD2, and secreted alkaline phosphatase (sAP), and were maintained 
in HEK-Blue™ Selection medium containing zeocin and normocin. Stable expression of secreted 
alkaline phosphatase (sAP) under control of NF-B/AP-1 promoters is inducible by the TLR7 
agonists, and extracellular sAP in the supernatant is proportional to NF-B induction. HEK-Blue cells 
were incubated at a density of ~105 cells/mL in a volume of 80 µL/well, in 384-well, flat-bottomed, cell 
culture-treated microtiter plates until confluency was achieved, and subsequently graded 
concentrations of stimuli.  sAP was assayed spectrophotometrically using an alkaline phosphatase-
specific chromogen (present in HEK-detection medium as supplied by the vendor) at 620 nm.  
 
Fluorescence microscopy: Murine macrophage J774.A1 cells were grown to confluency in optical-
grade flat-bottomed 96 well plates as described earlier.179;180 The cells were then exposed to graded 
concentrations of the fluorescently labeled compounds for 4h at 37 oC. Intravital epifluorescence and 
phase contrast images were obtained directly from the plated cells using an inverted Olympus IX-71 
microscope equipped with long working-distance air objectives and temperature-controlled stage, 
using appropriate filter sets for the various fluorescent analogues. Images were processed on Image-
J software. 
 
Flow-cytometric immunostimulation experiments: Detailed methods have been published by us.1 
Heparin-anticoagulated whole blood samples were obtained by venipuncture from healthy human 
volunteers with informed consent and as per guidelines approved by the University of Kansas 
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Human Subjects Experimentation Committee. Two mL aliquots of whole human blood samples were 
stimulated with graded concentrations of 7 in a 6-well polystyrene plate and incubated at 37 oC in a 
rotary (100 rpm) incubator for 30 min. Negative (endotoxin free water) controls were included in each 
experiment.  Following incubation, 200 µL aliquots of anticoagulated whole blood were stained with 
20 L of fluorochrome-conjugated antibodies (anti-CD3-PE, and anti-CD56-APC) at 37 oC in the dark 
for 30 min. Following staining, erythrocytes were lysed and leukocytes fixed in one step by mixing 
200 L of the samples in 4 mL pre-warmed Whole Blood Lyse/Fix Buffer (Becton-Dickinson 
Biosciences, San Jose, CA). After washing the cells twice at 200g for 8 minutes in saline, the cells 
were transferred to a 96-well plate.  Flow cytometry was performed using a BD FACSArray 
instrument in the tri-color mode. The primary gate for the lymphocytic population was obtained on 
FSC and SSC channels (100,000 gated events). Secondary gating included natural killer 
lymphocytes (NK cells: CD3-CD56+), nominal B lymphocytes (CD3-CD56-), and nominal T 
lymphocytes (CD3+CD56-). Post-acquisition analyses were performed using FlowJo v 7.0 software 
(Treestar, Ashland, OR). Compensation for spillover was computed for each experiment on singly-
stained samples.  
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6.1. Introduction. 
 
Unlike TLR7 and TLR8 which recognize single-stranded viral RNA (ssRNA), Toll-like receptor 3 
(TLR3), also present in the endosomal compartment,181 recognizes double-stranded RNA (dsRNA), a 
replication intermediate of many viruses, and triggers inflammatory responses characterized by the 
elaboration of type I interferon (IFN-) by virus-infected cells via activation of downstream NF-B 
and IFN- promoters.182-187 The secretion of IFN is a pivotal event in the induction of cellular antiviral 
immune responses.  
 
A synthetic analog of naturally occurring dsRNA, polyriboinosinic:polyribocytidylic acid, poly(I:C), is 
often used experimentally to probe TLR3 responses.188  The IFN-inducing properties of poly I:C has 
long been recognized, albeit empirically, predating the discovery of the involvement of TLR3 in its 
specific recognition by several decades. The safety profile of Ampligen®, also known as 
polyI:polyC12U [5'-Inosinic acid, homopolymer, complexed with 5'-cytidylic acid polymer with 5'-
uridylic acid (1:1)] has been established in the context of HIV therapy, and has been found to be 
generally well-tolerated.189  Poly(I:C(12)U) was found to be effective in inducing optimal phenotypic 
(elevated levels of MHC-Class I/Class II, CD83, CCR7, CD86 and CD40 molecules) and functional 
maturation of human DC in vitro, and capable of promoting the production of the Th1-type cytokine 
IL-12.190 The production of Type I IFN is thought to be crucial in enhancing the primary antibody 
response to soluble proteins, and in the stimulation of the production of all subclasses of IgG, and 
consequent induction of long-lived antibody production and immunological memory.191 Poly(I:C) also 
induced functional CD8+ T-cell responses against OVA peptides in murine models; antigen-specific 
CD8+ responses were found not onto be strongly IFN-I-dependent,192 but also on the cytokine milieu 
provided by activated NK cells.193 That poly I:C has strong adjuvant properties has been validated in 
multiple immunization models including the induction of mucosal (IgA-mediated) immunity.194-199  
TLR3, therefore, is an attractive target for adjuvant design and development. 
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The crystal structure of a complex between the ectodomains (ligand-binding region) of murine TLR3 
and dsRNA has been determined at 3.4 Å resolution.200 The TLR3 ectodomains bind dsRNA at two 
sites located at opposite ends of the TLR3 “horseshoe”, and an intermolecular contact between the 
two TLR3-ECD C-terminal domains coordinates and stabilizes the dimer (Fig. 1). 
 
 
Fig 1. dsRNA:TLR3 signaling complex. Murine TLR3 ectodomains (green and cyan) form a dimer on the dsRNA (blue and 
red). The N glycans are shown (light green and light blue). The proximity of the two C-termini permits association of the 
trans-membrane helices and the dimerization of the cytoplasmic domains (not shown). From Ref. 200. 
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No small molecule ligands for TLR3 have been described to date. An inspection of the complex 
showed that the ribose-phosphate backbone but not the individual bases (which are base-paired, 
and, therefore inaccessible) is the major determinants of binding at the C-terminal binding site (Fig. 
2).200 However, the structural bases for discrimination of dsRNA and dsDNA by TLR3 and TLR9 
remain unclear, and it is possible that additional recognition of the nucleobases may be contributory.   
 
We were interested in constructing dimeric imidazoquinoline constructs with varying configurations 
purely as an intellectual exercise to examine whether any of such dimeric molecules would modulate 
(agaonize or antagonize) TLR3 activities. This chapter describes the syntheses and characterization 
of dimeric imidazoquinolines on human TLR3, TLR7, and TLR8, as well as relevant secondary 
screens in human blood. 
Fig. 2. Left: An orthogonal view of the dsRNA-TLR3 ectodomain complex showing interactions at the C-terminal 
binding site with the backbone of the dsRNA. From Ref. 200. Arrow shows possible recognition elements of a dimeric 
molecule of about 20Å in length. Center: proposed recognition motif of the RNA scaffold by one unit of TLR3. Right: 
proposed dimer of imidazoquinoline (one possible dimeric configuration shown). 
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6.2. Results and Discussion. 
 
The first series of dimeric imidazoquinolines were linked at the C2 position and their syntheses 
necessitated two differenent routes. Whereas the hexamethylene- and decamethylene-bridged 
compounds 6a and 6b could be conveniently obtained from 5 by a direct, one-step, bis-amidation 
using the corresponding dicarboxylic acid chlorides and cyclization (Scheme 1), the shorter chain 
analogues were not amenable to this method because of intramolecular cyclization. Reaction of 
anhydrides with 1 yielded the monocarboxylic imidazoquinolines 2a and 2b; these intermediates 
were taken forward without purification and reacted with 1 to afford the des-amino 3 precursors.  The 
amines at C4 and C4’ were introduced by the protocol described in Chapter 2. 
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Reagents: Glutaric anhydride (n=1) or adipic anhydride (n=2), Et3N, THF, 110
oC; ii. 1, HBTU, Et3N,
DMAP, DMF, 90 oC; iii. (a) 3-Chloroperoxybenzoic acid, CH2Cl2, CHCl3, MeOH, 45
oC; (b) Benzoyl
isocyanate, CH2Cl2, 45
oC; (c) NaOCH3, MeOH, 80
oC; iv. (a) Suberoyl chloride (n=4) or
dodecanedioyl dichloride (n=8), Et3N, THF; (b) NH3/MeOH, 150
oC.
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Scheme 1. Syntheses of imidazoquinoline dimers linked at C2. 
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Next, the dimers linked via the C4-NH2 (8a-d) were synthesized by direct SNAr on 7 using -bis-
amino alkanes (Scheme 2). Similarly, dimers linked at the N1 position on the 4-aminomethylene 
benzyl group (10a-c) were obtained using appropriate dicarboxylic acid chlorides (Scheme 3). 
 
 
 
 
 
Scheme 2. Syntheses of imidazoquinoline dimers linked at C4-NH2. 
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Scheme 3. Syntheses of imidazoquinoline dimers linked at N1-(4-aminomethylene)benzyl. 
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Linking the 13 series of dimers via the quinoline ring required the introduction of an additional amine 
at position C8. This was achieved via carefully controlled nitration of 9 using 1.2-1.3 equiv. of HNO3, 
followed by N-Boc protection of the amine on the N1 substituent, and subsequent reduction. 
Dimerization of the 4,8-diaminoimidazoquinoline 12 proceeded smoothly using dicarboxylic acid 
chlorides as described in the previous schemes. It is to be noted that the mono-nitro and mono-
amino precursors 11 and 12 were N-Boc deprotected and tested for TLR-modulatory activities (see 
below, Table 1). 
 
 
 
 
 
 
Scheme 4. Syntheses of imidazoquinoline dimers linked at C8-NH2. 
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All compounds were unfortunately found to be inactive in TLR3 reporter gene assays (Fig. 3). 
However, with the exception of 4 and 6 series of compounds, all other dimers retained TLR7-
agonistic properties, the 10 series being the most potent (Fig. 4, Table 1). 
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Fig. 3. TLR3 (Top) and TLR7 (bottom) agonistic activities of the imidazoquinoline dimers. 
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Compound 
number 
Structure TLR3 TLR7 TLR8 
  Agonism (M) 
Antagonism 
(M) 
Agonism 
(M) 
Antagonism 
(M) 
Agonism 
(M) 
Antagonism 
(M) 
4a ND ND ND 0.65 ND 3.2 
4b ND ND ND 1.45 ND 15.63 
6a ND ND ND ND ND 10.92 
6b ND ND ND 17.88 ND 4.65 
8a ND ND 2.05 ND ND ND 
Table 1. Agonistic and antagonistic activities of the dimers in TLR3, TLR7, and TLR8 reporter gene assays. ND= not detected; NT=not tested. 
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8b 
ND ND 0.56 ND ND ND 
8c ND ND 3.00 ND ND ND 
8d ND ND 1.42 ND ND ND 
10a 
N
N
N
C4H9
NH2
N
H
N
N
N
C4H9
H2N
N
H
O O
ND ND 0.11 ND ND ND 
10b ND ND 0.24 ND ND ND 
Table 1 (contd). Agonistic and antagonistic activities of the dimers in TLR3, TLR7, and TLR8 reporter gene assays. ND= not detected; NT=not tested. 
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10c 
ND ND 0.17 ND 4.78 ND 
11a 
N
N
N
C4H9
H2N
H2N
NO2
NT NT 0.56 ND ND ND 
12a 
N
N
N
C4H9
H2N
H2N
NH2
NT NT 0.45 ND ND ND 
13a ND ND 7.24 ND ND ND 
Table 1 (contd). Agonistic and antagonistic activities of the dimers in TLR3, TLR7, and TLR8 reporter gene assays. ND= not detected; NT=not tested. 
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13b N
N
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ND ND 4.02 ND ND ND 
13c 
N
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8
 
ND ND 5.4 ND ND ND 
 
Table 1 (contd). Agonistic and antagonistic activities of the dimers in TLR3, TLR7, and TLR8 reporter gene assays. ND= not detected; NT=not tested. 
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The C2-liked dimeric compounds 4a, 4b, 6a, and 6b unexpectedly showed antagonistic activity in 
both TLR7 and TLR8 assays, with 4a being most potent (0.65 and 3.2 M IC50 values in TLR7 and 
TLR8 assays, respectively; Table 1). As discussed in Chapter 3, TLR7- and TLR8 antagonists are 
being actively pursued as therapeutic leads in HIV and autoimmune diseases, and this may be yet 
another chemotype worth following up.  
 
As mentioned in the Introduction to this Chapter, ligation of TLR7 and TLR8 trigger inflammatory 
responses characterized by the elaboration of type I interferon (IFN-) by virus-infected cells via 
activation of downstream NF-B and IFN- promoters.182-187 IFN production is a hallmark response 
underlying cellular antiviral immune responses. It was desirable to verify that TLR7 agonism that we 
had observed (Fig. 3) manifested in IFN production in secondary screens. Using an ex vivo 
stimulation model using human peripheral blood mononuclear cells (hPBMC), it was demonstrated 
that IFN- was indeed induced in a dose-dependent, bimodal manner as expected for innate immune 
responses (Fig. 4). Compound 10c was found to be the most potent. The 4 and 6 series were 
quiescent (Fig. 4), consistent with their apparent antagonistic behavior. 
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Fig. 4. IFN- induction by select dimers in human peripheral blood mononuclear cells. IFN- was assayed by analyte 
specific ELISA after incubation of hPBMC with graded concentrations of the test compound for 12h. 
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Despite the significant differences in physicochemical (and, structural) properties, several of the 
dimeric compounds seemed indistinguishable from the parent imidazoquinolines (31 in Chapters 4 
and 5d in Chapter 5) in terms of their TLR7-agonistic profiles in primary and secondary screens. In 
order to ensure that we were not overlooking possibly subtle differences, we performed 
transcriptomal analyses on 10c (Table 2). As expected, 10c strongly upregulated Type I IFN; 
however, the most prominent upregulated gene was IFN- (Table 2). A comparison of Type IFN- 
and IFN- transcriptional induction by these compounds show a very prominent inversion of IFN- 
and IFN- transcript ratios for 10c. A single functional gene in the human genome codes for IFN-, a 
monomeric glycoprotein distantly related in structure to IFN- and IFN-, but unrelated to IFN-.201-203 
 
Chronic hepatitis C (HCV) affects 2.2 - 3% of the world population. Pegylated IFN-α in combination 
with ribavirin, is the standard of care, leading to viral eradication in only about 50% of treated 
patients. The use of IFN- is associated with severe side effects, and endogenous Type I IFN 
inducers204-208 (such as the imidazoquinolines and 8-oxo-3-deazapurines) are being investigated 
intensively as less-expensive, and orally available therapeutic alternatives. In addition to prominent 
IFN- induction (Fig. 4), 10c strongly induces IFN- transcripts (Fig. 5), and whether this is 
paralleled by IFN- protein secretion is yet to be verified.  
 
The response of hepatitis C virus to IFN-α and ribavirin is known to be genotype-specific, and HCV 
genotype IV is known to respond poorly to IFN-.209 In patients resistant to therapy with conventional 
IFN-/ribavirin therapy, IFN- may be of value,210-213 and clinical trials are currently underway.  A 
synthetically accessible, orally bioavailable, small-molecule inducer of endogenous IFN- and IFN- 
may therefore be of considerable practical value, and we are currently evaluating this compound in 
detail. 
 
 
 
 148  
Table 2. Top 50 transcripts upregulated in human PBMCs by 10c as analyzed by transcriptomal profiling. 
Probe set ID  GeneSymbol  GeneName 
Fold 
change 
207817_at  IFNW1  interferon, omega 1  471.72
208173_at  IFNB1  interferon, beta 1, fibroblast  375.55
204533_at  CXCL10  chemokine (C‐X‐C motif) ligand 10  374.66
208344_x_at 
IFNA1 /// 
IFNA13  interferon, alpha 1 /// interferon, alpha 13  358.54
208075_s_at  CCL7  chemokine (C‐C motif) ligand 7  345.69
208375_at  IFNA1  interferon, alpha 1  293.33
209774_x_at  CXCL2  chemokine (C‐X‐C motif) ligand 2  227.91
208259_x_at  IFNA7  interferon, alpha 7  182.19
210163_at  CXCL11  chemokine (C‐X‐C motif) ligand 11  175.39
211506_s_at  IL8  interleukin 8  171.5
205476_at  CCL20  chemokine (C‐C motif) ligand 20  158.03
211338_at  IFNA2  interferon, alpha 2  150.95
205207_at  IL6  interleukin 6 (interferon, beta 2)  99.41
206025_s_at  TNFAIP6  tumor necrosis factor, alpha‐induced protein 6  87.87
207932_at  IFNA8  interferon, alpha 8  87.3
214569_at  IFNA5  interferon, alpha 5  85.58
211122_s_at  CXCL11  chemokine (C‐X‐C motif) ligand 11  85.49
1554997_a_a
t  PTGS2 
prostaglandin‐endoperoxide synthase 2 (prostaglandin 
G/H synthase and cyclooxygenase)  84.86
207194_s_at  ICAM4 
intercellular adhesion molecule 4 (Landsteiner‐Wiener 
blood group)  81.11
204748_at  PTGS2 
prostaglandin‐endoperoxide synthase 2 (prostaglandin 
G/H synthase and cyclooxygenase)  78.96
214038_at  CCL8  chemokine (C‐C motif) ligand 8  78.62
207850_at  CXCL3  chemokine (C‐X‐C motif) ligand 3  75.85
205114_s_at 
CCL3 /// 
CCL3L1 /// 
CCL3L3 /// 
LOC728830 
chemokine (C‐C motif) ligand 3 /// chemokine (C‐C motif) 
ligand 3‐like 1 /// chemokine (C‐C motif) ligand 3‐like 3  
/// similar to C‐C motif chemokine 3‐like 1 precursor 
(Small‐inducible cytokine A3‐like 1) (Tonsillar lymphocyte 
LD78 beta protein) (LD78‐be  75.65
216598_s_at  CCL2  chemokine (C‐C motif) ligand 2  74.27
208548_at  IFNA6  interferon, alpha 6  73.63
204103_at  CCL4  chemokine (C‐C motif) ligand 4  72.7
210118_s_at  IL1A  interleukin 1, alpha  71.52
203153_at  IFIT1 
interferon‐induced protein with tetratricopeptide repeats 
1  70.62
206026_s_at  TNFAIP6  tumor necrosis factor, alpha‐induced protein 6  64.93
217502_at  IFIT2 
interferon‐induced protein with tetratricopeptide repeats 
2  62.04
204747_at  IFIT3 
interferon‐induced protein with tetratricopeptide repeats 
3  60.1
205067_at  IL1B  interleukin 1, beta  58.33
206157_at  PTX3  pentraxin‐related gene, rapidly induced by IL‐1 beta  58.25
213797_at  RSAD2  radical S‐adenosyl methionine domain containing 2  57.87
242625_at  RSAD2  radical S‐adenosyl methionine domain containing 2  54.35
207113_s_at  TNF  tumor necrosis factor (TNF superfamily, member 2)  53.29
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39402_at  IL1B  interleukin 1, beta  51.61
216243_s_at  IL1RN  interleukin 1 receptor antagonist  49.11
229450_at  IFIT3 
interferon‐induced protein with tetratricopeptide repeats 
3  46.83
212657_s_at  IL1RN  interleukin 1 receptor antagonist  43.61
228377_at  KLHL14  kelch‐like 14 (Drosophila)  42.45
202859_x_at  IL8  interleukin 8  42.25
204363_at  F3  coagulation factor III (thromboplastin, tissue factor)  40.5
229437_at  MIRHG2  microRNA host gene 2 (non‐protein coding)  39.87
1552609_s_at  IL28A /// IL28B 
interleukin 28A (interferon, lambda 2) /// interleukin 28B 
(interferon, lambda 3)  39.49
205306_x_at  KMO  kynurenine 3‐monooxygenase (kynurenine 3‐hydroxylase)  37.06
240287_at  IRG1  immunoresponsive 1 homolog (mouse)  36.46
232504_at  LOC285628  hypothetical protein LOC285628  35.64
205767_at  EREG  epiregulin  34.7
211138_s_at  KMO  kynurenine 3‐monooxygenase (kynurenine 3‐hydroxylase)  32.37
204667_at  FOXA1  forkhead box A1  30.84
204614_at  SERPINB2 
serpin peptidase inhibitor, clade B (ovalbumin), member 
2  30.66
214438_at  HLX  H2.0‐like homeobox  28.34
208182_x_at  IFNA14  interferon, alpha 14  27.25
206765_at  KCNJ2 
potassium inwardly‐rectifying channel, subfamily J, 
member 2  26.81
208448_x_at  IFNA16  interferon, alpha 16  26.55
204803_s_at  RRAD  Ras‐related associated with diabetes  24.53
211405_x_at  IFNA17  interferon, alpha 17  24.38
213524_s_at  G0S2  G0/G1switch 2  24.38
218943_s_at  DDX58  DEAD (Asp‐Glu‐Ala‐Asp) box polypeptide 58  24.19
207964_x_at  IFNA4  interferon, alpha 4  23.98
216016_at  NLRP3  NLR family, pyrin domain containing 3  23.83
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Gene Symbol 
5d 
(Chapter 
5) 
31 
(Chapter 
4) 
10c 
IFNA1 243.22 319.58 293.33 
IFNA2 401.02 457.90 150.95 
IFNA4 182.68 179.17 23.98 
IFNA5 246.43 372.99 85.58 
IFNA6 71.46 62.91 73.63 
IFNA7 163.80 174.59 182.19 
IFNA8 144.11 151.51 87.3 
IFNA10 236.93 270.17 23.18 
IFNA1 /// IFNA13 141.41 152.78 358.54 
IFNA14 297.30 339.48 27.25 
IFNA16 669.73 739.23 26.55 
IFNA17 108.96 113.17 24.38 
IFNA21 161.56 168.01 18.66 
IFNB1 156.30 190.91 375.55 
    
IFNG 17.82 5.87 11.21 
    
IFNW1 23.71 31.85 471.72 
 
 
6.3. Conclusions. 
 
‘Homodimeric’ imidazoquinoline constructs connected by polymethylene units of varying lengths at 
C2, C4-NH2, N
1-(4-aminomethylene)benzyl and C8-NH2 have been synthesized to test whether any 
of such dimeric molecules would modulate (agonize or antagonize) TLR3 activities. No TLR3-
antagonistic activities were detected in any of the compounds. However, TLR7 and TLR8 dual-
antagonism was found in C2-linked dimers, typified by 4a. IFN- and IFN--inducing activities were 
found in the 10 series, with the most potent compound being 10c. These compounds serve as good 
leads for developing compounds for suppressing autoimmune phenomena (4a) and inducing 
endogenous IFNs for the treatment of hepatitis (10c).  
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Fig. 5. Left: Relative IFN- and IFN- gene upregulation in hPBMCs as determined by transcriptomal profiling. A 
concentration of 10 M of compound and 107 PBMCs/sample with 6 h incubation was used. Right: graph showing 
inversion of IFN- and IFN- transcript ratios for 10c. 
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6.4. Experimental. 
 
All of the solvents and reagents used were obtained commercially and used as such unless noted 
otherwise. Moisture- or air-sensitive reactions were conducted under nitrogen atmosphere in oven-
dried (120 oC) glass apparatus. The solvents were removed under reduced pressure using standard 
rotary evaporators. Flash column chromatography was carried out using RediSep Rf ‘Gold’ high 
performance silica columns on CombiFlash Rf instrument unless otherwise mentioned, while thin-
layer chromatography was carried out on silica gel CCM pre-coated aluminum sheets. Purity for all 
final compounds was confirmed to be greater than 97% by LC-MS using a Zorbax Eclipse Plus 4.6 
mm x 150 mm, 5 m analytical reverse phase C18 column with H2O-isopropanol or H2O-CH3CN 
gradients and an Agilent ESI-TOF mass spectrometer (mass accuracy of 3 ppm) operating in the 
positive ion acquisition mode. All the compounds synthesized were obtained as solids. 
 
Synthesis of Compound 4a: 2,2'-(propane-1,3-diyl)bis(1-benzyl-1H-imidazo[4,5-c]quinolin-4-
amine). 
 
To a solution of 1 (100 mg, 0.4 mmol) in anhydrous THF, were added triethylamine (53 mg, 0.52 
mmol) and glutaric anhydride (60 mg, 0.52 mmol) and the reaction vessel was heated in a 
microwave for 2 hours at 110 oC. The solvent was then removed under vacuum to obtain the crude 
product 2, which was then dissolved in anhydrous DMF and to this solution, were added HBTU (167 
mg, 0.44 mmol), triethylamine (53 mg, 0.52 mmol), 1 (100 mg, 0.4 mmol) and a catalytic amount of 
DMAP. The reaction mixture was stirred for 12 hours at 90 oC. The solvent was then removed under 
N
N
N
NH2
N
N
N
H2N
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vacuum and the residue was purified using column chromatography (12% MeOH/dichloromethane) 
to obtain the intermediate the compound 3 (157 mg). To a solution of 3 in solvent mixture of 
MeOH:dichloromethane:chloroform (0.1:1:1), was added 3-chloroperoxybenzoic acid (242 mg, 1.4 
mmol) and the reaction mixture was refluxed at 45 oC for 40 minutes. The solvent was then removed 
and the residue was purified using column chromatography (35 % MeOH/dichloromethane) to obtain 
the bis-N-oxide derivative (130 mg). bis-N-oxide derivative (110 mg, 0.19 mmol) was then dissolved 
in anhydrous dichloromethane, followed by addition of benzoyl isocyanate (96 mg, 0.67 mmol) and 
heated at 45 oC for 15 minutes. The solvent was then removed under vacuum and the residue was 
dissolved in anhydrous MeOH, followed by addition of excess of sodium methoxide and heated at 80 
oC for 2 hours. The solvent was then removed under vacuum and the residue was purified using 
column chromatography (50% MeOH/dichloromethane) to obtain the compound 2 (25 mg, 11%). 1H 
NMR (500 MHz, DMSO) δ 14.30 (s, 2H), 9.48 – 8.30 (bs, 4H), 7.93 (d, J = 8.3 Hz, 2H), 7.77 (d, J = 
8.3 Hz, 2H), 7.65 – 7.60 (m, 2H), 7.38 – 7.34 (m, 2H), 7.26 (t, J = 7.6 Hz, 4H), 7.17 (t, J = 7.4 Hz, 
2H), 7.03 (d, J = 7.4 Hz, 4H), 5.94 (s, 4H), 3.16 (t, J = 7.2 Hz, 4H), 2.44 – 2.35 (m, 2H). 13C NMR 
(126 MHz, DMSO) δ 156.22, 148.86, 135.32, 135.30, 133.48, 129.51, 128.93, 127.57, 125.47, 
124.72, 124.54, 121.49, 118.31, 112.16, 48.35, 25.21, 24.43. MS (ESI) calculated for C37H32N8, m/z 
588.2750, found 589.2860 (M + H)+. 
 
Compound 4b was synthesized similarly as described for compound 4a. 
Synthesis of Compound 4b: 2,2'-(butane-1,4-diyl)bis(1-benzyl-1H-imidazo[4,5-c]quinolin-4-
amine). 
 
1H NMR (500 MHz, DMSO) δ 13.86 (s, 2H), 8.88 (bs, 4H), 7.93 (d, J = 8.2 Hz, 2H), 7.83 – 7.79 (m, 
2H), 7.66 – 7.61 (m, 2H), 7.39 – 7.34 (m, 2H), 7.27 (t, J = 7.6 Hz, 4H), 7.18 (t, J = 7.4 Hz, 2H), 7.01 
N
N
N
Bn
NH2
N
N
N
Bn
H2N
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(d, J = 7.4 Hz, 4H), 5.94 (s, 4H), 2.99 (s, 4H), 1.83 (s, 4H). 13C NMR (126 MHz, DMSO) δ 156.55, 
148.75, 135.38, 133.62, 129.50, 128.95, 127.60, 125.42, 124.74, 124.54, 121.54, 118.48, 112.28, 
48.34, 26.49, 26.14. MS (ESI) calculated for C38H34N8, m/z 602.2906, found 603.3272 (M + H)
+
 and 
302.1705 (M + 2H)2+. 
 
Synthesis of Compound 6a: 2,2'-(hexane-1,6-diyl)bis(1-benzyl-1H-imidazo[4,5-c]quinolin-4-
amine).  
 
To a solution of 5 (60 mg, 0.21 mmol) in anhydrous THF, were added triethylamine (54 mg, 0.53 
mmol), and suberoyl chloride (23 mg, 0.11 mmol) and the reaction mixture was stirred for 6 hours. 
The solvent was then removed under vacuum and the residue was dissolved in EtOAc and washed 
with water/brine. The EtOAc fraction was then dried using sodium sulfate and evaporated under 
vacuum to obtain the intermediate amide compound, which was then dissolved in 1 mL solution of 
2M ammonia in MeOH and heated at 150 oC for 15 hours. The solvent was then removed under 
vacuum and the residue was purified using column chromatography (20% MeOH/dichloromethane) 
to obtain the compound 6a (8 mg, 12 %). 1H NMR (500 MHz, MeOD) δ 7.96 (d, J = 8.3 Hz, 2H), 7.77 
(d, J = 8.4 Hz, 2H), 7.65 (dd, J = 11.5, 4.2 Hz, 2H), 7.39 (t, J = 7.8 Hz, 2H), 7.31 (t, J = 7.4 Hz, 4H), 
7.25 (t, J = 7.3 Hz, 2H), 7.06 (d, J = 7.4 Hz, 4H), 5.93 (s, 4H), 2.97 (t, J = 7.5 Hz, 4H), 1.85 (d, J = 7.0 
Hz, 4H), 1.43 (s, 4H). 13C NMR (126 MHz, MeOD) δ 158.93, 137.73, 136.20, 135.30, 131.11, 130.47, 
129.31, 126.65, 126.57, 125.81, 122.94, 119.65, 114.20, 50.13, 29.70, 27.92. MS (ESI) calculated 
for C40H38N8, m/z 630.3219, found 631.3415 (M + H)
+. 
 
Compound 6b was synthesized similarly as described for compound 6a. 
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Synthesis of Compound 6b: 2,2'-(decane-1,10-diyl)bis(1-benzyl-1H-imidazo[4,5-c]quinolin-4-
amine). 
 
1H NMR (500 MHz, MeOD) δ 7.86 (d, J = 8.3 Hz, 2H), 7.69 (d, J = 8.4 Hz, 2H), 7.51 (t, J = 7.7 Hz, 
2H), 7.32 (t, J = 7.3 Hz, 4H), 7.28 (d, J = 7.2 Hz, 2H), 7.23 (t, J = 7.7 Hz, 2H), 7.06 (d, J = 7.4 Hz, 
4H), 5.88 (s, 4H), 2.96 (t, J = 7.6 Hz, 4H), 1.79 (dt, J = 15.3, 7.7 Hz, 4H), 1.37 (dd, J = 14.9, 7.4 Hz, 
4H), 1.32 – 1.24 (m, J = 11.6 Hz, 4H), 1.23 (d, J = 10.1 Hz, 4H). 13C NMR (126 MHz, MeOD) δ 
157.44, 151.60, 136.61, 130.41, 129.74, 129.22, 126.69, 126.46, 124.90, 123.38, 122.15, 115.12, 
50.05, 30.32, 30.25, 30.17, 28.49, 28.17. MS (ESI) calculated for C44H46N8, m/z 686.3845, found 
687.3749 (M + H)+ and 344.1949 (M + 2H)
2+
. 
 
Synthesis of Compound 8b: N1,N8-bis(1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-yl)octane-
1,8-diamine. 
 
To a solution of 7 (50 mg, 0.14 mmol) in 1 mL of anhydrous MeOH, was added 1,8-diaminooctane 
(10 mg, 0.07 mmol) and the reaction mixture was heated at 140 oC for 4 hours. The solvent was then 
removed under vacuum and the residue was purified using column chromatography (8% 
MeOH/dichloromethane) to obtain the compound 8b (12 mg, 22%). 1H NMR (400 MHz, CDCl3) δ 
7.87 (d, J = 8.3 Hz, 2H), 7.68 (d, J = 8.2 Hz, 2H), 7.41 (t, J = 7.7 Hz, 2H), 7.36 – 7.26 (m, 6H), 7.09 – 
7.01 (m, 6H), 5.78 (s, 2H), 5.72 (s, 4H), 3.77 (dd, J = 12.8, 6.6 Hz, 4H), 2.92 – 2.83 (m, 4H), 1.87 – 
1.74 (m, 8H), 1.58 – 1.50 (m, 4H), 1.45 (dt, J = 15.1, 7.5 Hz, 8H), 0.93 (t, J = 7.4 Hz, 6H). 13C NMR 
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(101 MHz, CDCl3) δ 153.34, 150.78, 145.51, 135.62, 129.20, 127.93, 127.41, 127.07, 126.68, 
125.59, 121.34, 119.52, 114.87, 48.81, 40.76, 30.18, 29.98, 29.50, 27.21, 22.56, 13.77. MS (ESI) 
calculated for C50H58N8, m/z 770.4784, found 771.4963 (M + H)
+
 and 386.2570 (M + 2H)
2+
. 
 
Compounds 8a, 8c and 8d were synthesized similarly as described for compound 8b. 
Synthesis of Compound 8a: N1,N4-bis(1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-yl)butane-
1,4-diamine. 
 
1H NMR (500 MHz, CDCl3) δ 7.86 (d, J = 8.2 Hz, 2H), 7.65 (dd, J = 8.2, 1.0 Hz, 2H), 7.41 – 7.35 (m, 
2H), 7.35 – 7.24 (m, 6H), 7.09 – 6.99 (m, 6H), 5.86 (s, 2H), 5.69 (s, 4H), 3.87 (s, 4H), 2.88 – 2.81 (m, 
4H), 2.00 (s, 4H), 1.76 (ddd, J = 13.0, 9.0, 7.7 Hz, 4H), 1.46 – 1.37 (m, 4H), 0.90 (t, J = 7.4 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 151.27, 148.66, 143.44, 133.52, 130.85, 128.77, 127.28, 127.13, 
125.85, 125.38, 124.95, 124.60, 123.50, 123.40, 119.29, 117.45, 112.81, 46.71, 38.40, 28.01, 25.51, 
25.10, 20.47, 11.68. MS (ESI) calculated for C46H50N8, m/z 714.4158, found 715.4333 (M + H)
+
 and 
358.2263 (M + 2H)2+. 
 
Synthesis of Compound 8c: N1,N10-bis(1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-yl)decane-
1,10-diamine. 
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1H NMR (500 MHz, CDCl3) δ 7.84 (d, J = 8.2 Hz, 2H), 7.66 (dd, J = 8.2, 1.0 Hz, 2H), 7.40 – 7.36 (m, 
2H), 7.33 – 7.26 (m, 6H), 7.07 – 7.01 (m, 6H), 5.73 (s, 2H), 5.70 (s, 4H), 3.74 (dd, J = 12.7, 6.5 Hz, 
4H), 2.88 – 2.83 (m, 4H), 1.80 – 1.72 (m, 8H), 1.53 – 1.24 (m, 16H), 0.91 (t, J = 7.4 Hz, 6H). 13C 
NMR (126 MHz, CDCl3) δ 151.76, 149.23, 143.97, 134.05, 131.32, 127.81, 127.63, 126.36, 125.85, 
125.50, 125.10, 124.01, 123.84, 119.75, 117.95, 113.30, 47.23, 39.17, 28.62, 28.39, 28.06, 27.95, 
25.65, 20.98, 12.20. MS (ESI) calculated for C52H62N8, m/z 798.5097, found 799.5416 (M + H)
+
 and 
400.2799 (M + 2H)2+. 
 
Synthesis of Compound 8d: N1,N12-bis(1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-
yl)dodecane-1,12-diamine. 
 
1H NMR (500 MHz, CDCl3) δ 7.84 (d, J = 8.2 Hz, 2H), 7.65 (dd, J = 8.2, 1.0 Hz, 2H), 7.38 (ddd, J = 
8.3, 7.1, 1.3 Hz, 2H), 7.34 – 7.24 (m, 6H), 7.06 – 7.00 (m, 6H), 5.74 (s, 2H), 5.69 (s, 4H), 3.74 (dd, J 
= 12.6, 6.5 Hz, 4H), 2.86 (dd, J = 17.4, 9.6 Hz, 4H), 1.83 – 1.69 (m, 8H), 1.56 – 1.30 (m, 20H), 0.91 
(t, J = 7.4 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 151.81, 149.27, 144.02, 134.08, 131.36, 127.68, 
126.41, 125.87, 125.53, 125.16, 124.05, 119.81, 118.00, 113.34, 47.27, 39.25, 28.65, 28.44, 28.15, 
28.13, 28.01, 25.70, 25.68, 21.03, 12.24. MS (ESI) calculated for C54H66N8, m/z 826.5410, found 
827.5796 (M + H)+ and 414.2977 (M + 2H)
2+
. 
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Synthesis of Compound 10b: N1,N8-bis(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-
yl)methyl)benzyl)octanediamide. 
To a solution of 9 (25 mg, 0.058 mmol) in anhydrous THF, were added triethylamine (15 mg, 0.15 
mmol) and suberoyl chloride (6 mg, 0.029 mmol). The reaction mixture was stirred for 1 hour and 
then the solvent was removed under vacuum. The residue was then purified using column 
chromatography (30% MeOH/dichloromethane) to obtain the compound 10b (8 mg, 32%) 1H NMR 
(500 MHz, MeOD) δ 7.65 (dd, J = 8.3, 0.9 Hz, 2H), 7.55 – 7.51 (m, 2H), 7.27 (ddd, J = 8.3, 7.1, 1.2 
Hz, 2H), 7.12 (d, J = 8.2 Hz, 4H), 6.95 (ddd, J = 8.2, 7.2, 1.1 Hz, 2H), 6.88 (d, J = 8.2 Hz, 4H), 5.69 
(s, 4H), 4.18 (s, 4H), 2.84 – 2.78 (m, 4H), 2.03 (t, J = 7.5 Hz, 4H), 1.64 (dt, J = 15.4, 7.6 Hz, 4H), 
1.47 – 1.37 (m, 4H), 1.30 (dq, J = 14.8, 7.4 Hz, 4H), 1.16 – 1.10 (m, 4H), 0.80 (t, J = 7.4 Hz, 6H). 13C 
NMR (126 MHz, MeOD) δ 176.03, 156.18, 152.62, 144.89, 140.08, 136.09, 135.55, 129.44, 128.54, 
126.95, 126.86, 126.21, 123.42, 121.58, 115.75, 49.58, 43.58, 36.85, 30.85, 29.75, 27.82, 26.74, 
23.43, 14.11. MS (ESI) calculated for C52H60N10O2, m/z 856.4901, found 879.4711 (M + Na
+) and 
429.2430 (M + 2H)2+. 
 
Compounds 10a and 10c were synthesized similarly as described for compound 10b. 
Synthesis of Compound 10a: N1,N6-bis(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-
yl)methyl)benzyl)adipamide. 
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1H NMR (400 MHz, MeOD) δ 7.85 (d, J = 7.6 Hz, 2H), 7.68 (d, J = 7.8 Hz, 2H), 7.52 – 7.45 (m, 2H), 
7.26 (d, J = 8.2 Hz, 4H), 7.23 – 7.16 (m, 2H), 7.02 (d, J = 8.2 Hz, 4H), 5.85 (s, 4H), 4.30 (s, 4H), 2.99 
– 2.93 (m, 4H), 2.19 (t, J = 6.0 Hz, 4H), 1.80 (dd, J = 15.3, 7.7 Hz, 4H), 1.58 (t, J = 3.1 Hz, 4H), 1.45 
(dd, J = 15.0, 7.5 Hz, 4H), 0.94 (t, J = 7.4 Hz, 6H). 13C NMR (101 MHz, MeOD) δ 174.28, 156.00, 
150.28, 138.78, 135.01, 134.27, 128.13, 128.05, 125.44, 123.28, 121.97, 120.73, 113.67, 48.28, 
42.15, 35.17, 29.21, 26.38, 25.03, 21.96, 12.68. MS (ESI) calculated for C50H56N10O2, m/z 828.4588, 
found 829.4440 (M + H)+ and 415.2244 (M + 2H)
2+
. 
 
Synthesis of Compound 10c: N1,N12-bis(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-
yl)methyl)benzyl)dodecanediamide. 
 
1H NMR (500 MHz, MeOD) δ 7.69 (dd, J = 8.3, 0.8 Hz, 2H), 7.54 (dd, J = 8.4, 0.7 Hz, 2H), 7.31 (ddd, 
J = 8.4, 7.2, 1.2 Hz, 2H), 7.14 (d, J = 8.2 Hz, 4H), 7.00 (ddd, J = 8.2, 7.2, 1.1 Hz, 2H), 6.90 (d, J = 8.2 
Hz, 4H), 5.73 (s, 4H), 4.20 (s, 4H), 2.85 – 2.81 (m, 4H), 2.06 (t, J = 7.4 Hz, 4H), 1.66 (dt, J = 15.4, 
7.6 Hz, 4H), 1.44 (dt, J = 14.4, 7.3 Hz, 4H), 1.31 (dq, J = 14.8, 7.4 Hz, 4H), 1.10 (dd, J = 29.4, 26.2 
Hz, 12H), 0.81 (t, J = 7.4 Hz, 6H). 13C NMR (126 MHz, MeOD) δ 176.17, 156.64, 152.26, 143.34, 
N
N
N
C4H9
NH2
N
H
N
N
N
C4H9
H2N
N
H
O O
7
N
N
N
C4H9
NH2
N
H
N
N
N
C4H9
H2N
N
H
O O
 159  
140.20, 135.93, 135.90, 129.44, 128.92, 126.85, 126.77, 125.13, 123.90, 121.81, 115.51, 49.64, 
43.55, 36.99, 30.78, 30.36, 30.23, 30.11, 27.82, 26.96, 23.41, 14.11. MS (ESI) calculated for 
C56H68N10O2, m/z 912.5527, found 913.5886 (M + H)
+
 and 457.2974 (M + 2H)
2+
. 
 
Synthesis of Compound 11: tert-butyl 4-((4-amino-2-butyl-8-nitro-1H-imidazo[4,5-c]quinolin-1-
yl)methyl)benzylcarbamate. 
To a solution of 9 (500 mg, 1.16 mmol) in H2SO4, was added HNO3 (95 mg, 1.511 mmol). The 
reaction mixture was stirred for 12 hours, followed by neutralization of sulfuric acid by slow addition 
of sodium carbonate solution. EtOAc was added to this solution to extract the compound, followed by 
washing with water/brine. The EtOAc fraction was then dried using sodium sulfate and evaporated 
under vacuum to obtain the residue. The residue as dissolved in MeOH and di-tert-butyl dicarbonate 
was added to it. The reaction was stirred for 30 minutes followed by removal of the solvent under 
vacuum to obtain the residue, which was purified using column chromatography (7% 
MeOH/dichloromethane) to obtain the compound 11 (200 mg, 34%).1H NMR (400 MHz, CDCl3) δ 
8.67 (d, J = 2.5 Hz, 1H), 8.24 – 8.18 (m, 1H), 7.76 (d, J = 9.2 Hz, 1H), 7.28 (d, J = 7.0 Hz, 2H), 7.08 
(d, J = 8.1 Hz, 2H), 5.95 (s, 2H), 5.76 (s, 2H), 4.87 (s, 1H), 4.29 (d, J = 5.5 Hz, 2H), 3.05 – 2.95 (m, 
2H), 1.88 (dt, J = 15.5, 7.6 Hz, 2H), 1.51 (dd, J = 14.9, 7.3 Hz, 2H), 1.45 (s, 9H), 0.99 (t, J = 7.4 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 155.18, 153.33, 148.68, 141.64, 139.53, 133.91, 133.29, 128.41, 
127.42, 127.25, 125.92, 121.27, 117.28, 113.88, 48.81, 44.09, 30.00, 28.35, 27.20, 22.54, 13.78. MS 
(ESI) calculated for C27H32N6O4, m/z 504.2485, found 505.2541 (M + H)
+
. 
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Synthesis of Compound 11a: 1-(4-(aminomethyl)benzyl)-2-butyl-8-nitro-1H-imidazo[4,5-
c]quinolin-4-amine. 
 
Compound 11 (10 mg, 0.02 mmol) was dissolved in 1 mL solution of HCl/dioxane and stirred for 12 
hours. The solvent was then removed under vacuum and the residue was washed with diethyl ether 
to afford the compound 11a in quantitative yields. 1H NMR (400 MHz, MeOD) δ 8.77 (d, J = 1.7 Hz, 
1H), 8.47 – 8.41 (m, 1H), 7.98 (d, J = 9.1 Hz, 1H), 7.54 (d, J = 7.7 Hz, 2H), 7.30 (d, J = 7.7 Hz, 2H), 
6.09 (s, 2H), 4.11 (s, 2H), 3.12 (t, J = 7.5 Hz, 2H), 1.98 – 1.88 (m, 2H), 1.59 – 1.49 (m, 2H), 1.00 (t, J 
= 7.3 Hz, 3H). 13C NMR (101 MHz, MeOD) δ 158.58, 150.14, 143.93, 137.46, 135.58, 135.36, 
133.41, 129.86, 126.29, 125.89, 123.43, 119.40, 117.94, 112.44, 48.52, 42.36, 29.05, 26.44, 21.94, 
12.71. MS (ESI) calculated for C22H24N6O2, m/z 404.1961, found 405.1993 (M + H)
+
. 
 
Synthesis of Compound 12: tert-butyl 4-((4,8-diamino-2-butyl-1H-imidazo[4,5-c]quinolin-1-
yl)methyl)benzylcarbamate. 
To a solution of 11 (190 mg, 0.377 mmol) in anhydrous MeOH, were added a catalytic amount of 
Pd/C and the reaction mixture was subjected to hydrogenation at 60 psi hydrogen pressure for 4 
hours. The reaction mixture was then filtered through celite and the filtrate was evaporated under 
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vacuum to obtain the compound 12 (160 mg, 90%).1H NMR (400 MHz, MeOD) δ 7.49 (d, J = 8.8 Hz, 
1H), 7.25 (d, J = 8.1 Hz, 2H), 7.14 (d, J = 2.3 Hz, 1H), 7.02 (d, J = 8.1 Hz, 2H), 6.97 (dd, J = 8.9, 2.4 
Hz, 1H), 5.75 (s, 2H), 4.19 (s, 2H), 2.92 – 2.86 (m, 2H), 1.73 (dt, J = 15.4, 7.6 Hz, 2H), 1.43 (s, 9H), 
0.92 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, MeOD) δ 154.56, 148.78, 142.89, 139.42, 136.71, 
134.64, 133.60, 127.53, 125.80, 125.57, 118.16, 115.16, 103.42, 78.81, 43.18, 29.41, 27.33, 26.41, 
22.01, 12.67. MS (ESI) calculated for C27H34N6O2, m/z 474.2743, found 475.2733 (M + H)
+
. 
 
Synthesis of Compound 12a: 1-(4-(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinoline-
4,8-diamine. 
 
Compound 12 (10 mg, 0.021 mmol) was dissolved in 1 mL of HCl/dioxane solution and stirred for 12 
hours. The solvent was then removed under vacuum and the residue was washed with diethyl ether 
to obtain the compound 12a in quantitative yields. 1H NMR (500 MHz, MeOD) δ 8.10 (s, 1H), 7.97 (d, 
J = 8.9 Hz, 1H), 7.67 (dd, J = 8.9, 2.2 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.23 (d, J = 8.1 Hz, 2H), 6.04 
(s, 2H), 4.12 (s, 2H), 3.03 (t, J = 7.6 Hz, 2H), 1.92 – 1.84 (m, 2H), 1.53 – 1.43 (m, 2H), 0.96 (t, J = 
7.4 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 156.84, 147.83, 135.56, 134.67, 133.58, 129.58, 129.54, 
126.08, 125.63, 124.97, 119.52, 113.08, 48.08, 41.64, 29.09, 26.17, 21.75, 13.66. MS (ESI) 
calculated for C22H26N6, m/z 374.2219, found 375.2508 (M + H)
+
. 
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Synthesis of Compound 13b: N1,N8-bis(4-amino-1-(4-(aminomethyl)benzyl)-2-butyl-1H-
imidazo[4,5-c]quinolin-8-yl)octanediamide. 
 
To a solution of 12 (74 mg, 0.156 mmol) in anhydrous THF, were added triethylamine (39 mg, 0.39 
mmol) and suberoyl chloride (15 mg, 0.07 mmol), and the reaction mixture was stirred for 1 hour. 
The solvent was then removed under vacuum and the residue was purified using column 
chromatography (20% MeOH/dichloromethane) to obtain the bis-N-Boc protected compound which 
was then dissolved in 1 mL of HCl/dioxane solution and stirred for 14 hours. The solvent was then 
removed under vacuum and the residue was washed with diethyl ether to afford the compound 13b 
(12 mg, 19%). 1H NMR (500 MHz, MeOD) δ 8.62 (s, 2H), 7.70 – 7.65 (m, 2H), 7.61 (d, J = 9.0 Hz, 
2H), 7.44 (d, J = 7.9 Hz, 4H), 7.18 (d, J = 7.7 Hz, 4H), 5.93 (s, 4H), 4.07 (s, 4H), 2.98 (t, J = 7.5 Hz, 
4H), 2.37 (dd, J = 16.6, 9.4 Hz, 4H), 1.85 (dt, J = 15.0, 7.6 Hz, 4H), 1.71 (s, 4H), 1.52 – 1.40 (m, 8H), 
0.94 (t, J = 7.3 Hz, 6H). 13C NMR (126 MHz, MeOD) δ 174.75, 159.05, 149.75, 137.64, 137.34, 
137.11, 134.51, 131.24, 130.93, 127.87, 126.22, 123.18, 119.97, 114.28, 111.99, 49.82, 43.82, 
37.93, 30.27, 30.01, 27.81, 26.63, 23.36, 14.11. MS (ESI) calculated for C52H62N12O2, m/z 886.5119, 
found 909.5031 (M + Na+) and 444.2632 (M + 2H)2+. 
 
Compounds 13a and 13c were synthesized similarly as described for compound 13b. 
Synthesis of Compound 13a: N1,N6-bis(4-amino-1-(4-(aminomethyl)benzyl)-2-butyl-1H-
imidazo[4,5-c]quinolin-8-yl)adipamide. 
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1H NMR (500 MHz, MeOD) δ 8.57 (s, 2H), 7.62 – 7.54 (m, 4H), 7.35 (d, J = 8.1 Hz, 4H), 7.10 (d, J = 
8.0 Hz, 4H), 5.85 (s, 4H), 3.98 (s, 4H), 2.90 (t, J = 7.6 Hz, 4H), 2.36 (s, 4H), 1.77 (dt, J = 15.2, 7.6 
Hz, 4H), 1.73 – 1.61 (m, 4H), 1.45 – 1.30 (m, 4H), 0.86 (t, J = 7.4 Hz, 6H). 13C NMR (126 MHz, 
MeOD) δ 174.43, 159.11, 149.83, 137.66, 137.40, 137.16, 134.53, 131.33, 130.94, 127.89, 126.30, 
123.18, 120.01, 114.38, 112.05, 49.82, 43.83, 37.65, 30.32, 27.81, 26.28, 23.37, 14.12. MS (ESI) 
calculated for C50H58N12O2, m/z 858.4806, found 859.4131 (M + H)
+ and 430.2113 (M + 2H)2+. 
 
Synthesis of Compound 13c: N1,N12-bis(4-amino-1-(4-(aminomethyl)benzyl)-2-butyl-1H-
imidazo[4,5-c]quinolin-8-yl)dodecanediamide. 
 
1H NMR (500 MHz, MeOD) δ 8.63 (s, 2H), 7.66 (d, J = 9.0 Hz, 2H), 7.58 (d, J = 8.9 Hz, 2H), 7.41 (d, 
J = 7.9 Hz, 4H), 7.15 (d, J = 7.8 Hz, 4H), 5.91 (s, 4H), 4.04 (s, 4H), 2.96 (t, J = 7.5 Hz, 4H), 2.33 (t, J 
= 7.1 Hz, 4H), 1.83 (dt, J = 15.2, 7.7 Hz, 4H), 1.65 (s, 4H), 1.44 (dq, J = 14.7, 7.3 Hz, 4H), 1.38 – 
1.21 (m, 12H), 0.92 (t, J = 7.3 Hz, 6H). 13C NMR (126 MHz, MeOD) δ 174.82, 159.01, 149.63, 
137.68, 137.27, 137.10, 134.50, 131.24, 130.93, 129.84, 127.86, 126.00, 123.16, 120.01, 114.24, 
111.92, 49.87, 43.82, 43.75, 38.04, 30.45, 30.34, 30.29, 30.23, 27.78, 26.78, 23.35, 14.11. MS (ESI) 
calculated for C56H70N12O2, m/z 942.5745, found 943.5746 (M + H)
+ and 472.2987 (M + 2H)2+. 
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TLR3/7/8 Reporter Gene assays (NF-B induction): Agonism assays were performed exactly as 
described in Chapter 4 using appropriate, stably transfected reporter cell-lines. Antagonism assays 
were done using the following agonists at a constant concentration: TLR3 Poly(I:C) (10 ng/mL); 
TLR7: gardiquimod (1 g/mL); TLR8: CL075(1 g/mL) mixed with graded concentrations of the test 
compounds.   
 
IFN- induction in human PBMCs: Aliquots (100 L) of hPBMCs isolated from blood obtained from 
healthy human donors after informed consent by conventional Ficoll-Hypaque gradient centrifugation 
were stimulated for 12 h with graded concentrations of test compounds. The supernatant was 
isolated by centrifugation, diluted 1:20, and IFN- was assayed in triplicate using a high-sensitivity 
human IFN--specific ELISA kit (PBL Interferon Source, Piscataway, NJ) as described in Chapter 4. 
 
Transcriptomal profiling in human PBMCs: Assays were performed as described by us 
previously.69 Briefly, peripheral blood mononuclear cells (PBMCs) isolated from fresh, heparin-
anticoagulated human blood was stimulated with 20 g/mL of the compounds for two hours, and total 
RNA was extracted from treated and negative control PBMC samples with QIAamp RNA Blood Mini 
Kit (Qiagen). 4 μg of each of the RNA samples was used for transcriptomal profiling, employing the 
Human Genome GeneChip U133 plus 2.0 oligonucleotide array (Affymetrix, Santa Clara, CA). 
Established standard protocols at the KU Genomics Facility were performed on cRNA target 
preparation, array hybridization, washing, staining and image scanning. The microarray data were 
collected using the Affymetrix GeneChip Command Console Software (AGCC) and then subjected to 
quality assessment before further analyses. QC criteria included low background, low noise, 
detection of positive controls, and a 5’/3’ ratio of < 3.0. To facilitate direct comparison of gene 
expression data between different samples, the GeneChip data were first subjected to 
preprocessing, which included scaling (in GCOS) data from all chips to a target intensity value of 500 
(in Affymetrix Expression Console Software), and further normalization in GeneSpring GX (Agilent 
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Technologies, Santa Clara, CA). Prior to identifying target genes, genes that were detected as non-
expressed in all samples, i.e., those with absence (A) cells were filtered out. Genes whose 
expression was changed by the test compounds by at least 2-fold (compared to the negative control) 
were identified to be differentially expressed.  
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7.1. Introduction. 
 
One aspect of our work in the area of evaluating TLR agonists as vaccine adjuvants69;137;150 focuses 
on developing self-adjuvanting vaccine constructs, i.e., antigen covalently coupled to a suitable 
adjuvant. The premise of covalently decorating protein antigens with potential adjuvants offers the 
possibility of drastically reducing systemic exposure of the adjuvant, and yet maintaining relatively 
high local concentrations at the site of vaccination.214  Most self-adjuvanting vaccine constructs to 
date have utilized TLR-2 agonistic 2,3-bis-(palmitoyloxy)propyl-cysteinyl peptides as the adjuvant.215-
220 The conjugation of the poorly soluble lipopeptide adjuvant to antigen has limited this approach to 
peptide216-219;221 or glycopeptide220 antigens, since native proteins are often irrevocably denatured 
under the coupling conditions employed, with potential loss of key epitopes. These limitations have 
recently been addressed by appending to the lipopeptide a long, water-solubilizing poly-lysine or 
polyethylene glycol moiety, and terminating in a free thiol.222 However, in addition to the potential 
problem of oxidation of lipopeptide thiol to the disulfide, free exposed thiols in proteins are rare.223 
Furthermore, TLR2 ligation has been associated with Th2 and Th17 responses224;225 which may, in 
many instances, be undesirable.  
 
As noted in Chapters 1 and 2, we have identified TLR7 agonists to be extraordinarily potent, 
stimulating virtually all subsets of lymphocytes, and yet without inducing dominant proinflammatory 
cytokine responses.69 A TLR7/8 dual-agonistic N1-(4-aminomethyl)benzyl substituted 
imidazoquinoline 1 (described as 5d in Chapter 5) served as a convenient precursor for the 
syntheses of isothiocyanate and maleimide derivatives for covalent attachment to free amine and 
thiol groups of peptides and proteins. 1 was also amenable to direct reductive amination with 
maltoheptaose without significant loss of activity. Covalent conjugation of the isothiocyanate 
derivative 2 to -lactalbumin could be achieved under mild, non-denaturing conditions, in a controlled 
 168  
manner and with full preservation of antigenicity. The self-adjuvanting -lactalbumin construct 
induced robust, high-affinity immunoglobulin titers in murine models. The premise of covalently 
decorating protein antigens with adjuvants offers the possibility of drastically reducing systemic 
exposure of the adjuvant, and yet eliciting strong, Th1-biased immune responses.  
 
7.2. Results and Discussion. 
 
Desirous of specifically identifying chemotypes with strong Th1-biased immunostimulatory 
signatures, we implemented additional screens examining the induction of Type I226-228 and Type 
II229;230 interferons  (IFN- and IFN-, respectively), Interleukin-12 (IL-12),231;232 and Interleukin-18 
(IL-18) using human PBMCs,233-235 all of which are strongly associated with dominant Th1 outcomes. 
These experiments were most instructive in that they enabled us to determine that of all of the 
diverse chemotypes of our rapidly expanding libraries of TLR agonists,132;137;150;236 an N1-(4-
aminomethyl)benzyl substituted imidazoquinoline 1 displayed a prominent Th1 bias (Fig. 1).  
 
Fig. 1. Induction of IFN-, IFN- (top) and IL-12 and IL-18 (bottom) by 1 in human PBMCs. IFN and cytokine levels 
were quantified by ELISA. Results of a representative experiment are shown. 
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Because the aqueous solubility of 1 and several of its congeners were excellent, we elected to 
evaluate direct covalent coupling to free amines and thiols on protein antigens via the introduction of 
conventional isothiocyanate and maleimide electrophilic handles on the imidazoquinoline scaffold. 
Our earlier attempts at incorporating the electrophilic isothiocyanate functionality on the C2-sidechain 
for covalent adduction to peptides and proteins had met with failure in that such adducts were bereft 
of TLR7-agonistic activity,132 and it occurred to us that not only could the free primary amine on the 
N1 substituent of 1 be converted directly to the corresponding isothiocyanate (2, Scheme 1), but also 
an additional, thiol-specific maleimide electrophile could be attached via a spacer group (5, Scheme 
1). The isothiocyanate derivative 2 reacted well with a tri-glycine methyl ester model peptide, yielding 
the adduct 3 (Scheme 1), which was purified to homogeneity, and found to be active (Fig. 2). Facile 
adduction of the maleimide derivative 5 with glutathione (reduced) also afforded the 6a in near-
quantitative yields.  
Scheme 1. Syntheses of isothiocyanate and maleimide derivatives of 1, and their corresponding model peptide conjugates. 
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The imidazoquinolines themselves are small, non-polar, and basic, and therefore gain access to the 
endolysosomal compartment in which TLR7 is predominantly sequestered. The human embryonic 
kidney reporter cell lines stably transfected with TLR7 (and reporter secreted alkaline phosphatase 
genes) that we employ in our primary screen are not professional phagocytic cells, and we were 
concerned if the trans-membrane permeability of the bulky, dianionic adduct 6a would be sufficient to 
trigger activation, and we therefore also obtained the conjugate of 5 with the dimethyl ester of 
reduced glutathione (6b). As could be predicted, the adducts 3 and 6b retained activity (EC50: 269 
nM and 2.2 M), while 6a was completely inactive (Fig. 2), indicating that trans-cellular transport of 
the polar adduct with two net negative charges was insufficient. 
 
Fig. 2. TLR7-agonistic activities of imidazoquinoline analogues in a human TLR7-specific reporter gene assay.   
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We elected to work with bovine -lactalbumin as a model antigen for self-adjuvanting vaccine 
constructs not only because it lent itself eminently well to rigorous characterization by electrospray 
ionization mass spectrometry (ESI-MS) methods (Fig. 3), but also because it is being evaluated as a 
potential antigen for breast cancer vaccines.237  
 
Fig. 3. Deconvoluted positive-mode ESI-MS spectra of native bovine -lactalbumin (left) showing a mass of 14178.83 Da, 
and -lactalbumin reacted with 5 eq. of 2, resulting in a stochastic coupling of the adjuvant with the centroid of the mass 
distribution corresponding to exactly 5 units of imidazoquinoline per protein molecule. 
 
We reacted 5 equivalents of 2 with bovine -lactalbumin in isotonic aqueous buffer at pH 8.5. Direct 
LC-ESI-MS evidence was obtained for covalent adduction of 2 with the protein, indicating a 
remarkably beautiful and precise Gaussian distribution of adducted species, with the preponderant 
conjugate corresponding to a 1:5 molar ratio of protein:2 (Fig. 3). 
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Encouraged by these results, we also attempted to conjugate 5 with human serum albumin (HSA), a 
66 kDa protein with a single free thiol. We elected to use clinical grade (meant for human parenteral 
use, formulated with amino acids) HSA rather than the purer, ‘essentially fatty acid free’ protein 
available commercially. Furthermore, HSA is a carrier protein which binds promiscuously to a vast 
range of ligands including heavy metals, bilirubin, fatty acids, etc. We anticipated for these reasons, 
that deconvoluted direct electrospray-time-of-flight mass (ESI-TOF) spectra would be polydisperse 
and microheterogeneous. In the HSA-alone control sample, we found two major peaks 
corresponding to 66439.9819 and 66558.3027 Da (Fig. 4). Reaction of HSA with 5 produced a shift 
in one of the peaks with a mass of 508.814 Da which corresponds to the maleimide derivative 5 
within instrument error (1.424 Da at 66KDa = 21.2 parts per million). The other peak at 66558 Da had 
remained unaltered upon addition of excess thiol-specific maleimide analogue 5, suggesting that the 
thiol was unreactive (Fig. 4). An examination of the difference between the species with the free, 
reactive thiol (66439 Da) and the unreactive thiol (66558 Da) in the control sample suggests that the 
‘blocking’ group is cysteine (expected exact mass of cysteine − 1 proton [disulfide] = 118.02; 
observed mass = 118.321 Da).  
Fig. 4. Covalent coupling of the thiol-specific maleimide derivative 5 with human serum albumin  showing addition of a 
single equivalent of 5 to albumin, as examined by LC-ESI-TOF. An excess (5 equiv.) of 5 was used. 
mass = 508.814 Da 
mass = 0.538 Da 
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Aside from engineering otherwise feebly immunogenic peptide and subunit protein vaccines for the 
induction of strong CTL responses, we are also interested in polysaccharide vaccines which have 
proved enormously useful in the prevention of infections by bacterial pathogens such as N. 
meningitidis and H. influenzae.238-240 Bacterial polysaccharides, unlike conventional protein antigens, 
have been considered classic T cell-independent antigens that do not elicit cell-mediated immune 
responses but rather elicit non-anamnestic responses characterized by low-affinity IgM and restricted 
classes of IgG immunoglobulins without the recruitment of T cell help. Conversion to canonical, T 
lymphocyte-dependent responses require their covalent coupling to immunogenic ‘carrier proteins’ 
such as diphtheria toxoid.241;242 This appears not to be the case for zwitterionic polysaccharides, 
however, which elicit potent CD4+ T cell responses.243;244 We are keen to re-examine the structural 
determinants of T-dependent and -independent humoral responses, especially in light of recent 
findings of intrinsic TLR2 activation by zwitterionic polysaccharides,245;246 and we are currently testing 
the hypothesis that polysaccharides with covalently linked TLR stimuli may be superior to carrier 
proteins. The free primary amine on the N1 substituent of 1 lent itself eminently well to direct 
reductive amination with maltoheptaose, a model oligosaccharide with a reducing terminal maltose 
unit (7, Scheme 2) which, gratifyingly, was found to be active in TLR7 assays (EC50: 528 nM; Fig. 5). 
We are currently exploring conjugating N. meningitidis Group C polysaccharide247 with 1. 
Scheme 2. Syntheses of the maltoheptaose conjugate. 
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Fig. 5. TLR7-agonistic activities of imidazoquinoline-maltoheptaose conjugate in a human TLR7-specific 
reporter gene assay. 
 
 
It was of particular interest to us to evaluate the well-characterized 2:-lactalbumin conjugate 
(Fig. 3) as a test-case for self-adjuvanting subunit vaccine construct. We specifically asked whether 
the conjugation procedure would preserve antigenicity of the protein, and whether the covalently-
adducted construct would be superior to a physical mixture of -lactalbumin and 1. Cohorts (5 per 
group) of outbred CF-1 mice were immunized with 50 g per animal of -lactalbumin, or 50 g of -
lactalbumin covalently conjugated with 5 equivalents of 2, or a mixture of 50 g of -lactalbumin and 
5 equivalents of 1. The animals were boosted once after two weeks following the priming dose, and 
bled after an additional week. -lactalbumin-specific IgM, IgG, as well as IgG1 and IgG2a (isotypes 
characteristic of Th2 and Th1 responses,248 respectively) were quantified by ELISA. As shown in Fig. 
6, dramatic enhancements in antibody titers were observed with both covalently- and non-covalently 
adjuvanted protein (relative to -lactalbumin alone); we also observed modest, but consistent, and 
statistically significant differences in titers between the covalently coupled self-adjuvanting construct, 
and mixture of antigen and adjuvant, indicating that self-adjuvanting subunit protein vaccines may 
indeed be generated with full preservation of antigenicity. 
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Fig. 6. Immunoglobulin profiles in outbred CF-1 mice immunized on Day 0 with 50 g/animal of -lactalbumin, or -
lactalbumin covalently coupled with 5 equivalents of 2, or -lactalbumin mixed with 5 equivalents of 1. Animals (5 per 
cohort) were boosted once on Day 14 exactly as mentioned above, and bled on Day 21. -lactalbumin-specific 
immunoglobulin levels were quantified by standard antibody-capture ELISA, performed in liquid handler-assisted 384-
well format.  
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Examination of the affinity of antigen-specific IgG using conventional chaotropic ELISA249;250 
also indicates higher quality IgG (Fig. 7) elicited by the self-adjuvanting construct. 
 
 
Fig. 7. Affinity IgG ELISA showing antibody titer as a function of chaotrope (NaSCN) concentration. IgG titers on the 
ordinate axis were calculated from absorbance values at 0.25 (which corresponds to 3 above that of naïve controls). 
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7.3. Conclusions. 
 
In conclusion, our continuing exploration of the TLR7-agonistic imidazoquinoline chemotype 
in tandem with expanded secondary and tertiary screens designed to specifically evaluate Th1-
orienting immunostimulatory profiles have enabled the identification of 1, whose free amine group 
can be conveniently exploited in constructing covalent conjugates with peptides, proteins, as well as 
polysaccharides with preservation of immunostimulatory activity.  
The feasibility of covalently coupling a small-molecule TLR7 agonist to proteins under mild, 
non-denaturing conditions to yield self-adjuvanting subunit vaccines is evident, and may have 
considerable practical value in significantly reducing systemic exposure of the adjuvant, and yet 
inducing high innate and adaptive immune responses. We are currently examining CD8+ CTL 
responses elicited by such constructs. 
 
7.4. Experimental. 
 
 
All of the solvents and reagents used were obtained commercially and used as such unless noted 
otherwise. Moisture- or air-sensitive reactions were conducted under nitrogen atmosphere in oven-
dried (120 oC) glass apparatus. The solvents were removed under reduced pressure using standard 
rotary evaporators. Flash column chromatography was carried out using RediSep Rf ‘Gold’ high 
performance silica columns on CombiFlash Rf instruments unless otherwise mentioned, while thin-
layer chromatography was carried out on silica gel CCM pre-coated aluminum sheets. Purity for all 
final compounds was confirmed to be greater than 97% by LC-MS using a Zorbax Eclipse Plus 4.6 
mm x 150 mm, 5 m analytical reverse phase C18 column with H2O-isopropanol or H2O-CH3CN 
gradients and an Agilent ESI-TOF mass spectrometer (mass accuracy of 3 ppm) operating in the 
positive ion acquisition mode. All the compounds synthesized were obtained as solids. 
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Synthesis of Compound 2: 2-Butyl-1-(4-(isothiocyanatomethyl)benzyl)-1H-imidazo[4,5-
c]quinolin-4-amine.  
 
To a solution of 1 (150 mg, 0.35 mmol) in anhydrous dichloromethane, were added carbon disulfide 
(266 mg, 3.5 mmol) and triethylamine (106 mg, 1.05 mmol). The reaction mixture was stirred for an 
hour and then was cooled to 0 oC. Di-tert-butyl dicarbonate (76 mg, 0.35 mmol) and a catalytic 
amount of DMAP were added to the reaction mixture. The reaction mixture was stirred for 18 hours 
and then the solvent was removed under vacuum. The residue was purified using column 
chromatography (7% MeOH/ dichloromethane) to obtain the compound 2 (105 mg, 75%). 1H NMR 
(400 MHz, CDCl3) δ 7.87 – 7.83 (m, 1H), 7.68 (dd, J = 8.3, 0.8 Hz, 1H), 7.51 – 7.45 (m, 1H), 7.32 (d, 
J = 8.2 Hz, 2H), 7.23 – 7.17 (m, 1H), 7.10 (d, J = 8.2 Hz, 2H), 6.52 (s, 2H), 5.78 (s, 2H), 4.71 (s, 2H), 
2.94 – 2.86 (m, 2H), 1.82 (dt, J = 15.5, 7.6 Hz, 2H), 1.52 – 1.41 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 155.19, 150.27, 135.10, 134.65, 134.57, 128.20, 127.95, 126.10, 125.92, 
124.08, 123.59, 119.94, 113.99, 48.74, 48.21, 29.71, 27.12, 22.47, 13.76. MS (ESI) calculated for 
C23H23N5S, m/z 401.17, found 402.18 (M + H)
+. 
 
Synthesis of Compound 3: Methyl 1-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-
yl)methyl)phenyl)-6,9-dioxo-3-thioxo-2,4,7,10-tetraazadodecan-12-oate.  
N NH2
N
N
C4H9
NCS
2
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To a solution of 2 (15 mg, 0.037 mmol) in anhydrous MeOH, were added triethylamine (6 mg, 0.056 
mmol) and methyl 2-(2-(2-aminoacetamido)acetamido)acetate hydrochloride (11mg, 0.044 mmol). 
The reaction was heated at 45 oC for 4 hours. The solvent was then removed under vacuum and the 
residue was purified using column chromatography (14 % MeOH/dichloromethane) to obtain the 
compound 3 (5 mg, 22%). 1H NMR (400 MHz, DMSO) δ 8.36 – 8.14 (m, 3H), 7.79 (d, J = 7.7 Hz, 
1H), 7.58 (d, J = 7.5 Hz, 2H), 7.33 (dd, J = 11.2, 4.1 Hz, 1H), 7.25 (d, J = 8.2 Hz, 2H), 7.05 (t, J = 7.1 
Hz, 1H), 7.00 (d, J = 8.1 Hz, 2H), 6.59 (s, 2H), 5.85 (s, 2H), 4.61 (s, 2H), 4.11 (s, 2H), 3.83 (d, J = 5.9 
Hz, 2H), 3.75 (d, J = 5.9 Hz, 2H), 3.62 (s, 3H), 2.96 – 2.86 (m, 2H), 1.72 (dt, J = 15.3, 7.6 Hz, 2H), 
1.45 – 1.31 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H). MS (ESI) calculated for C30H36N8O4S, m/z 604.26, found 
605.27 (M + H)+. 
 
Synthesis of Compound 5: N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl) 
benzyl)-3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamide.  
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To a solution of 4 (30 mg, 0.18 mmol) in anhydrous DMF, were added triethylamine (50 mg, 0.49 
mmol), HBTU (68 mg, 0.18 mmol), a catalytic amount of DMAP and 1 (70 mg, 0.16 mmol). The 
reaction mixture was stirred for 14 hours and then the solvent was removed under vacuum. The 
residue was dissolved in ethyl acetate and washed with water. The ethyl acetate fraction was then 
dried using Na2SO4 and evaporated under vacuum to obtain the residue, which was purified using 
column chromatography (5% MeOH/dichloromethane) to obtain the compound 5 (65 mg, 80%). 1H 
NMR (500 MHz, MeOD) δ 7.97 (dd, J = 8.4, 0.7 Hz, 1H), 7.74 – 7.71 (m, 1H), 7.64 (ddd, J = 8.4, 7.2, 
1.2 Hz, 1H), 7.38 (ddd, J = 8.4, 7.2, 1.2 Hz, 1H), 7.26 (d, J = 8.3 Hz, 2H), 7.04 (d, J = 8.3 Hz, 2H), 
6.73 (s, 2H), 5.93 (s, 2H), 4.27 (s, 2H), 3.75 (t, J = 7.0 Hz, 2H), 3.02 – 2.97 (m, 2H), 2.47 (t, J = 7.0 
Hz, 2H), 1.85 (dt, J = 21.1, 7.6 Hz, 2H), 1.46 (dq, J = 14.8, 7.4 Hz, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13C 
NMR (126 MHz, MeOD) δ 172.88, 172.10, 159.09, 150.46, 140.15, 137.66, 135.44, 135.36, 135.21, 
130.99, 129.71, 126.83, 126.50, 125.89, 123.02, 119.59, 114.25, 49.85, 43.65, 35.59, 35.40, 30.35, 
27.78, 23.33, 14.12. MS (ESI) calculated for C29H30N6O3, m/z  510.24, found 511.25 (M + H)
+. 
 
Synthesis of Compound 6b: (2R)-methyl 2-amino-5-((2S)-3-(1-(3-(4-((4-amino-2-butyl-1H-
imidazo[4,5-c]quinolin-1-yl)methyl)benzylamino)-3-oxopropyl)-2,5-dioxopyrrolidin-3-ylthio)-1-
(2-methoxy-2-oxoethylamino)-1-oxopropan-2-ylamino)-5-oxopentanoate.  
 
N OO
O
N NH2
N
N
C4H9
N
H
S
HN
H2N
O
O
O
HN
O
O
O
6b
 181  
To a solution of 5 (15 mg, 0.03 mmol) in anhydrous MeOH and a few drops of anhydrous 
dichloromethane, were added triethylamine (8 mg, 0.08 mmol) and glutathione reduced dimethyl 
ester (20 mg, 0.06 mmol). [Glutathione-reduced dimethyl ester was obtained from glutathione-
reduced by stirring in mixture of methanol and 1 mL of HCl/dioxane solution for 30 hours, followed by 
removal of the solvent under vacuum]. The reaction mixture was stirred for 30 minutes, followed by 
removal of solvent under vacuum. The residue was then purified using column chromatography (20% 
MeOH/dichloromethane) to obtain the compound 6b (5 mg, 60%). 1H NMR (500 MHz, MeOD) δ 7.75 
(d, J = 8.3 Hz, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.36 (t, J = 7.3 Hz, 1H), 7.17 (d, J = 8.2 Hz, 2H), 7.06 (t, 
J = 7.7 Hz, 1H), 6.94 (d, J = 8.1 Hz, 2H), 5.79 (s, 2H), 4.19 (qd, J = 15.2, 6.7 Hz, 2H), 3.84 (s, 2H), 
3.68 – 3.61 (m, 5H), 3.58 (s, 3H), 3.54 (dt, J = 10.7, 4.5 Hz, 1H), 3.14 – 2.93 (m, 3H), 2.93 – 2.82 (m, 
2H), 2.39 (td, J = 6.9, 2.4 Hz, 2H), 2.36 – 2.27 (m, 3H), 2.05 – 1.91 (m, 1H), 1.90 – 1.78 (m, 1H), 
1.75 – 1.66 (m, 2H), 1.40 – 1.30 (m, 2H), 1.21 (t, J = 7.3 Hz, 2H), 0.84 (t, J = 7.4 Hz, 3H). MS (ESI) 
calculated for C41H51N9O9S, m/z  845.35, found 868.33 (M + Na
+). 
 
Synthesis of Compound 7:  
 
To a solution of compound 1 (8 mg, 0.019mmol) in anhydrous DMF, were added 3-4 drops of acetic 
acid, maltoheptaose (20 mg, 0.018 mmol) and macroporous polystyrene-bound cyanoborohydride 
(15 mg, 0.033 mmol). The reaction mixture was heated at 50 oC for 24 hours. The solution was 
filtered to remove the solid resin and the filtrate was evaporated under vacuum to obtain the residue 
which was purified using C18 reverse-phase column chromatography (40% MeOH/H2O) to obtain the 
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compound 7 (12 mg, 45%). MS (ESI) calculated for C64H97N5O35, m/z  1495.60, found 1518.59 (M + 
Na+) and 759.83 (M + H + Na)2+. 
 
Immunoassays for Interferon (IFN)-, IFN-, Interleukin (IL)-12, and IL-18. Fresh human 
peripheral blood mononuclear cells (PBMC) were isolated from human blood obtained by 
venipuncture with informed consent and as per institutional guidelines on Ficoll-Hypaque gradients 
as described elsewhere.251 Aliquots of PBMCs (105 cells in 100 L/well) were stimulated for 12 h with 
graded concentrations of test compounds. Supernatants were isolated by centrifugation, diluted 1:20, 
and were assayed in triplicates using a high-sensitivity analyte-specific ELISA kits (PBL Interferon 
Source, Piscataway, NJ and R&D Systems, Inc., Minneapolis, MN). 
 
NF-B induction in human TLR7-expressing reporter gene assays: The induction of NF-B was 
quantified using HEK-Blue-7 cells as previously described by us.137;178 HEK293 cells were stably 
transfected with human TLR7, MD2, and secreted alkaline phosphatase (sAP), and were maintained 
in HEK-Blue™ Selection medium containing zeocin and normocin. Stable expression of secreted 
alkaline phosphatase (sAP) under control of NF-B/AP-1 promoters is inducible by the TLR7 (or 
TLR8) agonists, and extracellular sAP in the supernatant is proportional to NF-B induction. HEK-
Blue cells were incubated at a density of ~105 cells/mL in a volume of 80 µL/well, in 384-well, flat-
bottomed, cell culture-treated microtiter plates until confluency was achieved, and subsequently 
graded concentrations of stimuli.  sAP was assayed spectrophotometrically using an alkaline 
phosphatase-specific chromogen (present in HEK-detection medium as supplied by the vendor) at 
620 nm.  
 
Protein Adduction and Mass Spectrometry Experiments: Bovine -lactalbumin (Sigma-Aldrich 
Chemical Co., St. Louis, MO, and clinical grade human serum (Talecris Biotherapeutics, Research 
Triangle Park, NC) were incubated with 2 and 5, respectively at a molar ratio of 1:5 
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(protein:imidazoquinoline) in aqueous carbonate buffer at pH 8.0 overnight. The adducted proteins 
were analyzed by reverse-phase LC-ESI-MS performed on a Shimadzu LC system (LC-10AD binary 
pumps, SCL-10A diode array detector) using a Zorbax 3.0 mm x 150 mm 3.5 m stable-bond C18 
reverse-phase column with a forty-minute binary gradient (CH3CN/water, 0.1% HCOOH) from 5% to 
95% of CH3CN.  ESI-MS data was acquired on an Agilent LC/MSD-TOF instrument with a mass 
accuracy of 20 ppm and a range of 100 - 3500 Daltons. Calibration drift was minimized on a scan-by-
scan basis by using internal standards corresponding to 922.0001 and 2721.0201 marker ions 
infused concurrently through a second nebulizer in the ionization chamber. Deconvolution was 
performed using on-board Agilent MassHunter software.  
 
Animal Experiments: All experiments were performed in accordance with animal care protocols 
approved by the University of Kansas IACUC Committee. Cohorts of 5 outbred CF-1 mice per group 
were immunized on Day 0 with vehicle (control 1), 50 g/animal of bovine -lactalbumin alone 
(control 2), or -lactalbumin covalently coupled with 5 equivalents of 2, or -lactalbumin mixed with 5 
equivalents of 1 (control 3). All antigen preparations were in sterile, physiological saline (vehicle). A 
volume of 0.2 mL was injected intramuscularly into the flank region. Animals were boosted once on 
Day 14, and bled by terminal cardiac puncture (under isoflurane anesthesia) on Day 21. Sera were 
obtained from clotted blood by centrifugation at 3000g X 10 min, and stored at -80 oC until assayed. 
 
Enzyme-linked immunosorbent assays (ELISA): A precision 2000 liquid handler (Bio-Tek, 
Winooski, VT) was used for all serial dilution and reagent addition steps, and a Bio-Tek ELx405 384-
well plate washer was employed for plate washes; 100 mM phosphate-buffered saline (PBS) pH 7.4, 
containing 0.1% Tween-20 was used as wash buffer. Nunc-Immuno MaxiSorp (384-well) plates were 
coated with 30 L of -lactalbumin in 100 mM carbonate buffer, pH 9.0 overnight at 4 oC. After 3 
washes, the plates were blocked with 3% bovine serum albumin (in PBS, pH 7.4) for 1 h at rt. Serum 
samples (in quadruplicate) were serially diluted in a separate 384-well plate using the liquid handler. 
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After three additional washes of the assay plate, 30 L of the serum dilutions were transferred using 
the liquid handler, and the plate incubated at 37 oC for 2 h. The assay plate was washed three times, 
and 30 L of 1:10,000 diluted appropriate anti-mouse immunoglobulin (IgG [ chain], IgM [ chain], 
IgG1, IgG2a) conjugated with horseradish peroxidase was added to all wells. Following an incubation 
step at 37 oC for 1 h, and three washes, tetramethylbenzidine substrate was added at concentrations 
recommended by vendor (Sigma). The Chromogenic reaction was terminated at 30 min by the 
addition of 2M H2SO4. Plates were then read at 450 nm using a SpectraMax M4 device (Molecular 
Devices, Sunnyvale, CA). Data visualization and statistics (Student’s T test for significance) were 
performed using Origin 7.0 (Northampton, MA). 
 
 185  
 
REFERENCES 
 
 
 
 1.  Ramon, G. Procedes pour accroïtre la production des antitoxins. Ann. Inst. Pasteur 1926, 40, 1-10. 
 2.  Ramon, G. Sur l'augmentation anormale de l'antitoxine chez les chevaux producteurs de serum 
antidiphtherique. Bull. Soc. Centr. Med. Vet. 1925, 101, 227-234. 
 3.  Glenny, A. T.; Pope, C. G.; Waddington, H.; and Wallace, V. The antigenic value of toxoid precipitated 
by potassium-alum. J. Path. Bact. 1926, 29, 38-45. 
 4.  Vogel, F. R. and Powell, M. F. A compendium of vaccine adjuvants and excipients. Pharm. Biotechnol. 
1995, 6, 141-228. 
 5.  Relyveld, E. H.; Bizzini, B.; and Gupta, R. K. Rational approaches to reduce adverse reactions in man 
to vaccines containing tetanus and diphtheria toxoids. Vaccine 1998, 16, 1016-1023. 
 6.  Gupta, R. K. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 1998, 32, 155-172. 
 7.  Eisenbarth, S. C.; Colegio, O. R.; O'Connor, W.; Sutterwala, F. S.; and Flavell, R. A. Crucial role for the 
Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008. 
 8.  Seubert, A.; Monaci, E.; Pizza, M.; O'Hagan, D. T.; and Wack, A. The adjuvants aluminum hydroxide 
and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte 
differentiation toward dendritic cells. J. Immunol. 2008, 180, 5402-5412. 
 9.  Kool, M.; Soullie, T.; van Nimwegen, M.; Willart, M. A.; Muskens, F.; Jung, S.; Hoogsteden, H. C.; 
Hammad, H.; and Lambrecht, B. N. Alum adjuvant boosts adaptive immunity by inducing uric acid 
and activating inflammatory dendritic cells. J. Exp. Med. 2008, 205, 869-882. 
 10.  Dresser, D. W. A study of the adoptive secondary response to a protein antigen in mice. Proc. R. Soc. 
Lond B Biol. Sci. 1961, 154, 398-417. 
 11.  Dresser, D. W. Effectiveness of lipid and lipidophilic substances as adjuvants. Nature 1961, 191, 1169-
1171. 
 12.  Dresser, D. W. Specific inhibition of antibody production. II. Paralysis induced in adult mice by small 
quantities of protein antigen. Immunology 1962, 5, 378-388. 
 13.  Dresser, D. W. An assay for adjuvanticity. Clin. Exp. Immunol. 1968, 3, 877-888. 
 14.  Johnson, A. J.; Gaines, S.; and Landy, M. Studies on the O antigen of Salmonella typhosa. V. 
Enhancement of the antibody response to protein antigens by the purified lipopolysaccharide. J. 
Exp. Med. 1956, 103, 225-233. 
 15.  Ishii, K. J. and Akira, S. Toll or toll-free adjuvant path toward the optimal vaccine development. J. Clin. 
Immunol. 2007, 27, 363-371. 
 16.  Janeway, C. A., Jr. and Medzhitov, R. Introduction: the role of innate immunity in the adaptive immune 
response. Semin. Immunol. 1998, 10, 349-350. 
 17.  Medzhitov, R. and Janeway, C. A., Jr. An ancient system of host defense. Curr. Opin. Immunol. 1998, 
10, 12-15. 
 186  
 18.  Medzhitov, R. and Janeway, C. A., Jr. Innate immune recognition and control of adaptive immune 
responses. Semin. Immunol. 1998, 10, 351-353. 
 19.  Medzhitov, R. and Janeway, C. A., Jr. Innate immunity: impact on the adaptive immune response. 
Curr. Opin. Immunol. 1997, 9, 4-9. 
 20.  Medzhitov, R. and Janeway, C. A., Jr. Innate immunity: the virtues of a nonclonal system of 
recognition. Cell 1997, 91, 295-298. 
 21.  Akira, S.; Uematsu, S.; and Takeuchi, O. Pathogen recognition and innate immunity. Cell 2006, 124, 
783-801. 
 22.  Akira, S. Toll-like receptors and innate immunity. Adv. Immunol. 1902, 78, 1-56. 
 23.  Kaisho, T. and Akira, S. Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta 2002, 1589, 
1-13. 
 24.  Kawai, T. and Akira, S. TLR signaling. Semin. Immunol. 2007, 19, 24-32. 
 25.  Uematsu, S. and Akira, S. Toll-like receptors and innate immunity. J. Mol. Med. 2006, 84, 712-725. 
 26.  Rosenstiel, P.; Till, A.; and Schreiber, S. NOD-like receptors and human diseases. Microbes. Infect. 
2007, 9, 648-657. 
 27.  Lee, M. S. and Kim, Y. J. Signaling pathways downstream of pattern-recognition receptors and their 
cross talk. Annu. Rev. Biochem. 2007, 76, 447-480. 
 28.  Kufer, T. A. and Sansonetti, P. J. Sensing of bacteria: NOD a lonely job. Curr. Opin. Microbiol. 2007, 
10, 62-69. 
 29.  Delbridge, L. M. and O'Riordan, M. X. Innate recognition of intracellular bacteria. Curr. Opin. Immunol. 
2007, 19, 10-16. 
 30.  Fritz, J. H.; Ferrero, R. L.; Philpott, D. J.; and Girardin, S. E. Nod-like proteins in immunity, 
inflammation and disease. Nat. Immunol. 2006, 7, 1250-1257. 
 31.  Fritz, J. H. and Girardin, S. E. How Toll-like receptors and Nod-like receptors contribute to innate 
immunity in mammals. J. Endotoxin. Res. 2005, 11, 390-394. 
 32.  Thompson, A. J. and Locarnini, S. A. Toll-like receptors, RIG-I-like RNA helicases and the antiviral 
innate immune response. Immunol. Cell Biol. 2007, 85, 435-445. 
 33.  Lee, M. S. and Kim, Y. J. Pattern-recognition receptor signaling initiated from extracellular, membrane, 
and cytoplasmic space. Mol. Cells 2007, 23, 1-10. 
 34.  Bowie, A. G. and Fitzgerald, K. A. RIG-I: tri-ing to discriminate between self and non-self RNA. Trends 
Immunol. 2007, 28, 147-150. 
 35.  Mogensen, T. H. and Paludan, S. R. Reading the viral signature by Toll-like receptors and other 
pattern recognition receptors. J. Mol. Med. 2005, 83, 180-192. 
 36.  Yoneyama, M. and Fujita, T. RIG-I family RNA helicases: cytoplasmic sensor for antiviral innate 
immunity. Cytokine Growth Factor Rev. 2007, 18, 545-551. 
 37.  Stuart-Harris, C. H. Adjuvant influenza vaccines. Bull. World Health Organ 1969, 41, 617-621. 
 38.  Aucouturier, J.; Dupuis, L.; Deville, S.; Ascarateil, S.; and Ganne, V. Montanide ISA 720 and 51: a new 
generation of water in oil emulsions as adjuvants for human vaccines. Expert. Rev. Vaccines. 
2002, 1, 111-118. 
 187  
 39.   A controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in the Philippines. 
Preliminary report; Philippines Cholera Committee. Bull. World Health Organ 1965, 32, 603-625. 
 40.  MacLennan, R.; Schofield, F. D.; Pittman, M.; Hardegree, M. C.; and Barile, M. F. Immunization 
against neonatal tetanus in New Guinea. Antitoxin response of pregnant women to adjuvant and 
plain toxoids. Bull. World Health Organ 1965, 32, 683-697. 
 41.  Fletcher, S.; Steffy, K.; and Averett, D. Masked oral prodrugs of toll-like receptor 7 agonists: a new 
approach for the treatment of infectious disease. Curr. Opin. Investig. Drugs 2006, 7, 702-708. 
 42.  Horsmans, Y.; Berg, T.; Desager, J. P.; Mueller, T.; Schott, E.; Fletcher, S. P.; Steffy, K. R.; Bauman, 
L. A.; Kerr, B. M.; and Averett, D. R. Isatoribine, an agonist of TLR7, reduces plasma virus 
concentration in chronic hepatitis C infection. Hepatology 2005, 42, 724-731. 
 43.  Smee, D. F.; Alaghamandan, H. A.; Cottam, H. B.; Sharma, B. S.; Jolley, W. B.; and Robins, R. K. 
Broad-spectrum in vivo antiviral activity of 7-thia-8-oxoguanosine, a novel immunopotentiating 
agent. Antimicrob. Agents Chemother. 1989, 33, 1487-1492. 
 44.  Schmidt, C. Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat. Biotechnol. 2007, 25, 825-
826. 
 45.  Kumagai, Y.; Takeuchi, O.; and Akira, S. Pathogen recognition by innate receptors. J. Infect. 
Chemother. 2008, 14, 86-92. 
 46.  Kumagai, Y.; Takeuchi, O.; and Akira, S. Pathogen recognition by innate receptors. J. Infect. 
Chemother. 2008, 14, 86-92. 
 47.  Takeda, K. and Akira, S. Toll-like receptors. Curr. Protoc. Immunol. 2007, Chapter 14, Unit. 
 48.  Akira, S.; Takeda, K.; and Kaisho, T. Toll-like receptors: critical proteins linking innate and acquired 
immunity. Nature Immunol. 2001, 2, 675-680. 
 49.  Cottalorda, A.; Verschelde, C.; Marcais, A.; Tomkowiak, M.; Musette, P.; Uematsu, S.; Akira, S.; 
Marvel, J.; and Bonnefoy-Berard, N. TLR2 engagement on CD8 T cells lowers the threshold for 
optimal antigen-induced T cell activation. Eur. J. Immunol. 2006, 36, 1684-1693. 
 50.  Baker, P. J.; Hiernaux, J. R.; Fauntleroy, M. B.; Prescott, B.; Cantrell, J. L.; and Rudbach, J. A. 
Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A. Infect. Immun. 1988, 
56, 1076-1083. 
 51.  Baker, P. J.; Hiernaux, J. R.; Fauntleroy, M. B.; Stashak, P. W.; Prescott, B.; Cantrell, J. L.; and 
Rudbach, J. A. Ability of monophosphoryl lipid A to augment the antibody response of young mice. 
Infect. Immun. 1988, 56, 3064-3066. 
 52.  Johnson, A. G.; Tomai, M.; Solem, L.; Beck, L.; and Ribi, E. Characterization of a nontoxic 
monophosphoryl lipid A. Rev. Infect. Dis. 1987, 9 Suppl 5, S512-S516. 
 53.  Qureshi, N.; Mascagni, P.; Ribi, E.; and Takayama, K. Monophosphoryl lipid A obtained from 
lipopolysaccharides of Salmonella minnesota R595. Purification of the dimethyl derivative by high 
performance liquid chromatography and complete structural determination. J. Biol. Chem. 1985, 
260, 5271-5278. 
 188  
 54.  Qureshi, N.; Takayama, K.; and Ribi, E. Purification and structural determination of nontoxic lipid A 
obtained from the lipopolysaccharide of Salmonella typhimurium. J. Biol. Chem. 1982, 257, 11808-
11815. 
 55.  Galanos, C.; Lüderitz, O.; Rietschel, E. T.; Westphal, O.; Brade, H.; Brade, L.; Freudenberg, M. A.; 
Schade, U. F.; Imoto, M.; Yoshimura, S.; Kusumoto, S.; and Shiba, T. Synthetic and natural 
Escherichia coli free lipid A express identical endotoxic activities. Eur. J. Biochem. 1985, 148, 1-5. 
 56.  Baker, P. J.; Hraba, T.; Taylor, C. E.; Stashak, P. W.; Fauntleroy, M. B.; Z„hringer, U.; Takayama, K.; 
Sievert, T. R.; Hronowski, X.; Cotter, R. J.; and Perez-Perez, G. Molecular structures that influence 
the immunomodulatory properties of the lipid A and inner core region oligosaccharides of bacterial 
lipopolysaccharides. Infect. Immun. 1994, 62, 2257-2269. 
 57.  Baker, P. J.; Hraba, T.; Taylor, C. E.; Myers, K. R.; Takayama, K.; Qureshi, N.; Stuetz, P.; Kusumoto, 
S.; and Hasegawa, A. Structural features that influence the ability of lipid A and its analogs to 
abolish expression of suppressor T cell activity. Infect. Immun. 1992, 60, 2694-2701. 
 58.  Beutler, B. and Poltorak, A. The sole gateway to endotoxin response: how LPS was identified as TLR4, 
and its role in innate immunity. Drug Metab. Dispos. 2001, 29, 474-478. 
 59.  Beutler, B. Tlr4: central component of the sole mammalian LPS sensor. Curr. Opin. Immunol. 2000, 12, 
20-26. 
 60.  Poltorak, A.; He, X.; Smirnova, I.; Liu, M. Y.; Huffel, C. V.; Du, X.; Birdwell, D.; Alejos, E.; Silva, M.; 
Galanos, C.; Freudenberg, M.; Ricciardi, C. P.; Layton, B.; and Beutler, B. Defective LPS signaling 
in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282, 2085-2088. 
 61.  Akira, S. and Takeda, K. Functions of toll-like receptors: lessons from KO mice. C. R. Biol. 2004, 327, 
581-589. 
 62.  Takeda, K. and Akira, S. TLR signaling pathways. Semin. Immunol. 2004, 16, 3-9. 
 63.  Takeuchi, O.; Hoshino, K.; Kawai, T.; Sanjo, H.; Takada, H.; Ogawa, T.; Takeda, K.; and Akira, S. 
Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell 
wall components. Immunity. 1999, 11, 443-451. 
 64.  McGettrick, A. F.; Brint, E. K.; Palsson-McDermott, E. M.; Rowe, D. C.; Golenbock, D. T.; Gay, N. J.; 
Fitzgerald, K. A.; and O'Neill, L. A. Trif-related adapter molecule is phosphorylated by 
PKC{epsilon} during Toll-like receptor 4 signaling. Proc. Natl. Acad. Sci. U. S. A 2006, 103, 9196-
9201. 
 65.  Miggin, S. M. and O'Neill, L. A. New insights into the regulation of TLR signaling. J. Leukoc. Biol. 2006, 
80, 220-226. 
 66.  O'Neill, L. A. and Bowie, A. G. The family of five: TIR-domain-containing adaptors in Toll-like receptor 
signalling. Nat. Rev. Immunol. 2007, 7, 353-364. 
 67.  Watters, T. M.; Kenny, E. F.; and O'Neill, L. A. Structure, function and regulation of the Toll/IL-1 
receptor adaptor proteins. Immunol. Cell Biol. 2007. 
 68.  Mata-Haro, V.; Cekic, C.; Martin, M.; Chilton, P. M.; Casella, C. R.; and Mitchell, T. C. The vaccine 
adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316, 1628-
1632. 
 189  
 69.  Hood, J. D.; Warshakoon, H. J.; Kimbrell, M. R.; Shukla, N. M.; Malladi, S.; Wang, X.; and David, S. A. 
Immunoprofiling toll-like receptor ligands: Comparison of immunostimulatory and proinflammatory profiles 
in ex vivo human blood models. Hum. Vaccin. 2010, 6, 1-14. 
 70.  Lee, J.; Chuang, T. H.; Redecke, V.; She, L.; Pitha, P. M.; Carson, D. A.; Raz, E.; and Cottam, H. B. 
Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of 
Toll-like receptor 7. Proc. Natl. Acad. Sci. U. S. A 2003, 100, 6646-6651. 
 71.  Diebold, S. S.; Kaisho, T.; Hemmi, H.; Akira, S.; and Reis e Sousa, C. Innate antiviral responses by 
means of TLR7-mediated recognition of single-stranded RNA. Science 2004, 303, 1529-1531. 
 72.  Crozat, K. and Beutler, B. TLR7: A new sensor of viral infection. Proc. Natl. Acad. Sci. U. S. A 2004, 
101, 6835-6836. 
 73.  Dockrell, D. H. and Kinghorn, G. R. Imiquimod and resiquimod as novel immunomodulators. J. 
Antimicrob. Chemother. 2001, 48, 751-755. 
 74.  Garland, S. M. Imiquimod. Curr. Opin. Infect. Dis. 2003, 16, 85-89. 
 75.  Miller, R. L.; Meng, T. C.; and Tomai, M. A. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. 
Drug News Perspect. 2008, 21, 69-87. 
 76.  Pope, B. L.; Chourmouzis, E.; Sigindere, J.; Capetola, R. J.; and Lau, C. Y. In vivo enhancement of 
murine natural killer cell activity by 7-allyl-8-oxoguanosine (loxoribine). Int. J. Immunopharmacol. 
1992, 14, 1375-1382. 
 77.  Reitz, A. B.; Goodman, M. G.; Pope, B. L.; Argentieri, D. C.; Bell, S. C.; Burr, L. E.; Chourmouzis, E.; 
Come, J.; Goodman, J. H.; Klaubert, D. H.; and . Small-molecule immunostimulants. Synthesis and 
activity of 7,8-disubstituted guanosines and structurally related compounds. J. Med. Chem. 1994, 
37, 3561-3578. 
 78.  Gupta, S.; Vayuvegula, B.; and Gollapudi, S. Substituted guanine ribonucleosides as B cell activators. 
Clin. Immunol. Immunopathol. 1991, 61, S21-S27. 
 79.  Pope, B. L.; Chourmouzis, E.; Sigindere, J.; MacIntyre, J. P.; Capetola, R. J.; and Lau, C. Y. In vivo 
activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-
oxoguanosine). Cell Immunol. 1993, 147, 302-312. 
 80.  Pope, B. L.; Chourmouzis, E.; Victorino, L.; MacIntyre, J. P.; Capetola, R. J.; and Lau, C. Y. Loxoribine 
(7-allyl-8-oxoguanosine) activates natural killer cells and primes cytolytic precursor cells for 
activation by IL-2. J. Immunol. 1993, 151, 3007-3017. 
 81.  Goodman, M. G. A new approach to vaccine adjuvants. Immunopotentiation by intracellular T-helper-
like signals transmitted by loxoribine. Pharm. Biotechnol. 1995, 6, 581-609. 
 82.  Ambach, A.; Bonnekoh, B.; Nguyen, M.; Schon, M. P.; and Gollnick, H. Imiquimod, a Toll-like receptor-
7 agonist, induces perforin in cytotoxic T lymphocytes in vitro. Mol. Immunol. 2004, 40, 1307-1314. 
 83.  Durand, V.; Wong, S. Y.; Tough, D. F.; and Le Bon, A. Shaping of adaptive immune responses to 
soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol. Cell Biol. 2004, 82, 596-602. 
 84.  Heil, F.; Ahmad-Nejad, P.; Hemmi, H.; Hochrein, H.; Ampenberger, F.; Gellert, T.; Dietrich, H.; Lipford, 
G.; Takeda, K.; Akira, S.; Wagner, H.; and Bauer, S. The Toll-like receptor 7 (TLR7)-specific 
 190  
stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur. J. 
Immunol. 2003, 33, 2987-2997. 
 85.  Ito, T.; Amakawa, R.; Kaisho, T.; Hemmi, H.; Tajima, K.; Uehira, K.; Ozaki, Y.; Tomizawa, H.; Akira, S.; 
and Fukuhara, S. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 
7 ligands in human blood dendritic cell subsets. J. Exp. Med. 2002, 195, 1507-1512. 
 86.  Wille-Reece, U.; Flynn, B. J.; Lore, K.; Koup, R. A.; Kedl, R. M.; Mattapallil, J. J.; Weiss, W. R.; 
Roederer, M.; and Seder, R. A. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist 
improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. 
Proc. Natl. Acad. Sci. U. S. A 2005, 102, 15190-15194. 
 87.  Adams, S.; O'Neill, D. W.; Nonaka, D.; Hardin, E.; Chiriboga, L.; Siu, K.; Cruz, C. M.; Angiulli, A.; 
Angiulli, F.; Ritter, E.; Holman, R. M.; Shapiro, R. L.; Berman, R. S.; Berner, N.; Shao, Y.; 
Manches, O.; Pan, L.; Venhaus, R. R.; Hoffman, E. W.; Jungbluth, A.; Gnjatic, S.; Old, L.; Pavlick, 
A. C.; and Bhardwaj, N. Immunization of malignant melanoma patients with full-length NY-ESO-1 
protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 2008, 181, 776-784. 
 88.  Zhang, W. W. and Matlashewski, G. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine 
adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect. Immun. 
2008, 76, 3777-3783. 
 89.  Fransen, F.; Boog, C. J.; van Putten, J. P.; and van der, L. P. Agonists of Toll-like receptors 3, 4, 7, 
and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria 
meningitidis serogroup B. Infect. Immun. 2007, 75, 5939-5946. 
 90.  Ma, R.; Du, J. L.; Huang, J.; and Wu, C. Y. Additive effects of CpG ODN and R-848 as adjuvants on 
augmenting immune responses to HBsAg vaccination. Biochem. Biophys. Res. Commun. 2007, 
361, 537-542. 
 91.  Johnston, D.; Zaidi, B.; and Bystryn, J. C. TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant 
for pure protein prototype vaccines. Cancer Immunol. Immunother. 2007, 56, 1133-1141. 
 92.  Wille-Reece, U.; Flynn, B. J.; Lore, K.; Koup, R. A.; Miles, A. P.; Saul, A.; Kedl, R. M.; Mattapallil, J. J.; 
Weiss, W. R.; Roederer, M.; and Seder, R. A. Toll-like receptor agonists influence the magnitude 
and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. 
Exp. Med. 2006, 203, 1249-1258. 
 93.  Heil, F.; Hemmi, H.; Hochrein, H.; Ampenberger, F.; Kirschning, C.; Akira, S.; Lipford, G.; Wagner, H.; 
and Bauer, S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. 
Science 2004, 303, 1526-1529. 
 94.  Gorden, K. B.; Gorski, K. S.; Gibson, S. J.; Kedl, R. M.; Kieper, W. C.; Qiu, X.; Tomai, M. A.; Alkan, S. 
S.; and Vasilakos, J. P. Synthetic TLR agonists reveal functional differences between human TLR7 
and TLR8. J. Immunol. 2005, 174, 1259-1268. 
 95.  Philbin, V. J. and Levy, O. Immunostimulatory activity of Toll-like receptor 8 agonists towards human 
leucocytes: basic mechanisms and translational opportunities. Biochem. Soc. Trans. 2007, 35, 
1485-1491. 
 191  
 96.  Qin, J.; Yao, J.; Cui, G.; Xiao, H.; Kim, T. W.; Fraczek, J.; Wightman, P.; Sato, S.; Akira, S.; Puel, A.; 
Casanova, J. L.; Su, B.; and Li, X. TLR8-mediated NF-kappaB and JNK activation are TAK1-
independent and MEKK3-dependent. J. Biol. Chem. 2006, 281, 21013-21021. 
 97.  Hart, O. M.; Athie-Morales, V.; O'Connor, G. M.; and Gardiner, C. M. TLR7/8-mediated activation of 
human NK cells results in accessory cell-dependent IFN-gamma production. J. Immunol. 2005, 
175, 1636-1642. 
 98.  Levy, O.; Suter, E. E.; Miller, R. L.; and Wessels, M. R. Unique efficacy of Toll-like receptor 8 agonists 
in activating human neonatal antigen-presenting cells. Blood 2006, 108, 1284-1290. 
 99.  Smith, T. R. and Kumar, V. Revival of CD8+ Treg-mediated suppression. Trends Immunol. 2008, 29, 
337-342. 
 100.  Gupta, S.; Shang, W.; and Sun, Z. Mechanisms regulating the development and function of natural 
regulatory T cells. Arch. Immunol. Ther. Exp. (Warsz. ) 2008, 56, 85-102. 
 101.  Cools, N.; Ponsaerts, P.; Van Tendeloo, V. F.; and Berneman, Z. N. Regulatory T cells and human 
disease. Clin. Dev. Immunol. 2007, 2007, 89195. 
 102.  Germain, R. N. Special regulatory T-cell review: A rose by any other name: from suppressor T cells to 
Tregs, approbation to unbridled enthusiasm. Immunology 2008, 123, 20-27. 
 103.  Wan, Y. Y. and Flavell, R. A. Regulatory T cells, transforming growth factor-beta, and immune 
suppression. Proc. Am. Thorac. Soc. 2007, 4, 271-276. 
 104.  Kim, C. H. Trafficking of FoxP3+ regulatory T cells: myths and facts. Arch. Immunol. Ther. Exp. 
(Warsz. ) 2007, 55, 151-159. 
 105.  Long, E. T. and Wood, K. J. Regulatory T cells--a journey from rodents to the clinic. Front Biosci. 2007, 
12, 4042-4049. 
 106.  Sutmuller, R. P.; Morgan, M. E.; Netea, M. G.; Grauer, O.; and Adema, G. J. Toll-like receptors on 
regulatory T cells: expanding immune regulation. Trends Immunol. 2006, 27, 387-393. 
 107.  Pasare, C. and Medzhitov, R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated 
suppression by dendritic cells. Science 2003, 299, 1033-1036. 
 108.  Xiang, A. X.; Webber, S. E.; Kerr, B. M.; Rueden, E. J.; Lennox, J. R.; Haley, G. J.; Wang, T.; Ng, J. S.; 
Herbert, M. R.; Clark, D. L.; Banh, V. N.; Li, W.; Fletcher, S. P.; Steffy, K. R.; Bartkowski, D. M.; 
Kirkovsky, L. I.; Bauman, L. A.; and Averett, D. R. Discovery of ANA975: an oral prodrug of the 
TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids 2007, 26, 635-640. 
 109.  Boasso, A. and Shearer, G. M. Chronic innate immune activation as a cause of HIV-1 
immunopathogenesis. Clin. Immunol. 2008, 126, 235-242. 
 110.  Douek, D. C.; Roederer, M.; and Koup, R. A. Emerging Concepts in the Immunopathogenesis of AIDS. 
Annu. Rev. Med. 2008. 
 111.  Pantaleo, G.; Graziosi, C.; Demarest, J. F.; Butini, L.; Montroni, M.; Fox, C. H.; Orenstein, J. M.; Kotler, 
D. P.; and Fauci, A. S. HIV infection is active and progressive in lymphoid tissue during the 
clinically latent stage of disease. Nature. 1993, 362, 355-358. 
 192  
 112.  Brenchley, J. M.; Schacker, T. W.; Ruff, L. E.; Price, D. A.; Taylor, J. H.; Beilman, G. J.; Nguyen, P. L.; 
Khoruts, A.; Larson, M.; Haase, A. T.; and Douek, D. C. CD4+ T cell depletion during all stages of 
HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 2004, 200, 749-759. 
 113.  Brenchley, J. M. and Douek, D. C. HIV infection and the gastrointestinal immune system. Mucosal. 
Immunol. 2008, 1, 23-30. 
 114.  Mehandru, S.; Poles, M. A.; Tenner-Racz, K.; Horowitz, A.; Hurley, A.; Hogan, C.; Boden, D.; Racz, P.; 
and Markowitz, M. Primary HIV-1 infection is associated with preferential depletion of CD4+ T 
lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 2004, 200, 761-770. 
 115.  Douek, D. HIV disease progression: immune activation, microbes, and a leaky gut. Top. HIV. Med. 
2007, 15, 114-117. 
 116.  Akira, S. Innate immunity to pathogens: diversity in receptors for microbial recognition. Immunol. Rev. 
2009, 227, 5-8. 
 117.  Mandl, J. N.; Barry, A. P.; Vanderford, T. H.; Kozyr, N.; Chavan, R.; Klucking, S.; Barrat, F. J.; 
Coffman, R. L.; Staprans, S. I.; and Feinberg, M. B. Divergent TLR7 and TLR9 signaling and type I 
interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat. Med. 
2008, 14, 1077-1087. 
 118.  Barrat, F. J.; Meeker, T.; Gregorio, J.; Chan, J. H.; Uematsu, S.; Akira, S.; Chang, B.; Duramad, O.; 
and Coffman, R. L. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like 
receptors and may promote systemic lupus erythematosus. J. Exp. Med. 2005, 202, 1131-1139. 
 119.  Hemmi, H.; Kaisho, T.; Takeuchi, O.; Sato, S.; Sanjo, H.; Hoshino, K.; Horiuchi, T.; Tomizawa, H.; 
Takeda, K.; and Akira, S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-
dependent signaling pathway. Nat. Immunol. 2002, 3, 196-200. 
 120.  Goblyos, A.; Gao, Z. G.; Brussee, J.; Connestari, R.; Santiago, S. N.; Ye, K.; Ijzerman, A. P.; and 
Jacobson, K. A. Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine 
derivatives as allosteric enhancers of the A3 adenosine receptor. J. Med. Chem. 2006, 49, 3354-
3361. 
 121.  Gerster, J. F.; Lindstrom, K. J.; Miller, R. L.; Tomai, M. A.; Birmachu, W.; Bomersine, S. N.; Gibson, S. 
J.; Imbertson, L. M.; Jacobson, J. R.; Knafla, R. T.; Maye, P. V.; Nikolaides, N.; Oneyemi, F. Y.; 
Parkhurst, G. J.; Pecore, S. E.; Reiter, M. J.; Scribner, L. S.; Testerman, T. L.; Thompson, N. J.; 
Wagner, T. L.; Weeks, C. E.; Andre, J. D.; Lagain, D.; Bastard, Y.; and Lupu, M. Synthesis and 
structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production. J. 
Med. Chem. 2005, 48, 3481-3491. 
 122.  Gerster, J. F.; Lindstrom, K. J.; Miller, R. L.; Tomai, M. A.; Birmachu, W.; Bomersine, S. N.; Gibson, S. 
J.; Imbertson, L. M.; Jacobson, J. R.; Knafla, R. T.; Maye, P. V.; Nikolaides, N.; Oneyemi, F. Y.; 
Parkhurst, G. J.; Pecore, S. E.; Reiter, M. J.; Scribner, L. S.; Testerman, T. L.; Thompson, N. J.; 
Wagner, T. L.; Weeks, C. E.; Andre, J. D.; Lagain, D.; Bastard, Y.; and Lupu, M. Synthesis and 
structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production. J. 
Med. Chem. 2005, 48, 3481-3491. 
 193  
 123.  Kimbrell, M. R.; Warshakoon, H.; Cromer, J. R.; Malladi, S.; Hood, J. D.; Balakrishna, R.; Scholdberg, 
T. A.; and David, S. A. Comparison of the immunostimulatory and proinflammatory activities of 
candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine 
and human cells. Immunol. Lett. 2008, 118, 132-141. 
 124.  Lau, C. M.; Broughton, C.; Tabor, A. S.; Akira, S.; Flavell, R. A.; Mamula, M. J.; Christensen, S. R.; 
Shlomchik, M. J.; Viglianti, G. A.; Rifkin, I. R.; and Marshak-Rothstein, A. RNA-associated 
autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. 
J. Exp. Med. 2005, 202, 1171-1177. 
 125.  Rifkin, I. R.; Leadbetter, E. A.; Busconi, L.; Viglianti, G.; and Marshak-Rothstein, A. Toll-like receptors, 
endogenous ligands, and systemic autoimmune disease. Immunol. Rev. 2005, 204:27-42., 27-42. 
 126.  Alspaugh, M. A.; Talal, N.; and Tan, E. M. Differentiation and characterization of autoantibodies and 
their antigens in Sjogren's syndrome. Arthritis Rheum. 1976, 19, 216-222. 
 127.  Richez, C.; Blanco, P.; Rifkin, I.; Moreau, J. F.; and Schaeverbeke, T. Role for toll-like receptors in 
autoimmune disease: The example of systemic lupus erythematosus. Joint Bone Spine. 2010. 
 128.  Avalos, A. M.; Busconi, L.; and Marshak-Rothstein, A. Regulation of autoreactive B cell responses to 
endogenous TLR ligands. Autoimmunity. 2010, 43, 76-83. 
 129.  Santiago-Raber, M. L.; Dunand-Sauthier, I.; Wu, T.; Li, Q. Z.; Uematsu, S.; Akira, S.; Reith, W.; Mohan, 
C.; Kotzin, B. L.; and Izui, S. Critical role of TLR7 in the acceleration of systemic lupus 
erythematosus in TLR9-deficient mice. J. Autoimmun. 2010, 34, 339-348. 
 130.  O'Neill, L. A.; Bryant, C. E.; and Doyle, S. L. Therapeutic targeting of Toll-like receptors for infectious 
and inflammatory diseases and cancer. Pharmacol. Rev. 2009, 61, 177-197. 
 131.  Hennessy, E. J.; Parker, A. E.; and O'Neill, L. A. Targeting Toll-like receptors: emerging therapeutics? 
Nat. Rev. Drug Discov. 2010, 9, 293-307. 
 132.  Shukla, N. M.; Malladi, S. S.; Mutz, C. A.; Balakrishna, R.; and David, S. A. Structure-activity 
relationships in human toll-like receptor 7-active imidazoquinoline analogues. J. Med. Chem. 2010, 
53, 4450-4465. 
 133.  Robbins, M.; Judge, A.; Liang, L.; McClintock, K.; Yaworski, E.; and MacLachlan, I. 2'-O-methyl-
modified RNAs act as TLR7 antagonists. Mol. Ther. 2007, 15, 1663-1669. 
 134.  Wang, D.; Bhagat, L.; Yu, D.; Zhu, F. G.; Tang, J. X.; Kandimalla, E. R.; and Agrawal, S. 
Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9. J. Med. Chem. 2009, 
52, 551-558. 
 135.  Yu, D.; Wang, D.; Zhu, F. G.; Bhagat, L.; Dai, M.; Kandimalla, E. R.; and Agrawal, S. Modifications 
incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 
7 and 9. J. Med. Chem. 2009, 52, 5108-5114. 
 136.  Hamm, S.; Latz, E.; Hangel, D.; Muller, T.; Yu, P.; Golenbock, D.; Sparwasser, T.; Wagner, H.; and 
Bauer, S. Alternating 2'-O-ribose methylation is a universal approach for generating non-
stimulatory siRNA by acting as TLR7 antagonist. Immunobiology. 2010, 215, 559-569. 
 137.  Shukla, N. M.; Kimbrell, M. R.; Malladi, S. S.; and David, S. A. Regioisomerism-dependent TLR7 
agonism and antagonism in an imidazoquinoline. Bioorg. Med. Chem. Lett. 2009, 19, 2211-2214. 
 194  
 138.  Shukla, N. M.; Mutz, C. A.; Ukani, R.; Warshakoon, H. J.; Moore, D. S.; and David, S. A. Syntheses of 
fluorescent imidazoquinoline conjugates as probes of Toll-like receptor 7. Bioorg. Med. Chem. Lett. 
2010, 20, 6384-6386. 
 139.  Wierenga, W.; Skulnick, H. I.; Stringfellow, D. A.; Weed, S. D.; Renis, H. E.; and Eidson, E. E. 5-
substituted 2-amino-6-phenyl-4(3H)-pyrimidinones. Antiviral- and interferon-inducing agents. J. 
Med. Chem. 1980, 23, 237-239. 
 140.  Li, L. H.; Wallace, T. L.; Wierenga, W.; Skulnick, H. I.; and DeKoning, T. F. Antitumor activity of 
pyrimidinones, a class of small-molecule biological response modifiers. J. Biol. Response Mod. 
1987, 6, 44-55. 
 141.  Stringfellow, D. A. and Glasgow, L. A. Tilorone hydrochloride: an oral interferon-inducing agent. 
Antimicrob. Agents Chemother. 1972, 2, 73-78. 
 142.  Stringfellow, D. A. Comparation interferon- inducing and antiviral properties of 2-amino-5-bromo-6-
methyl-4-pyrimidinol (U-25,166), tilorone hydrochloride, and polyinosinic-polycytidylic acid. 
Antimicrob. Agents Chemother. 1977, 11, 984-992. 
 143.  Hamilton, R. D.; Wynalda, M. A.; Fitzpatrick, F. A.; Teagarden, D. L.; Hamdy, A. H.; Snider, B. G.; 
Weed, S. D.; and Stringfellow, D. A. Comparison between circulating interferon and drug levels 
following administration of 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP) to different 
animal species. J. Interferon Res. 1982, 2, 317-327. 
 144.  Gerster, J. F.; Lindstrom, K. J.; Miller, R. L.; Tomai, M. A.; Birmachu, W.; Bomersine, S. N.; Gibson, S. 
J.; Imbertson, L. M.; Jacobson, J. R.; Knafla, R. T.; Maye, P. V.; Nikolaides, N.; Oneyemi, F. Y.; 
Parkhurst, G. J.; Pecore, S. E.; Reiter, M. J.; Scribner, L. S.; Testerman, T. L.; Thompson, N. J.; 
Wagner, T. L.; Weeks, C. E.; Andre, J. D.; Lagain, D.; Bastard, Y.; and Lupu, M. Synthesis and 
structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production. J. 
Med. Chem. 2005, 48, 3481-3491. 
 145.  Miller, R. L.; Gerster, J. F.; Owens, M. L.; Slade, H. B.; and Tomai, M. A. Imiquimod applied topically: a 
novel immune response modifier and new class of drug. Int. J. Immunopharmacol. 1999, 21, 1-14. 
 146.  Weterings, J. J.; Khan, S.; van der Heden van Noort GJ; Melief, C. J.; Overkleeft, H. S.; van der Burg, 
S. H.; Ossendorp, F.; Van der Marel, G. A.; and Filippov, D. V. 2-Azidoalkoxy-7-hydro-8-
oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation. Bioorg. Med. Chem. 
Lett. 2009, 19, 2249-2251. 
 147.  Hirota, K.; Kazaoka, K.; Niimoto, I.; Kumihara, H.; Sajiki, H.; Isobe, Y.; Takaku, H.; Tobe, M.; Ogita, H.; 
Ogino, T.; Ichii, S.; Kurimoto, A.; and Kawakami, H. Discovery of 8-hydroxyadenines as a novel 
type of interferon inducer. J. Med. Chem. 2002, 45, 5419-5422. 
 148.  Isobe, Y.; Tobe, M.; Ogita, H.; Kurimoto, A.; Ogino, T.; Kawakami, H.; Takaku, H.; Sajiki, H.; Hirota, K.; 
and Hayashi, H. Synthesis and structure-activity relationships of 2-substituted-8-hydroxyadenine 
derivatives as orally available interferon inducers without emetic side effects. Bioorg. Med. Chem. 
2003, 11, 3641-3647. 
 195  
 149.  Kurimoto, A.; Ogino, T.; Ichii, S.; Isobe, Y.; Tobe, M.; Ogita, H.; Takaku, H.; Sajiki, H.; Hirota, K.; and 
Kawakami, H. Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon 
inducers with improved oral bioavailabilities. Bioorg. Med. Chem. 2004, 12, 1091-1099. 
 150.  Warshakoon, H. J.; Hood, J. D.; Kimbrell, M. R.; Malladi, S.; Wu, W. Y.; Shukla, N. M.; Agnihotri, G.; 
Sil, D.; and David, S. A. Potential adjuvantic properties of innate immune stimuli. Hum. Vaccin. 
2009, 5, 381-394. 
 151.  Nicolas, J. F. and Guy, B. Intradermal, epidermal and transcutaneous vaccination: from immunology to 
clinical practice. Expert. Rev. Vaccines. 2008, 7, 1201-1214. 
 152.  Skountzou, I. and Kang, S. M. Transcutaneous immunization with influenza vaccines. Curr. Top. 
Microbiol. Immunol. 2009, 333:347-68., 347-368. 
 153.  Giudice, E. L. and Campbell, J. D. Needle-free vaccine delivery. Adv. Drug Deliv. Rev. 2006, 58, 68-
89. 
 154.  Goldstein, G. and Chicca, J. J. A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and 
self-adjuvanting. Vaccine. 2010, 28, 1008-1014. 
 155.  Fujita, Y.; Abdel-Aal, A. B.; Wimmer, N.; Batzloff, M. R.; Good, M. F.; and Toth, I. Synthesis and 
immunological evaluation of self-adjuvanting glycolipopeptide vaccine candidates. Bioorg. Med. 
Chem. 2008, 16, 8907-8913. 
 156.  Baldwin, S. L.; Bertholet, S.; Kahn, M.; Zharkikh, I.; Ireton, G. C.; Vedvick, T. S.; Reed, S. G.; and 
Coler, R. N. Intradermal immunization improves protective efficacy of a novel TB vaccine 
candidate. Vaccine. 2009, 27, 3063-3071. 
 157.  Zhang, W. W. and Matlashewski, G. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine 
adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect. Immun. 
2008, 76, 3777-3783. 
 158.  Zaba, L. C.; Krueger, J. G.; and Lowes, M. A. Resident and "inflammatory" dendritic cells in human 
skin. J. Invest Dermatol. 2009, 129, 302-308. 
 159.  Miller, L. S. and Modlin, R. L. Toll-like receptors in the skin. Semin. Immunopathol. 2007, 29, 15-26. 
 160.  Mathers, A. R. and Larregina, A. T. Professional antigen-presenting cells of the skin. Immunol. Res. 
2006, 36, 127-136. 
 161.  Rajagopal, D.; Paturel, C.; Morel, Y.; Uematsu, S.; Akira, S.; and Diebold, S. S. Plasmacytoid dendritic 
cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. 
Blood. 2010, 115, 1949-1957. 
 162.  Jin, M. S. and Lee, J. O. Structures of TLR-ligand complexes. Curr. Opin. Immunol. 2008, 20, 414-419. 
 163.  Adediran, S. A.; Day, T. P.; Sil, D.; Kimbrell, M. R.; Warshakoon, H. J.; Malladi, S. S.; and David, S. A. 
Synthesis of a highly water-soluble derivative of amphotericin B with attenuated proinflammatory 
activity. Mol. Pharm. 2009, 6, 1582-1590. 
 164.  Nguyen, T. B.; Kumar, E. V.; Sil, D.; Wood, S. J.; Miller, K. A.; Warshakoon, H. J.; Datta, A.; and David, 
S. A. Controlling plasma protein binding: structural correlates of interactions of hydrophobic 
polyamine endotoxin sequestrants with human serum albumin. Mol. Pharm. 2008, 5, 1131-1137. 
 196  
 165.  Gorden, K. B.; Gorski, K. S.; Gibson, S. J.; Kedl, R. M.; Kieper, W. C.; Qiu, X.; Tomai, M. A.; Alkan, S. 
S.; and Vasilakos, J. P. Synthetic TLR agonists reveal functional differences between human TLR7 
and TLR8. J. Immunol. 2005, 174, 1259-1268. 
 166.  Gorski, K. S.; Waller, E. L.; Bjornton-Severson, J.; Hanten, J. A.; Riter, C. L.; Kieper, W. C.; Gorden, K. 
B.; Miller, J. S.; Vasilakos, J. P.; Tomai, M. A.; and Alkan, S. S. Distinct indirect pathways govern 
human NK-cell activation by TLR-7 and TLR-8 agonists. Int. Immunol. 2006, 18, 1115-1126. 
 167.  Middlebrooks, B. L.; Voss, P. G.; Douglas, W. L.; and Toom, P. M. Procedure for selecting monoclonal 
antibodies for use in a ligand displacement assay of serum antibody levels. J. Immunoassay. 1991, 
12, 125-144. 
 168.  Simon, F.; Rahimy, C.; Krivine, A.; Levine, M.; Pepin, J. M.; Lapierre, D.; Denamur, E.; Vernoux, L.; De 
Crepy, A.; Blot, P.; and . Antibody avidity measurement and immune complex dissociation for 
serological diagnosis of vertically acquired HIV-1 infection. J. Acquir. Immune. Defic. Syndr. 1993, 
6, 201-207. 
 169.  Liu, X.; Hefesha, H.; Tanaka, H.; Scriba, G.; and Fahr, A. Lipophilicity measurement of drugs by 
reversed phase HPLC over wide pH range using an alkaline-resistant silica-based stationary 
phase, XBridge Shield RP(18). Chem. Pharm. Bull. (Tokyo). 2008, 56, 1417-1422. 
 170.  Fuguet, E.; Rafols, C.; Bosch, E.; and Roses, M. Determination of the chromatographic hydrophobicity 
index for ionisable solutes. J. Chromatogr. A. 2007, 1173, 110-119. 
 171.  Aghemo, A.; Rumi, M. G.; and Colombo, M. Pegylated IFN-alpha2a and ribavirin in the treatment of 
hepatitis C. Expert. Rev. Anti. Infect. Ther. 2009, 7, 925-935. 
 172.  Guilhot, F.; Roy, L.; Saulnier, P. J.; and Guilhot, J. Interferon in chronic myeloid leukaemia: past and 
future. Best Pract. Res. Clin. Haematol. 2009, 22, 315-329. 
 173.  Cannon, T.; Mobarek, D.; Wegge, J.; and Tabbara, I. A. Hairy cell leukemia: current concepts. Cancer 
Invest. 2008, 26, 860-865. 
 174.  Liu, Y. J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. 
Annu. Rev. Immunol. 2005, 23:275-306., 275-306. 
 175.  Padhan, K. and Varma, R. Immunological synapse: a multi-protein signalling cellular apparatus for 
controlling gene expression. Immunology. 2010, 129, 322-328. 
 176.  Manz, B. N. and Groves, J. T. Spatial organization and signal transduction at intercellular junctions. 
Nat. Rev. Mol. Cell Biol. 2010, 11, 342-352. 
 177.  Kawai, T. and Akira, S. Antiviral signaling through pattern recognition receptors. J. Biochem. 2007, 
141, 137-145. 
 178.  Hood, J. D.; Warshakoon, H. J.; Kimbrell, M. R.; Shukla, N. M.; Malladi, S.; Wang, X.; and David, S. A. 
Immunoprofiling toll-like receptor ligands Comparison of immunostimulatory and proinflammatory profiles 
in ex vivo human blood models. Hum. Vaccin. 2010, 6, 1-14. 
 179.  David, S. A.; Silverstein, R.; Amura, C. R.; Kielian, T.; and Morrison, D. C. Lipopolyamines: novel 
antiendotoxin compounds that reduce mortality in experimental sepsis caused by gram-negative 
bacteria. Antimicrob. Agents Chemother. 1999, 43, 912-919. 
 197  
 180.  Miller, K. A.; Suresh Kumar, E. V. K.; Wood, S. J.; Cromer, J. R.; Datta, A.; and David, S. A. 
Lipopolysaccharide Sequestrants: Structural Correlates of Activity and Toxicity in Novel 
Acylhomospermines. J. Med. Chem. 2005, 48, 2589-2599. 
 181.  Matsumoto, M.; Funami, K.; Tanabe, M.; Oshiumi, H.; Shingai, M.; Seto, Y.; Yamamoto, A.; and Seya, 
T. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J. Immunol. 2003, 171, 
3154-3162. 
 182.  Matsumoto, M.; Funami, K.; Oshiumi, H.; and Seya, T. Toll-like receptor 3: a link between toll-like 
receptor, interferon and viruses. Microbiol. Immunol. 2004, 48, 147-154. 
 183.  Hoebe, K. and Beutler, B. LPS, dsRNA and the interferon bridge to adaptive immune responses: Trif, 
Tram, and other TIR adaptor proteins. J. Endotoxin. Res. 2004, 10, 130-136. 
 184.  Sen, G. C. and Sarkar, S. N. Transcriptional signaling by double-stranded RNA: role of TLR3. Cytokine 
Growth Factor Rev. 2005, 16, 1-14. 
 185.  Sioud, M. Innate sensing of self and non-self RNAs by Toll-like receptors. Trends Mol. Med. 2006, 12, 
167-176. 
 186.  Kawai, T. and Akira, S. Antiviral signaling through pattern recognition receptors. J. Biochem. 2007, 
141, 137-145. 
 187.  Uematsu, S. and Akira, S. Toll-like receptors and Type I interferons. J. Biol. Chem. 2007, 282, 15319-
15323. 
 188.  Matsumoto, M. and Seya, T. TLR3: interferon induction by double-stranded RNA including poly(I:C). 
Adv. Drug Deliv. Rev. 2008, 60, 805-812. 
 189.  Thompson, K. A.; Strayer, D. R.; Salvato, P. D.; Thompson, C. E.; Klimas, N.; Molavi, A.; Hamill, A. K.; 
Zheng, Z.; Ventura, D.; and Carter, W. A. Results of a double-blind placebo-controlled study of the 
double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. Eur. J. Clin. Microbiol. 
Infect. Dis. 1996, 15, 580-587. 
 190.  Navabi, H.; Jasani, B.; Reece, A.; Clayton, A.; Tabi, Z.; Donninger, C.; Mason, M.; and Adams, M. A 
clinical grade poly I:C-analogue (Ampligen((R))) promotes optimal DC maturation and Th1-type T 
cell responses of healthy donors and cancer patients in vitro. Vaccine 2008. 
 191.  Le Bon, A.; Schiavoni, G.; D'Agostino, G.; Gresser, I.; Belardelli, F.; and Tough, D. F. Type i interferons 
potently enhance humoral immunity and can promote isotype switching by stimulating dendritic 
cells in vivo. Immunity. 2001, 14, 461-470. 
 192.  Durand, V.; Wong, S. Y.; Tough, D. F.; and Le Bon, A. Shaping of adaptive immune responses to 
soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol. Cell Biol. 2004, 82, 596-602. 
 193.  Salem, M. L.; El Naggar, S. A.; Kadima, A.; Gillanders, W. E.; and Cole, D. J. The adjuvant effects of 
the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell 
responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. 
Vaccine 2006, 24, 5119-5132. 
 194.  Adams, M.; Navabi, H.; Jasani, B.; Man, S.; Fiander, A.; Evans, A. S.; Donninger, C.; and Mason, M. 
Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and 
 198  
matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly 
[C(12)U] (Ampligen R). Vaccine 2003, 21, 787-790. 
 195.  Ichinohe, T.; Watanabe, I.; Ito, S.; Fujii, H.; Moriyama, M.; Tamura, S.; Takahashi, H.; Sawa, H.; Chiba, 
J.; Kurata, T.; Sata, T.; and Hasegawa, H. Synthetic double-stranded RNA poly(I:C) combined with 
mucosal vaccine protects against influenza virus infection. J. Virol. 2005, 79, 2910-2919. 
 196.  Ma, Y. and Ross, A. C. The anti-tetanus immune response of neonatal mice is augmented by retinoic 
acid combined with polyriboinosinic:polyribocytidylic acid. Proc. Natl. Acad. Sci. U. S. A 2005, 102, 
13556-13561. 
 197.  Cui, Z. and Qiu, F. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: 
therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol. 
Immunother. 2006, 55, 1267-1279. 
 198.  Ichinohe, T.; Kawaguchi, A.; Tamura, S.; Takahashi, H.; Sawa, H.; Ninomiya, A.; Imai, M.; Itamura, S.; 
Odagiri, T.; Tashiro, M.; Chiba, J.; Sata, T.; Kurata, T.; and Hasegawa, H. Intranasal immunization 
with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against 
homologous and heterologous virus challenge. Microbes. Infect. 2007, 9, 1333-1340. 
 199.  Houston, W. E.; Crabbs, C. L.; Stephen, E. L.; and Levy, H. B. Modified polyriboinosinic-
polyribocytidylic acid, an immunological adjuvant. Infect. Immun. 1976, 14, 318-319. 
 200.  Liu, L.; Botos, I.; Wang, Y.; Leonard, J. N.; Shiloach, J.; Segal, D. M.; and Davies, D. R. Structural 
basis of toll-like receptor 3 signaling with double-stranded RNA. Science 2008, 320, 379-381. 
 201.  Hauptmann, R. and Swetly, P. A novel class of human type I interferons. Nucleic Acids Res. 1985, 13, 
4739-4749. 
 202.  Adolf, G. R. Human interferon omega--a review. Mult. Scler. 1995, 1 Suppl 1:S44-7., S44-S47. 
 203.  Roberts, R. M.; Liu, L.; and Alexenko, A. New and atypical families of type I interferons in mammals: 
comparative functions, structures, and evolutionary relationships. Prog. Nucleic Acid Res. Mol. 
Biol. 1997, 56:287-325., 287-325. 
 204.  Miller, R. L.; Meng, T. C.; and Tomai, M. A. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. 
Drug News Perspect. 2008, 21, 69-87. 
 205.  Thomas, A.; Laxton, C.; Rodman, J.; Myangar, N.; Horscroft, N.; and Parkinson, T. Investigating Toll-
like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob. Agents 
Chemother. 2007, 51, 2969-2978. 
 206.  Fletcher, S.; Steffy, K.; and Averett, D. Masked oral prodrugs of toll-like receptor 7 agonists: a new 
approach for the treatment of infectious disease. Curr. Opin. Investig. Drugs. 2006, 7, 702-708. 
 207.  Lee, J.; Wu, C. C.; Lee, K. J.; Chuang, T. H.; Katakura, K.; Liu, Y. T.; Chan, M.; Tawatao, R.; Chung, 
M.; Shen, C.; Cottam, H. B.; Lai, M. M.; Raz, E.; and Carson, D. A. Activation of anti-hepatitis C 
virus responses via Toll-like receptor 7. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 1828-1833. 
 208.  Horsmans, Y.; Berg, T.; Desager, J. P.; Mueller, T.; Schott, E.; Fletcher, S. P.; Steffy, K. R.; Bauman, 
L. A.; Kerr, B. M.; and Averett, D. R. Isatoribine, an agonist of TLR7, reduces plasma virus 
concentration in chronic hepatitis C infection. Hepatology. 2005, 42, 724-731. 
 199  
 209.  Nguyen, M. H. and Keeffe, E. B. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. 
Clin. Gastroenterol. Hepatol. 2005, 3, S97-S101. 
 210.  Buckwold, V. E.; Wei, J.; Huang, Z.; Huang, C.; Nalca, A.; Wells, J.; Russell, J.; Collins, B.; Ptak, R.; 
Lang, W.; Scribner, C.; Blanchett, D.; Alessi, T.; and Langecker, P. Antiviral activity of CHO-SS 
cell-derived human omega interferon and other human interferons against HCV RNA replicons and 
related viruses. Antiviral Res. 2007, 73, 118-125. 
 211.  Buckwold, V. E.; Lang, W.; Scribner, C.; Blanchett, D.; Alessi, T.; and Langecker, P. Safety 
pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega-
interferon produced from CHO-SS cells. Basic Clin. Pharmacol. Toxicol. 2006, 99, 62-70. 
 212.  Okuse, C.; Rinaudo, J. A.; Farrar, K.; Wells, F.; and Korba, B. E. Enhancement of antiviral activity 
against hepatitis C virus in vitro by interferon combination therapy. Antiviral Res. 2005, 65, 23-34. 
 213.  Bekisz, J.; Schmeisser, H.; Hernandez, J.; Goldman, N. D.; and Zoon, K. C. Human interferons alpha, 
beta and omega. Growth Factors. 2004, 22, 243-251. 
 214.  Bachmann, M. F. and Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and 
molecular patterns. Nat. Rev. Immunol. 2010, 10, 787-796. 
 215.  Zeng, W.; Ghosh, S.; Lau, Y. F.; Brown, L. E.; and Jackson, D. C. Highly immunogenic and totally 
synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J. Immunol. 2002, 169, 
4905-4912. 
 216.  Bettahi, I.; Zhang, X.; Afifi, R. E.; and BenMohamed, L. Protective immunity to genital herpes simplex 
virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation 
and elicit a polarized Th1 immune response. Viral Immunol. 2006, 19, 220-236. 
 217.  Abdel-Aal, A. B.; Batzloff, M. R.; Fujita, Y.; Barozzi, N.; Faria, A.; Simerska, P.; Moyle, P. M.; Good, M. 
F.; and Toth, I. Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting 
group a streptococcal vaccine candidates. J. Med. Chem. 2008, 51, 167-172. 
 218.  Moyle, P. M. and Toth, I. Self-adjuvanting lipopeptide vaccines. Curr. Med. Chem. 2008, 15, 506-516. 
 219.  Zeng, W.; Horrocks, K. J.; Robevska, G.; Wong, C. Y.; Azzopardi, K.; Tauschek, M.; Robins-Browne, 
R. M.; and Jackson, D. C. A modular approach to assembly of totally synthetic self-adjuvanting 
lipopeptide-based vaccines allows conformational epitope building. J. Biol. Chem. 2011. 
 220.  Wilkinson, B. L.; Day, S.; Malins, L. R.; Apostolopoulos, V.; and Payne, R. J. Self-Adjuvanting 
Multicomponent Cancer Vaccine Candidates Combining Per-Glycosylated MUC1 Glycopeptides 
and the Toll-like Receptor 2 Agonist Pam(3) CysSer. Angew. Chem. Int. Ed Engl. 2011, 50, 1635-
1639. 
 221.  Zeng, W.; Ghosh, S.; Lau, Y. F.; Brown, L. E.; and Jackson, D. C. Highly immunogenic and totally 
synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J. Immunol. 2002, 169, 
4905-4912. 
 222.  Zeng, W.; Eriksson, E. M.; Lew, A.; and Jackson, D. C. Lipidation of intact proteins produces highly 
immunogenic vaccine candidates. Mol. Immunol. 2011, 48, 490-496. 
 223.  Hill, B. G.; Reily, C.; Oh, J. Y.; Johnson, M. S.; and Landar, A. Methods for the determination and 
quantification of the reactive thiol proteome. Free Radic. Biol. Med. 2009, 47, 675-683. 
 200  
 224.  Wenink, M. H.; Santegoets, K. C.; Broen, J. C.; van Bon, L.; Abdollahi-Roodsaz, S.; Popa, C.; 
Huijbens, R.; Remijn, T.; Lubberts, E.; van Riel, P. L.; van den Berg, W. B.; and Radstake, T. R. 
TLR2 promotes Th2/Th17 responses via TLR4 and TLR7/8 by abrogating the type I IFN 
amplification loop. J. Immunol. 2009, 183, 6960-6970. 
 225.  Aliahmadi, E.; Gramlich, R.; Grutzkau, A.; Hitzler, M.; Kruger, M.; Baumgrass, R.; Schreiner, M.; Wittig, 
B.; Wanner, R.; and Peiser, M. TLR2-activated human langerhans cells promote Th17 polarization 
via IL-1beta, TGF-beta and IL-23. Eur. J. Immunol. 2009, 39, 1221-1230. 
 226.  Bracci, L.; La, S., V; Belardelli, F.; and Proietti, E. Type I interferons as vaccine adjuvants against 
infectious diseases and cancer. Expert. Rev. Vaccines. 2008, 7, 373-381. 
 227.  Tovey, M. G.; Lallemand, C.; and Thyphronitis, G. Adjuvant activity of type I interferons. Biol. Chem. 
2008, 389, 541-545. 
 228.  Rajagopal, D.; Paturel, C.; Morel, Y.; Uematsu, S.; Akira, S.; and Diebold, S. S. Plasmacytoid dendritic 
cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. 
Blood. 2010, 115, 1949-1957. 
 229.  Berenson, L. S.; Ota, N.; and Murphy, K. M. Issues in T-helper 1 development--resolved and 
unresolved. Immunol. Rev. 2004, 202, 157-174. 
 230.  Pulendran, B. Modulating TH1/TH2 responses with microbes, dendritic cells, and pathogen recognition 
receptors. Immunol. Res. 2004, 29, 187-196. 
 231.  Gately, M. K. and Brunda, M. J. Interleukin-12: a pivotal regulator of cell-mediated immunity. Cancer 
Treat. Res. 1995, 80, 341-366. 
 232.  Scott, P. and Trinchieri, G. IL-12 as an adjuvant for cell-mediated immunity. Semin. Immunol. 1997, 9, 
285-291. 
 233.  Eberl, M.; Beck, E.; Coulson, P. S.; Okamura, H.; Wilson, R. A.; and Mountford, A. P. IL-18 potentiates 
the adjuvant properties of IL-12 in the induction of a strong Th1 type immune response against a 
recombinant antigen. Vaccine. 2000, 18, 2002-2008. 
 234.  Tough, D. F.; Zhang, X.; and Sprent, J. An IFN-gamma-dependent pathway controls stimulation of 
memory phenotype CD8+ T cell turnover in vivo by IL-12, IL-18, and IFN-gamma. J. Immunol. 
2001, 166, 6007-6011. 
 235.  Marshall, D. J.; Rudnick, K. A.; McCarthy, S. G.; Mateo, L. R.; Harris, M. C.; McCauley, C.; and 
Snyder, L. A. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine. 
Vaccine. 2006, 24, 244-253. 
 236.  Wu, W.; Li, R.; Malladi, S. S.; Warshakoon, H. J.; Kimbrell, M. R.; Amolins, M. W.; Ukani, R.; Datta, A.; 
and David, S. A. Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol 
lipopeptides. J. Med. Chem. 2010, 53, 3198-3213. 
 237.  Jaini, R.; Kesaraju, P.; Johnson, J. M.; Altuntas, C. Z.; Jane-Wit, D.; and Tuohy, V. K. An autoimmune-
mediated strategy for prophylactic breast cancer vaccination. Nat. Med. 2010, 16, 799-803. 
 238.  Rappuoli, R. Conjugates and reverse vaccinology to eliminate bacterial meningitis. Vaccine. 2001, 19, 
2319-2322. 
 201  
 239.  Mawas, F.; Peyre, M.; Beignon, A. S.; Frost, L.; Del Giudice, G.; Rappuoli, R.; Muller, S.; Sesardic, D.; 
and Partidos, C. D. Successful induction of protective antibody responses against Haemophilus 
influenzae type b and diphtheria after transcutaneous immunization with the glycoconjugate 
polyribosyl ribitol phosphate-cross-reacting material 197 vaccine. J. Infect. Dis. 2004, 190, 1177-
1182. 
 240.  Broker, M.; Dull, P. M.; Rappuoli, R.; and Costantino, P. Chemistry of a new investigational 
quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine. 2009, 27, 
5574-5580. 
 241.  Falugi, F.; Petracca, R.; Mariani, M.; Luzzi, E.; Mancianti, S.; Carinci, V.; Melli, M. L.; Finco, O.; Wack, 
A.; Di Tommaso, A.; De Magistris, M. T.; Costantino, P.; Del Giudice, G.; Abrignani, S.; Rappuoli, 
R.; and Grandi, G. Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help 
to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines. Eur. J. 
Immunol. 2001, 31, 3816-3824. 
 242.  Costantino, P.; Viti, S.; Podda, A.; Velmonte, M. A.; Nencioni, L.; and Rappuoli, R. Development and 
phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine. 1992, 10, 
691-698. 
 243.  Avci, F. Y. and Kasper, D. L. How bacterial carbohydrates influence the adaptive immune system. 
Annu. Rev. Immunol. 2010, 28:107-30., 107-130. 
 244.  Kalka-Moll, W. M.; Tzianabos, A. O.; Bryant, P. W.; Niemeyer, M.; Ploegh, H. L.; and Kasper, D. L. 
Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions. J. Immunol. 
2002, 169, 6149-6153. 
 245.  Gallorini, S.; Berti, F.; Mancuso, G.; Cozzi, R.; Tortoli, M.; Volpini, G.; Telford, J. L.; Beninati, C.; 
Maione, D.; and Wack, A. Toll-like receptor 2 dependent immunogenicity of glycoconjugate 
vaccines containing chemically derived zwitterionic polysaccharides. Proc. Natl. Acad. Sci. U. S. A. 
2009, 106, 17481-17486. 
 246.  Gallorini, S.; Berti, F.; Parente, P.; Baronio, R.; Aprea, S.; D'Oro, U.; Pizza, M.; Telford, J. L.; and 
Wack, A. Introduction of zwitterionic motifs into bacterial polysaccharides generates TLR2 agonists 
able to activate APCs. J. Immunol. 2007, 179, 8208-8215. 
 247.  Costantino, P.; Viti, S.; Podda, A.; Velmonte, M. A.; Nencioni, L.; and Rappuoli, R. Development and 
phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine. 1992, 10, 
691-698. 
 248.  Kaplan, C.; Valdez, J. C.; Chandrasekaran, R.; Eibel, H.; Mikecz, K.; Glant, T. T.; and Finnegan, A. 
Th1 and Th2 cytokines regulate proteoglycan-specific autoantibody isotypes and arthritis. Arthritis 
Res. 2002, 4, 54-58. 
 249.  Pullen, G. R.; Fitzgerald, M. G.; and Hosking, C. S. Antibody avidity determination by ELISA using 
thiocyanate elution. J. Immunol. Methods. 1986, 86, 83-87. 
 250.  Macdonald, R. A.; Hosking, C. S.; and Jones, C. L. The measurement of relative antibody affinity by 
ELISA using thiocyanate elution. J. Immunol. Methods. 1988, 106, 191-194. 
 202  
 251.  David, S. A.; Smith, M. S.; Lopez, G.; Mukherjee, S.; Buch, S.; and Narayan, O. Selective transmission 
of R5-tropic HIV-1 from dendritic cells to resting CD4+ T cells. AIDS Res. Human Retrovir. 2001, 
17, 59-68. 
 
 
 
